Friedreich Ataxia

Mendelian MONDO:0100339 Pathograph 39 Show in embeddings browser Hereditary Ataxia Mitochondrial Disorder

Friedreich ataxia (FRDA) is the most common inherited ataxia, caused by homozygous GAA trinucleotide repeat expansion in intron 1 of the FXN gene encoding frataxin, a mitochondrial protein essential for iron-sulfur cluster biogenesis. Frataxin deficiency leads to mitochondrial iron accumulation, impaired oxidative phosphorylation, and oxidative stress. The disease is characterized by progressive gait and limb ataxia, dysarthria, loss of deep tendon reflexes, sensory neuropathy, hypertrophic cardiomyopathy, scoliosis, pes cavus, and diabetes mellitus. Onset is typically around puberty with progressive disability and shortened lifespan, often due to cardiac complications.

Ask OpenScientist

Ask a research question about Friedreich Ataxia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🔗

Mappings

MONDO

MONDO:0100339 Friedreich ataxia

Orphanet lists MONDO:0100339 as an exact cross-reference for the ORPHA:95 Friedreich ataxia record.

MONDO:0100340 Friedreich ataxia 1 Not Yet Curated

MONDO:0100340 (Friedreich ataxia 1, FRDA1) is the FXN-caused child of the MONDO:0100339 grouping this entry is bound to, defined by MONDO as "Any Friedreich ataxia in which the cause of the disease is a mutation in the FXN gene" and carrying the RO:0004003 causal relation to hgnc:3951. Every mechanism, phenotype, and treatment curated here is FXN GAA-repeat disease, and the OMIM identifier the entry already records as an exact cross-reference (OMIM:229300) is the one MONDO uses to define FRDA1. The entry is bound one level up because it also covers the FARR subtype (MONDO:0800301), a MONDO sibling of FRDA1 rather than a descendant, so the grouping term is the narrowest single term spanning what is curated.

👪

Inheritance

Autosomal recessive inheritance HP:0000007

Friedreich ataxia is caused by biallelic pathogenic FXN alleles, most often homozygous intron 1 GAA repeat expansions, and follows autosomal recessive inheritance.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:23859346 SUPPORT Human Clinical

"Inheritance is autosomal recessive with the vast majority of cases showing an unstable intronic GAA expansion in both alleles of the frataxin gene on chromosome 9q13."

Defines the inheritance pattern and the usual biallelic FXN repeat-expansion genotype.

ORPHA:95 SUPPORT Other

"Autosomal recessive"

Orphanet records autosomal recessive inheritance for Friedreich ataxia.

◆

Subtypes

Typical Friedreich ataxia

FXN hgnc:3951

Classic Friedreich ataxia, accounting for about 75% of biallelic FXN cases, with onset from early childhood to early adulthood (mean age at onset 10-15 years) and the full progressive multisystem phenotype including areflexia.

Show evidence (2 references)

PMID:20301458 SUPPORT Human Clinical

"mean age at onset from 10 to 15 years"

GeneReviews gives the typical FRDA onset window of 10-15 years for the classic form.

PMID:20301458 SUPPORT Human Clinical

"individuals with FRDA, about 75% have "typical Friedreich ataxia""

GeneReviews states about 75% of individuals with FRDA have the typical form (and about 25% atypical), supporting the subtype proportions.

Late-onset Friedreich ataxia (LOFA)

FXN hgnc:3951

Atypical form with onset after age 25 years, part of the ~25% of biallelic FXN cases that are atypical. Later onset is generally associated with smaller GAA expansions and slower progression.

Show evidence (1 reference)

PMID:20301458 SUPPORT Human Clinical

"late-onset FRDA (LOFA)"

GeneReviews defines late-onset FRDA (LOFA) as onset after age 25 within the atypical FRDA group.

Very late-onset Friedreich ataxia (VLOFA)

FXN hgnc:3951

Atypical form with onset after age 40 years, the latest-onset end of the atypical FRDA spectrum.

Show evidence (1 reference)

PMID:20301458 SUPPORT Human Clinical

"very late-onset FRDA (VLOFA)"

GeneReviews defines very late-onset FRDA (VLOFA) as onset after age 40.

Friedreich ataxia with retained reflexes (FARR) MONDO:0800301

FXN hgnc:3951

Atypical form in which deep tendon reflexes are preserved rather than lost, so the cardinal lower-limb areflexia of typical FRDA is absent. Part of the ~25% atypical FRDA group.

Show evidence (1 reference)

PMID:20301458 SUPPORT Human Clinical

"FRDA with retained reflexes (FARR)"

GeneReviews defines FRDA with retained reflexes (FARR) as an atypical form in which reflexes are preserved.

◈

Mechanistic Hypotheses

Canonical FXN Loss-of-Function Mitochondrial Pathograph

canonical_fxn_loss_of_function CANONICAL

Evidence balance 12 support

Biallelic FXN intron 1 GAA repeat expansion causes epigenetic transcriptional silencing and frataxin deficiency. Frataxin deficiency impairs mitochondrial Fe-S cluster biogenesis, oxidative phosphorylation, and iron handling, creating tissue-selective vulnerability in dorsal root ganglion sensory neurons, dentate/spinal pathways, cardiomyocytes, pancreatic beta cells, and the skeleton.

Retained as CANONICAL. The 2026 openscientist hypothesis-search report (kb/hypotheses/Friedreich_Ataxia/canonical_fxn_loss_of_function) reviewed 105 papers and confirmed the canonical causal chain (GAA expansion → epigenetic silencing → frataxin deficiency → impaired Fe-S cluster biogenesis → mitochondrial dysfunction → tissue-selective degeneration) at every link, capped by secretable-frataxin gene therapy achieving dual cardiac and neurological rescue in mouse models with a single intra-CSF AAV injection (the non-human primate arm of that study established biodistribution and protein repletion, not phenotype correction). Three qualifications expand the model to a branching tissue-specific pathograph rather than a single linear cascade: (1) DRG-neuron pathology is driven by ferroptosis (iron-dependent lipid peroxidation, impaired NRF2 response via LKB1/AMPK, KEAP1, GSK3β) and is rescued by the NRF2 activator omaveloxolone; (2) cardiac pathology involves mitochondrial iron overload with impaired mitophagy via the mTOR-TFEB axis, paradoxically WITHOUT increased oxidative stress; (3) frataxin's function has been refined from an iron donor to an allosteric activator of the NFS1-ISD11-ACP-ISCU2 Fe-S cluster assembly complex. Negative trial data (deferiprone worsened ataxia at 40 mg/kg) and gene-therapy overexpression toxicity (>20-fold normal cardiotoxic) collectively define a narrow therapeutic window and indicate that Fe-S cluster deficiency — not iron excess — is the primary neurological lesion.

Pathograph links

FXN GAA Repeat Expansion and Epigenetic Silencing -> Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect INDIRECT KNOWN INTERMEDIATES FXN transcriptional silencing reduces frataxin, the mitochondrial protein required for the canonical FRDA loss-of-function path. Intermediates: expanded intron 1 GAA repeat; repressive chromatin flanking the repeat; reduced FXN transcription

Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect -> Mitochondrial Bioenergetic Failure and Oxidative Stress DIRECT Defective Fe-S cluster biogenesis lowers activity of mitochondrial respiratory-chain and Fe-S enzymes, producing energy failure, iron dysregulation, and oxidative stress.

Mitochondrial Bioenergetic Failure and Oxidative Stress -> Dorsal Root Ganglion Sensory Neuronopathy INDIRECT KNOWN INTERMEDIATES Sensory neurons in dorsal root ganglia are especially vulnerable to the mitochondrial consequences of frataxin deficiency, causing the proprioceptive sensory branch of FRDA. Intermediates: reduced respiratory-chain complex I and II activity; mitochondrial superoxide generation; sensory neuron lethality

Mitochondrial Bioenergetic Failure and Oxidative Stress -> Dentate Nucleus and Spinocerebellar Tract Degeneration INDIRECT KNOWN INTERMEDIATES Mitochondrial frataxin deficiency also injures the cerebellar dentate nucleus and spinocerebellar/dorsal-column systems, adding a central cerebellar component to the sensory ataxia path. Intermediates: dentate nucleus atrophy; dorsal column and spinocerebellar tract fiber loss

Mitochondrial Bioenergetic Failure and Oxidative Stress -> Corticospinal Tract Degeneration INDIRECT KNOWN INTERMEDIATES Mitochondrial frataxin deficiency injures the corticospinal (pyramidal) tracts as a separate intrinsic CNS lesion, in parallel with the DRG, dentate, and optic-nerve lesions. Intermediates: corticospinal tract fiber loss; upper motor neuron degeneration

Mitochondrial Bioenergetic Failure and Oxidative Stress -> Optic Atrophy INDIRECT KNOWN INTERMEDIATES Optic atrophy is a separate intrinsic central nervous system lesion of FRDA, reflecting degeneration of the optic nerve and retinal ganglion cell visual pathway rather than the dentate/spinocerebellar system. Intermediates: retinal ganglion cell and optic nerve neurodegeneration; visual pathway involvement

Mitochondrial Bioenergetic Failure and Oxidative Stress -> Muscle Weakness INDIRECT KNOWN INTERMEDIATES Mitochondrial bioenergetic failure in FRDA affects skeletal muscle and contributes to progressive limb weakness and fatigue. Intermediates: skeletal muscle mitochondrial dysfunction; neuromuscular weakness

Mitochondrial Bioenergetic Failure and Oxidative Stress -> Cardiomyocyte Mitochondrial Injury INDIRECT KNOWN INTERMEDIATES Frataxin-deficient cardiomyocytes accumulate iron-positive mitochondrial injury and structural myocyte pathology, producing the cardiac branch of FRDA. Intermediates: mitochondrial iron dysmetabolism; cardiomyocyte hypertrophy; disrupted intercalated discs

Mitochondrial Bioenergetic Failure and Oxidative Stress -> Pancreatic Beta-Cell Apoptosis INDIRECT KNOWN INTERMEDIATES In pancreatic beta cells, frataxin deficiency causes mitochondrial dysfunction and oxidative stress-mediated intrinsic apoptosis, explaining the diabetes branch of FRDA. Intermediates: beta-cell mitochondrial dysfunction; oxidative stress-mediated intrinsic apoptosis

Mitochondrial Bioenergetic Failure and Oxidative Stress -> Progressive Skeletal Deformity INDIRECT KNOWN INTERMEDIATES Neurologic imbalance, sensory neuropathy, weakness, and FRDA skeletal involvement converge on progressive spinal and foot deformity. Intermediates: proprioceptive impairment; progressive neuromuscular weakness; skeletal involvement

Dorsal Root Ganglion Sensory Neuronopathy -> Peripheral Neuropathy DIRECT DRG and sensory nerve injury produces the peripheral sensory neuropathy phenotype with loss of proprioception and vibration sense.

Dorsal Root Ganglion Sensory Neuronopathy -> Progressive Gait and Limb Ataxia INDIRECT KNOWN INTERMEDIATES Loss of proprioceptive sensory input from DRG injury produces sensory ataxia that combines with cerebellar pathway degeneration. Intermediates: impaired proprioception; impaired vibration sense; sensory ataxia

Dorsal Root Ganglion Sensory Neuronopathy -> Areflexia of Lower Limbs INDIRECT KNOWN INTERMEDIATES Loss of large sensory afferents from dorsal root ganglion neuronopathy interrupts the deep tendon reflex arc, producing the early lower-limb areflexia that is a cardinal diagnostic sign of FRDA. Intermediates: loss of large-diameter sensory afferents; interrupted monosynaptic stretch reflex arc

Dorsal Root Ganglion Sensory Neuronopathy -> Impaired Proprioception DIRECT Destruction of the large primary sensory neurons of the dorsal root ganglia removes the joint-position afferents carried in the dorsal columns, producing the proprioceptive deficit directly.

Dorsal Root Ganglion Sensory Neuronopathy -> Impaired Vibratory Sensation DIRECT The same loss of large-diameter dorsal root ganglion afferents and their dorsal column projections removes vibration sense, which is carried by the same pathway as joint position sense.

Dentate Nucleus and Spinocerebellar Tract Degeneration -> Progressive Gait and Limb Ataxia DIRECT Dentate and spinocerebellar tract degeneration add a cerebellar motor control deficit to the sensory ataxia branch.

Dentate Nucleus and Spinocerebellar Tract Degeneration -> Dysarthria INDIRECT KNOWN INTERMEDIATES Cerebellar and bulbar pathway degeneration contributes to impaired speech motor coordination. Intermediates: cerebellar motor pathway dysfunction; bulbar motor involvement

Dentate Nucleus and Spinocerebellar Tract Degeneration -> Dysphagia INDIRECT KNOWN INTERMEDIATES Cerebellar and bulbar pathway dysfunction can impair swallowing motor coordination, producing dysphagia as part of the classical FRDA neurologic phenotype. Intermediates: impaired bulbar motor coordination; progressive neurologic dysfunction

Dentate Nucleus and Spinocerebellar Tract Degeneration -> Nystagmus INDIRECT KNOWN INTERMEDIATES Central nervous system involvement in FRDA produces oculomotor disturbance, including nystagmus. Intermediates: cerebellar oculomotor pathway dysfunction; abnormal saccades and square wave jerks

Corticospinal Tract Degeneration -> Extensor Plantar Response (Babinski Sign) DIRECT Corticospinal (pyramidal) tract degeneration produces upper motor neuron signs, including an extensor plantar (Babinski) response.

Corticospinal Tract Degeneration -> Spasticity DIRECT Corticospinal tract degeneration also produces lower-limb spasticity and hyperreflexia as the disease progresses.

Cardiomyocyte Mitochondrial Injury -> Hypertrophic Cardiomyopathy DIRECT Cardiomyocyte hypertrophy and mitochondrial injury produce the common hypertrophic cardiomyopathy phenotype.

Pancreatic Beta-Cell Apoptosis -> Diabetes Mellitus DIRECT Beta-cell dysfunction and death reduce insulin secretory capacity and produce the FRDA diabetes phenotype.

Progressive Skeletal Deformity -> Scoliosis DIRECT Progressive skeletal deformity manifests as scoliosis in the FRDA phenotype list.

Progressive Skeletal Deformity -> Pes Cavus DIRECT Progressive skeletal and neuromuscular involvement manifests as pes cavus in the FRDA phenotype list.

Deep research

OpenScientist citations 31 citations 2026-05-23T02:40:42.620302

Show evidence (12 references)

PMID:21315377 SUPPORT Human Clinical

"Deficiency of frataxin, a small mitochondrial protein, is responsible for all clinical and morphological manifestations of FRDA."

Establishes frataxin deficiency as the common causal mechanism underlying the multisystem FRDA phenotype.

PMID:42157962 SUPPORT Model Organism

"broad protein repletion across key target tissues-heart, dorsal root ganglia,"

Engineered secretable frataxin delivered via a single intra-CSF AAV injection achieves broad protein repletion across heart, DRG, and cerebellum in both mouse and non-human primate. Rescue of cardiac and neurological phenotypes was demonstrated in the mouse models; the non-human primate arm establishes biodistribution and repletion rather than phenotype correction. Still the strongest interventional support for the unified frataxin-deficiency causal hypothesis.

PMID:31511419 SUPPORT In Vitro

"FXN specifically accelerates each of these individual steps in the mechanism."

Biochemical reconstitution shows frataxin acts as an allosteric activator of the NFS1-ISD11-ACP-ISCU2 cysteine desulfurase complex, refining the canonical model from an iron-donor function to an activator of Fe-S cluster biogenesis.

+ 9 more references

Discussions and Knowledge Gaps

How frequent is clinically apparent optic atrophy with visual loss in FRDA versus subclinical optic-nerve / retinal-ganglion-cell involvement detectable only on quantitative testing, and how should the phenotype frequency band be interpreted given this divergence?

KNOWLEDGE GAP OPEN optic_atrophy_subclinical_vs_clinical_frda

Attached to

phenotypes#Optic Atrophy

Orphanet annotates optic atrophy as a frequent (79-30%) FRDA phenotype, whereas the Koeppen pathology review states that clinically apparent optic atrophy is uncommon (though some patients become blind). The discrepancy most likely reflects common subclinical optic-nerve / retinal-ganglion-cell involvement versus less-frequent overt visual loss. The entry carries frequency: FREQUENT (ORPHA-sourced) alongside the Koeppen quote; this discussion records the divergence so it is machine-visible rather than prose-only.

Show evidence (1 reference)

PMID:21315377 SUPPORT Human Clinical

"Optic atrophy is uncommon but some patients become blind."

Koeppen review states clinically apparent optic atrophy is uncommon, in tension with the Orphanet frequent annotation for the HPO term.

Is mitochondrial iron accumulation in FRDA a driver of tissue injury, or a late consequence of Fe-S cluster enzyme inactivation that has already occurred?

KNOWLEDGE GAP OPEN iron_accumulation_cause_or_consequence_frda

Attached to

pathophysiology#Mitochondrial Bioenergetic Failure and Oxidative Stress animal_models#Conditional Fxn knockout mouse (MCK-Cre and NSE-Cre)

The entry's mechanism chain places abnormal mitochondrial iron handling inside the bioenergetic-failure node without committing to its causal rank. The conditional-knockout mouse shows iron deposition appearing only after Fe-S enzyme inactivation and after pathology onset, which argues iron is downstream rather than initiating. That ordering is a mouse result and has not been established in human tissue, and it bears directly on whether iron chelation can be disease-modifying rather than merely a biomarker-directed intervention. Recorded so the open question is machine-visible rather than settled by omission.

Show evidence (1 reference)

PMID:11175786 SUPPORT Model Organism

"time-dependent intramitochondrial iron accumulation in a frataxin-deficient mammal, which occurs after onset of the pathology and after inactivation of the Fe-S-dependent enzymes"

Places iron accumulation after Fe-S enzyme inactivation and after pathology onset, the observation that motivates this question.

Why does a single upstream lesion — frataxin deficiency with impaired Fe-S cluster biogenesis — produce ferroptotic death in dorsal root ganglion neurons but mitophagy failure without increased oxidative stress in cardiomyocytes?

KNOWLEDGE GAP OPEN tissue_specific_effector_divergence_frda

Attached to

pathophysiology#Dorsal Root Ganglion Sensory Neuronopathy pathophysiology#Cardiomyocyte Mitochondrial Injury pathophysiology#Mitochondrial Bioenergetic Failure and Oxidative Stress

The entry models a shared mitochondrial branch point that feeds every tissue arm, and annotates that shared node with increased oxidative stress. Cardiac data complicate that reading: in heart-specific frataxin-knockout mice, respiration is markedly impaired and mitochondrial iron aggregates accumulate while oxidative stress does not rise, and the lesion instead tracks with disrupted mitophagy through the mTOR-TFEB lysosomal axis. In DRG neurons the dominant mode is ferroptosis, an explicitly oxidative, iron-dependent death. Nothing in the current model explains the divergence, and it is not merely academic: it predicts that anti-ferroptotic and pro-mitophagy agents would have organ-specific rather than global benefit, which is one reading of why antioxidant trials did not improve cardiac endpoints. The evidence is also internally contested, because the biomineral iron deposits characterised in the muscle-creatine-kinase conditional frataxin-knockout mouse heart were argued to contribute to oxidative stress there. Resolution needs oxidative-stress and mitophagy markers measured side by side in the two tissues, ideally in patient material rather than in complete tissue-specific knockouts, which model a deeper deficiency than the 5-30% residual frataxin that patients carry.

Show evidence (2 references)

PMID:41628678 SUPPORT Model Organism

"mitochondrial respiration was markedly impaired in FRDA hearts, despite the absence of increased oxidative stress"

States the cardiac exception to a uniformly oxidative downstream mechanism, which is what makes the tissue divergence a gap.

PMID:23169664 REFUTE Model Organism

"These mitochondrial aggregates of Fe, phosphorus, and sulfur, probably contribute to the oxidative stress and pathology observed in the absence of frataxin."

Argues the opposite in a muscle-creatine-kinase conditional frataxin-knockout mouse heart, so the claim that cardiac pathology proceeds without oxidative stress is contested rather than settled.

Why is cardiomyopathy severity uncorrelated with neurological severity in FRDA, and what tissue-specific modifiers decouple the two arms of the pathograph?

KNOWLEDGE GAP OPEN cardiac_neurologic_severity_dissociation_frda

Attached to

pathophysiology#Cardiomyocyte Mitochondrial Injury phenotypes#Hypertrophic Cardiomyopathy

A comprehensive cardiac assessment of 205 FRDA patients, combining echocardiography, colour Doppler myocardial imaging and cardiac magnetic resonance, found no clear correlation between cardiomyopathy grouping and neurological function. The entry draws both the cardiac and the neurological branches from one shared mitochondrial node, which implicitly predicts that they should track together. They do not. Candidate explanations include tissue-specific somatic GAA repeat lengths, differing effector pathways, and modifier loci, none of which is established. This matters for trial design, because a therapy chosen on a neurological endpoint may say nothing about cardiac benefit. The observation is cross-sectional and grouping-based, so it establishes a dissociation rather than independent causation; longitudinal organ-specific progression data would be needed to go further.

Show evidence (1 reference)

PMID:22379112 SUPPORT Human Clinical

"Importantly, no clear correlation was found between FA-CM groups and neurological function."

Cross-sectional study of 205 patients reporting the dissociation between cardiac and neurological severity that this gap records.

Is the loss of microglial homeostatic function in frataxin deficiency an independent driver of cerebellar degeneration, or a secondary response to neuronal injury?

KNOWLEDGE GAP OPEN neuroinflammation_primary_vs_secondary_frda

Attached to

pathophysiology#Dentate Nucleus and Spinocerebellar Tract Degeneration

Single-cell RNA sequencing of the cerebellum in an FRDA mouse model shows frataxin-deficient microglia losing their homeostatic signature, responding more strongly to inflammatory stimuli, and shifting metabolically toward glycolysis and itaconate production; butyrate reverses those changes and improves neuromotor performance. If neuroinflammation amplifies degeneration independently, anti-inflammatory therapy could slow progression without restoring frataxin, which would be a therapeutic route the current pathograph does not contain. The supporting evidence is one mouse single-cell dataset, with no human FRDA cerebellar microglial profiling, so the mechanism is deliberately not modelled as a pathophysiology node. A microglia-specific conditional FXN knockout with intact neuronal frataxin would separate the two readings.

Show evidence (1 reference)

PMID:38631900 SUPPORT Model Organism

"emphasizing a significant loss in the homeostatic response of microglial cells lacking FXN"

Single-cell RNA sequencing in an FRDA mouse cerebellum establishes the microglial phenotype whose causal position this gap leaves open.

How much of FRDA tissue-selective vulnerability is explained by somatic GAA repeat instability, given that heart and pancreas carry longer tracts than the dorsal root ganglia that are affected earliest?

KNOWLEDGE GAP OPEN somatic_gaa_instability_tissue_selectivity_frda

Attached to

genetic#FXN pathophysiology#FXN GAA Repeat Expansion and Epigenetic Silencing

GAA tracts measured across heart, cerebral cortex, spinal cord, cerebellar cortex and pancreas from 15 FRDA patients are significantly longer in heart and pancreas than elsewhere, and lymphocyte tracts expand progressively by up to about nine repeats per year over 7 to 9 years of follow-up. Because repeat length is inversely related to residual frataxin, somatic expansion is an obvious candidate for tissue selectivity, and if it is a major driver then mismatch-repair modulation aimed at repeat contraction becomes a disease-modifying strategy. The candidate does not fit the clinical ordering, however: dorsal root ganglion pathology appears earliest and most severely despite shorter tracts than heart. No study has yet paired tissue-specific repeat length with tissue-specific frataxin protein levels and organ-specific progression in the same patients, so the quantitative contribution is unresolved and the entry does not model somatic instability as a causal step.

Show evidence (1 reference)

PMID:29261783 SUPPORT Human Clinical

"Results demonstrate differences in the lengths of the expanded GAAs among different tissues, with significantly longer GAA tracts detected in heart and pancreas than in other tissues."

Establishes tissue-specific somatic repeat lengths in patient autopsy tissue, the observation whose pathogenic weight this gap records as unquantified.

⚙

Pathophysiology

FXN GAA Repeat Expansion and Epigenetic Silencing

Biallelic expansion of the GAA repeat in intron 1 of FXN produces a non-coding repeat-expansion loss-of-expression mechanism. Repressive chromatin around the expanded repeat lowers FXN transcription and reduces frataxin abundance, establishing the upstream genetic lesion for all downstream FRDA pathograph paths.

Canonical FXN Loss-of-Function Mitochondrial Pathograph

FXN hgnc:3951

regulation of gene expression GO:0010468 ↓ DECREASED chromatin organization GO:0006325 ↕ DYSREGULATED

Animal models

Humanized FXN GAA-repeat YAC transgenic mouse (YG8R/YG22R) Mouse recapitulates Frataxin reduction arises from an unstable human GAA expansion within the appropriate genomic context, which is what makes this model usable for testing repeat- and chromatin-directed strategies.

Downstream

Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect FXN transcriptional silencing reduces frataxin, the mitochondrial protein required for the canonical FRDA loss-of-function path.

Show evidence (2 references)

PMID:32826895 SUPPORT In Vitro

"Friedreich's ataxia (FRDA) is an autosomal-recessive neurodegenerative and cardiac disorder which occurs when transcription of the FXN gene is silenced due to an excessive expansion of GAA repeats into its first intron."

Defines the upstream FXN repeat-expansion silencing mechanism in a human iPSC-derived DRG organoid study.

PMID:21315377 SUPPORT Human Clinical

"The pathogenic mutation in Friedreich's ataxia (FRDA) is a homozygous guanine-adenine-adenine (GAA) trinucleotide repeat expansion on chromosome 9q13 that causes a transcriptional defect of the frataxin gene."

Human pathology review states that the repeat expansion causes a transcriptional defect of FXN.

Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect

Reduced frataxin impairs mitochondrial iron-sulfur cluster biosynthesis, oxidative phosphorylation, and iron handling. This common biochemical lesion feeds the tissue-specific branches that explain sensory ataxia, dysarthria, cardiomyopathy, diabetes, and skeletal deformity.

Canonical FXN Loss-of-Function Mitochondrial Pathograph

sensory neuron of dorsal root ganglion CL:1001451 neuron CL:0000540 cardiac muscle cell CL:0000746 pancreatic beta cell CL:0000169

FXN hgnc:3951

iron-sulfur cluster assembly GO:0016226 ↓ DECREASED oxidative phosphorylation GO:0006119 ↓ DECREASED intracellular iron ion homeostasis GO:0006879 ↕ DYSREGULATED

mitochondrion GO:0005739

dorsal root ganglion UBERON:0000044 cerebellum UBERON:0002037 heart UBERON:0000948 pancreas UBERON:0001264

Downstream

Mitochondrial Bioenergetic Failure and Oxidative Stress Defective Fe-S cluster biogenesis lowers activity of mitochondrial respiratory-chain and Fe-S enzymes, producing energy failure, iron dysregulation, and oxidative stress.

Show evidence (3 references)

PMID:14653404 SUPPORT Human Clinical

"the unstable GAA expansion that underlies FA causes a deficiency of the mitochondrial protein frataxin, leading to potentially harmful oxidative injury associated with excessive iron deposits in mitochondria. In addition, pathogenesis may involve a primary defect in synthesis of iron-sulfur..."

Confirms frataxin deficiency, mitochondrial iron accumulation, and iron-sulfur cluster assembly defect as the pathogenic mechanism.

PMID:31456208 SUPPORT Human Clinical

"This protein is essential for mitochondrial function by the involvement of iron-sulfur cluster biogenesis. The effects of its deficiency also include disruption of cellular, particularly mitochondrial, iron homeostasis, i.e., relatively more iron accumulated in mitochondria and less iron..."

Confirms frataxin's role in iron-sulfur cluster biogenesis and mitochondrial iron accumulation upon deficiency.

PMID:39337401 SUPPORT Human Clinical

"At a cellular level, frataxin deficiency results in insufficient iron-sulfur cluster biosynthesis and impaired mitochondrial function and adenosine triphosphate production."

Recent review states the core biochemical consequence that bridges frataxin deficiency to mitochondrial energy failure.

Mitochondrial Bioenergetic Failure and Oxidative Stress

Frataxin-deficient cells show impaired electron transport, altered mitochondrial morphology, abnormal iron handling, and oxidative stress. This shared mitochondrial stress state is the branch point for sensory neuronal, cerebellar, cardiac, pancreatic beta-cell, and musculoskeletal outcomes.

Canonical FXN Loss-of-Function Mitochondrial Pathograph

sensory neuron of dorsal root ganglion CL:1001451 cardiac muscle cell CL:0000746 pancreatic beta cell CL:0000169

oxidative phosphorylation GO:0006119 ↓ DECREASED response to oxidative stress GO:0006979 ↑ INCREASED intracellular iron ion homeostasis GO:0006879 ↕ DYSREGULATED

mitochondrion GO:0005739

Animal models

Conditional Fxn knockout mouse (MCK-Cre and NSE-Cre) Mouse recapitulates Establishes the ordering within this node: Fe-S-dependent enzyme inactivation and overt pathology precede intramitochondrial iron accumulation, so iron deposition is a consequence rather than an initiator.

Downstream

Dorsal Root Ganglion Sensory Neuronopathy Sensory neurons in dorsal root ganglia are especially vulnerable to the mitochondrial consequences of frataxin deficiency, causing the proprioceptive sensory branch of FRDA.

Dentate Nucleus and Spinocerebellar Tract Degeneration Mitochondrial frataxin deficiency also injures the cerebellar dentate nucleus and spinocerebellar/dorsal-column systems, adding a central cerebellar component to the sensory ataxia path.

Corticospinal Tract Degeneration Mitochondrial frataxin deficiency injures the corticospinal (pyramidal) tracts as a separate intrinsic CNS lesion, in parallel with the DRG, dentate, and optic-nerve lesions.

Optic Atrophy Optic atrophy is a separate intrinsic central nervous system lesion of FRDA, reflecting degeneration of the optic nerve and retinal ganglion cell visual pathway rather than the dentate/spinocerebellar system.

Muscle Weakness Mitochondrial bioenergetic failure in FRDA affects skeletal muscle and contributes to progressive limb weakness and fatigue.

Cardiomyocyte Mitochondrial Injury Frataxin-deficient cardiomyocytes accumulate iron-positive mitochondrial injury and structural myocyte pathology, producing the cardiac branch of FRDA.

Pancreatic Beta-Cell Apoptosis In pancreatic beta cells, frataxin deficiency causes mitochondrial dysfunction and oxidative stress-mediated intrinsic apoptosis, explaining the diabetes branch of FRDA.

Progressive Skeletal Deformity Neurologic imbalance, sensory neuropathy, weakness, and FRDA skeletal involvement converge on progressive spinal and foot deformity.

Show evidence (1 reference)

PMID:38129330 SUPPORT Model Organism

"Mitochondrial dysfunction, a reduction in the activity of iron-sulfur enzymes, iron accumulation, and increased oxidative stress have been described."

Summarizes the shared mitochondrial and oxidative-stress state produced by frataxin deficiency.

Dorsal Root Ganglion Sensory Neuronopathy

FRDA injures dorsal root ganglion sensory neurons and their satellite-cell niche, causing loss of proprioceptive and vibration-sense input. This explains sensory neuropathy, areflexia, impaired balance, and a major upstream component of progressive gait and limb ataxia. Human neuropathology describes the ganglion lesion as dual-phase rather than purely degenerative: developmental hypoplasia of the sensory neurons, on which progressive atrophy and satellite-cell absorption are later superimposed. The dominant cell-death mode in frataxin-deficient DRG neurons is ferroptosis, driven by an impaired NRF2 response with loss of SLC7A11 and glutathione peroxidase 4 and consequent lipid peroxidation, which distinguishes this arm of the pathograph from the mitophagy-failure arm in cardiomyocytes.

Canonical FXN Loss-of-Function Mitochondrial Pathograph

sensory neuron of dorsal root ganglion CL:1001451 glial cell CL:0000125

ferroptosis GO:0097707 ↑ INCREASED

dorsal root ganglion UBERON:0000044

Animal models

Conditional Fxn knockout mouse (MCK-Cre and NSE-Cre) Mouse recapitulates The NSE-Cre line reproduces large sensory neuron dysfunction while sparing small sensory and motor neurons, the same fibre-size selectivity seen in human FRDA.

Humanized FXN GAA-repeat YAC transgenic mouse (YG8R/YG22R) Mouse partially recapitulates Dorsal root ganglion neurons develop large vacuoles with a lumbar-to-cervical progression, alongside coordination deficits on rotarod.

Downstream

Peripheral Neuropathy DRG and sensory nerve injury produces the peripheral sensory neuropathy phenotype with loss of proprioception and vibration sense.

Progressive Gait and Limb Ataxia Loss of proprioceptive sensory input from DRG injury produces sensory ataxia that combines with cerebellar pathway degeneration.

Areflexia of Lower Limbs Loss of large sensory afferents from dorsal root ganglion neuronopathy interrupts the deep tendon reflex arc, producing the early lower-limb areflexia that is a cardinal diagnostic sign of FRDA.

Impaired Proprioception Destruction of the large primary sensory neurons of the dorsal root ganglia removes the joint-position afferents carried in the dorsal columns, producing the proprioceptive deficit directly.

Impaired Vibratory Sensation The same loss of large-diameter dorsal root ganglion afferents and their dorsal column projections removes vibration sense, which is carried by the same pathway as joint position sense.

Show evidence (3 references)

PMID:27142428 SUPPORT Human Clinical

"FA causes major primary changes in satellite cells and inflammatory destruction of neurons."

Human DRG pathology supports neuron and satellite-cell injury as a proximal neuropathologic event.

PMID:23334592 SUPPORT Human Clinical

"This review of the neuropathology of Friedreich ataxia stresses the critical role of hypoplasia and superimposed atrophy of dorsal root ganglia."

Systematic neuropathology of 35 FRDA patients establishes the dual-phase ganglion lesion, adding a developmental hypoplasia component that a purely degenerative reading of this node would miss.

PMID:39243573 SUPPORT Model Organism

"frataxin deficiency in DRG neurons disrupts iron homeostasis and the intricate regulation of molecular pathways affecting NRF2 activation and the cellular response to oxidative stress, leading to ferroptosis"

Primary DRG cultures and FXNI151F mouse ganglia both show the NRF2 and GPX4 loss that drives lipid peroxidation, grounding the ferroptosis annotation on this node.

Dentate Nucleus and Spinocerebellar Tract Degeneration

FRDA affects the dentate nucleus, dorsal columns, and spinocerebellar tracts. This central cerebellar and spinocerebellar involvement combines with sensory neuronopathy to drive progressive ataxia and dysarthria. (The corticospinal/pyramidal lesion is modeled separately as the Corticospinal Tract Degeneration node.)

Canonical FXN Loss-of-Function Mitochondrial Pathograph

neuron CL:0000540

dentate nucleus UBERON:0002132 spinal cord UBERON:0002240

Downstream

Progressive Gait and Limb Ataxia Dentate and spinocerebellar tract degeneration add a cerebellar motor control deficit to the sensory ataxia branch.

Dysarthria Cerebellar and bulbar pathway degeneration contributes to impaired speech motor coordination.

Dysphagia Cerebellar and bulbar pathway dysfunction can impair swallowing motor coordination, producing dysphagia as part of the classical FRDA neurologic phenotype.

Nystagmus Central nervous system involvement in FRDA produces oculomotor disturbance, including nystagmus.

Show evidence (1 reference)

PMID:21315377 SUPPORT Human Clinical

"Destruction of the DN, optic atrophy, and degeneration of the corticospinal tracts are intrinsic central nervous system lesions."

Supports dentate nucleus (DN) degeneration as an intrinsic CNS lesion in FRDA.

Corticospinal Tract Degeneration

Degeneration of the corticospinal (pyramidal) tracts is an intrinsic central nervous system lesion of FRDA, distinct from the DRG-secondary spinocerebellar and dorsal-column involvement. It produces the upper motor neuron signs of the disease (extensor plantar response and lower-limb spasticity/hyperreflexia), which coexist with the areflexia caused by the peripheral sensory neuropathy.

Canonical FXN Loss-of-Function Mitochondrial Pathograph

Betz upper motor neuron CL:4023052

corticospinal tract UBERON:0002707

Downstream

Extensor Plantar Response (Babinski Sign) Corticospinal (pyramidal) tract degeneration produces upper motor neuron signs, including an extensor plantar (Babinski) response.

Spasticity Corticospinal tract degeneration also produces lower-limb spasticity and hyperreflexia as the disease progresses.

Show evidence (1 reference)

PMID:21315377 SUPPORT Human Clinical

"Destruction of the DN, optic atrophy, and degeneration of the corticospinal tracts are intrinsic central nervous system lesions."

Human pathology review identifies corticospinal tract degeneration as an intrinsic CNS lesion of FRDA, distinct from the DRG-secondary spinocerebellar/dorsal-column lesions.

Cardiomyocyte Mitochondrial Injury

In the heart, frataxin deficiency produces cardiomyocyte hypertrophy, iron-positive inclusions, and disrupted intercalated discs. The clinical downstream manifestation is hypertrophic cardiomyopathy, a major determinant of premature mortality in FRDA. Heart-specific frataxin-knockout mice locate the cardiac lesion in a failure of mitochondrial quality control rather than in oxidative injury: mitochondrial iron aggregates and severely altered ultrastructure accumulate alongside p62 and Parkin, indicating disrupted mitophagy through a dysregulated mTOR-TFEB lysosomal axis, and respiration is markedly impaired without a rise in oxidative stress. That mouse result is not the whole picture, since the biomineral iron aggregates of the muscle-creatine-kinase conditional frataxin-knockout mouse heart have separately been argued to contribute to cardiac oxidative stress; the disagreement is recorded in the tissue-divergence discussion.

Canonical FXN Loss-of-Function Mitochondrial Pathograph

cardiac muscle cell CL:0000746

oxidative phosphorylation GO:0006119 ↓ DECREASED mitophagy GO:0000423 ↓ DECREASED

myocardium UBERON:0002349

Animal models

Conditional Fxn knockout mouse (MCK-Cre and NSE-Cre) Mouse recapitulates The MCK-Cre line reproduces cardiac hypertrophy without skeletal muscle involvement, matching the organ selectivity of human FRDA cardiomyopathy.

AAV9-hFXN gene therapy rescue in conditional Fxn knockout mice Mouse rescues A single systemic dose preserved cardiac systolic function and more than doubled survival, which is the preclinical basis for the AAV gene therapy programmes curated under treatments.

Downstream

Hypertrophic Cardiomyopathy Cardiomyocyte hypertrophy and mitochondrial injury produce the common hypertrophic cardiomyopathy phenotype.

Show evidence (2 references)

PMID:28789479 SUPPORT Human Clinical

"Microscopy showed cardiomyocyte hypertrophy, iron-positive inclusions, and disrupted intercalated discs."

Human tissue pathology supports the cardiomyocyte injury node.

PMID:41628678 SUPPORT Model Organism

"the clearance of damaged or dysfunctional mitochondria (i.e., mitophagy) is disrupted, as evidenced by excessive accumulation of p62 and Parkin proteins"

Heart-specific frataxin-knockout mice show p62 and Parkin accumulation with lysosomal mTOR-TFEB dysregulation, grounding the mitophagy annotation on this node.

Pancreatic Beta-Cell Apoptosis

Frataxin-deficient pancreatic beta cells undergo mitochondrial dysfunction, oxidative stress, and intrinsic apoptosis, explaining why a subset of FRDA patients develop diabetes mellitus.

Canonical FXN Loss-of-Function Mitochondrial Pathograph

pancreatic beta cell CL:0000169

apoptotic process GO:0006915 ↑ INCREASED response to oxidative stress GO:0006979 ↑ INCREASED

pancreas UBERON:0001264

Downstream

Diabetes Mellitus Beta-cell dysfunction and death reduce insulin secretory capacity and produce the FRDA diabetes phenotype.

Show evidence (1 reference)

PMID:25552656 SUPPORT In Vitro

"Here we show that β-cell demise in frataxin deficiency is the consequence of oxidative stress-mediated activation of the intrinsic pathway of apoptosis."

Demonstrates the beta-cell apoptosis mechanism downstream of frataxin deficiency.

Progressive Skeletal Deformity

FRDA skeletal involvement includes progressive scoliosis and pes cavus. The mechanism is represented as an indirect downstream path from the FXN loss-of-function multisystem disorder through neuromuscular imbalance, weakness, sensory neuropathy, and skeletal involvement.

Canonical FXN Loss-of-Function Mitochondrial Pathograph

skeleton UBERON:0001434

Downstream

Scoliosis Progressive skeletal deformity manifests as scoliosis in the FRDA phenotype list.

Pes Cavus Progressive skeletal and neuromuscular involvement manifests as pes cavus in the FRDA phenotype list.

Show evidence (1 reference)

PMID:21315377 SUPPORT Human Clinical

"Scoliosis and foot deformity (pes cavus) may also be early signs and precede ataxia."

Human clinical-pathology review supports scoliosis and pes cavus as FRDA skeletal manifestations.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Cardiovascular 1

Hypertrophic Cardiomyopathy FREQUENT HP:0001639

Show evidence (3 references)

PMID:23859346 SUPPORT Human Clinical

"his description remains at the core of the classical clinical phenotype of gait and limb ataxia, poor balance and coordination, leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes."

Cardiomyopathy is listed as part of the classical Friedreich ataxia phenotype.

ORPHA:95 SUPPORT Other

"HP:0001638 | Cardiomyopathy | Frequent (79-30%)"

Orphanet's HPO table supports cardiomyopathy as a frequent Friedreich ataxia phenotype.

PMID:20301458 SUPPORT Human Clinical

"Hypertrophic cardiomyopathy is present in about two thirds of individuals"

GeneReviews states hypertrophic cardiomyopathy is present in about two-thirds of individuals, supporting the FREQUENT band.

Digestive 1

Dysphagia OCCASIONAL HP:0002015

Show evidence (2 references)

PMID:23859346 SUPPORT Human Clinical

"leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities"

Lists dysphagia among the classical FRDA clinical features.

ORPHA:95 SUPPORT Other

"HP:0002015 | Dysphagia | Occasional (29-5%)"

Orphanet's HPO table supports dysphagia as an occasional Friedreich ataxia phenotype.

Ear 1

Hearing Impairment OCCASIONAL HP:0000365

Bound to the generic HP:0000365 rather than a sensorineural child term. Orphanet's own row uses the generic term, and the audiological picture in FRDA is an auditory neuropathy, so a cochlear-sensorineural binding would be narrower than the cited evidence supports.

Show evidence (5 references)

ORPHA:95 SUPPORT Other

"HP:0000365 | Hearing impairment | Occasional (29-5%)"

Orphanet's HPO table classifies hearing impairment as an occasional Friedreich ataxia phenotype.

PMID:25928624 SUPPORT INDIRECT Other

"Conventional hearing aids and cochlear implants may not improve the hearing impairment related to FRDA."

Supports the retrocochlear character of the deficit by inference: the guidelines state that devices addressing cochlear and conductive loss may not help, rather than naming the lesion site directly. Graded OTHER because this particular recommendation carries the guideline's GPP (good practice point) marker, i.e. expert consensus, where its neighbours in the same block carry graded evidence.

PMID:21315377 SUPPORT Human Clinical

"Despite normal pure-tone audiometry, patients with FRDA may have problems with speech perception"

Documents preserved pure-tone thresholds alongside impaired speech perception, the audiometric signature of a retrocochlear rather than cochlear lesion.

+ 2 more references

Endocrine 1

Diabetes Mellitus OCCASIONAL HP:0000819

Show evidence (2 references)

PMID:23859346 SUPPORT Human Clinical

"scoliosis, foot deformities, cardiomyopathy and diabetes."

Diabetes is part of the classical phenotype description.

ORPHA:95 SUPPORT Other

"HP:0000819 | Diabetes mellitus | Occasional (29-5%)"

Orphanet's HPO table supports diabetes mellitus as an occasional Friedreich ataxia phenotype.

Eye 2

Nystagmus FREQUENT HP:0000639

Show evidence (3 references)

PMID:23859346 SUPPORT Human Clinical

"dysarthria, dysphagia, eye movement abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes"

Lists eye movement abnormalities among the classical FRDA clinical features.

PMID:21315377 SUPPORT Human Clinical

"Many patients with FRDA have nystagmus."

Directly supports nystagmus as a common FRDA neurologic manifestation.

ORPHA:95 SUPPORT Other

"HP:0000639 | Nystagmus | Frequent (79-30%)"

Orphanet's HPO table supports nystagmus as a frequent Friedreich ataxia phenotype.

Optic Atrophy FREQUENT HP:0000648

Show evidence (3 references)

PMID:20301458 SUPPORT Human Clinical

"and often abnormal eye movements and optic atrophy"

GeneReviews lists optic atrophy among the clinical characteristics of Friedreich ataxia.

PMID:21315377 SUPPORT Human Clinical

"Optic atrophy is uncommon but some patients become blind."

Human pathology review notes clinically apparent optic atrophy is uncommon but can progress to blindness, qualifying the frequency of overt visual loss.

ORPHA:95 SUPPORT Other

"HP:0000648 | Optic atrophy | Frequent (79-30%)"

Orphanet's HPO table classifies optic atrophy as a frequent Friedreich ataxia phenotype.

Limbs 2

Pes Cavus FREQUENT HP:0001761

Show evidence (2 references)

PMID:23859346 SUPPORT Human Clinical

"Early-onset cases tend to have more rapid progression and a higher frequency of non-neurological features such as diabetes, cardiomyopathy, scoliosis and pes cavus."

Pes cavus is more frequent in early-onset cases.

ORPHA:95 SUPPORT Other

"HP:0001761 | Pes cavus | Frequent (79-30%)"

Orphanet's HPO table supports pes cavus as a frequent Friedreich ataxia phenotype.

Areflexia of Lower Limbs FREQUENT HP:0002522

Show evidence (2 references)

PMID:21315377 SUPPORT Human Clinical

"atrophy and weakness of the distal extremities, absence of muscle stretch reflexes"

Human pathology review lists absence of muscle stretch reflexes among the most frequent neurologic signs in FRDA.

ORPHA:95 SUPPORT Other

"HP:0002522 | Areflexia of lower limbs | Frequent (79-30%)"

Orphanet's HPO table classifies areflexia of lower limbs as a frequent Friedreich ataxia phenotype.

Musculoskeletal 3

Muscle Weakness FREQUENT HP:0001324

Show evidence (3 references)

PMID:23859346 SUPPORT Human Clinical

"leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities"

Lists leg weakness among the classical FRDA clinical features.

PMID:21315377 SUPPORT Human Clinical

"The following neurological signs are most frequent: Gait ataxia, dysmetria of arms and legs, dysarthria, head titubation, atrophy and weakness of the distal extremities"

Identifies distal extremity weakness among the most frequent neurologic signs in FRDA.

ORPHA:95 SUPPORT Other

"HP:0001324 | Muscle weakness | Frequent (79-30%)"

Orphanet's HPO table supports muscle weakness as a frequent Friedreich ataxia phenotype.

Scoliosis FREQUENT HP:0002650

Show evidence (2 references)

PMID:23859346 SUPPORT Human Clinical

"scoliosis, foot deformities, cardiomyopathy and diabetes."

Scoliosis is part of the classical phenotype.

ORPHA:95 SUPPORT Other

"HP:0002650 | Scoliosis | Frequent (79-30%)"

Orphanet's HPO table supports scoliosis as a frequent Friedreich ataxia phenotype.

Spasticity OCCASIONAL HP:0001257

Show evidence (2 references)

PMID:21315377 SUPPORT Human Clinical

"Spasticity and hyperreflexia in the legs are no longer rare."

Human pathology review documents lower-limb spasticity and hyperreflexia in FRDA from corticospinal tract involvement.

ORPHA:95 SUPPORT Other

"HP:0001257 | Spasticity | Occasional (29-5%)"

Orphanet's HPO table classifies spasticity as an occasional Friedreich ataxia phenotype.

Nervous System 6

Progressive Gait and Limb Ataxia VERY_FREQUENT HP:0001251

Show evidence (2 references)

PMID:23859346 SUPPORT Human Clinical

Comprehensive description of the classical Friedreich ataxia phenotype with ataxia as the core feature.

ORPHA:95 SUPPORT Other

"HP:0002070 | Limb ataxia | Very frequent (99-80%)"

Orphanet's HPO table supports very frequent limb ataxia in Friedreich ataxia.

Dysarthria VERY_FREQUENT HP:0001260

Show evidence (2 references)

PMID:23859346 SUPPORT Human Clinical

"gait and limb ataxia, poor balance and coordination, leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia"

Dysarthria is part of the classical phenotype.

ORPHA:95 SUPPORT Other

"HP:0001260 | Dysarthria | Very frequent (99-80%)"

Orphanet's HPO table supports dysarthria as a very frequent Friedreich ataxia phenotype.

Peripheral Neuropathy VERY_FREQUENT HP:0009830

Show evidence (2 references)

PMID:20301458 SUPPORT Human Clinical

"peripheral motor and sensory neuropathy, spasticity, autonomic disturbance"

GeneReviews lists peripheral motor and sensory neuropathy among the core clinical characteristics of typical Friedreich ataxia.

PMID:21315377 SUPPORT Human Clinical

"loss of joint and vibratory senses, and superimposed stocking-and-glove type sensory neuropathy"

Human pathology review documents the sensory (proprioceptive/vibratory) loss and stocking-and-glove sensory neuropathy of FRDA.

Extensor Plantar Response (Babinski Sign) VERY_FREQUENT HP:0003487

Show evidence (2 references)

PMID:21315377 SUPPORT Human Clinical

"absence of muscle stretch reflexes, Babinski signs, loss of joint and vibratory senses"

Human pathology review lists Babinski signs among the most frequent neurologic signs in FRDA, reflecting corticospinal tract degeneration.

ORPHA:95 SUPPORT Other

"HP:0003487 | Babinski sign | Very frequent (99-80%)"

Orphanet's HPO table classifies Babinski sign as a very frequent Friedreich ataxia phenotype.

Impaired Proprioception VERY_FREQUENT HP:0010831

Show evidence (2 references)

PMID:25928624 SUPPORT Human Clinical

"The hallmark clinical features of FRDA include progressive afferent and cerebellar ataxia, dysarthria, impaired vibration sense and proprioception, absent tendon reflexes in lower limbs, pyramidal weakness, scoliosis, foot deformity and cardiomyopathy"

The international consensus management guidelines list impaired proprioception among the hallmark clinical features of FRDA.

ORPHA:95 SUPPORT Other

"HP:0010831 | Impaired proprioception | Very frequent (99-80%)"

Orphanet's HPO table classifies impaired proprioception as a very frequent Friedreich ataxia phenotype.

Impaired Vibratory Sensation FREQUENT HP:0002495

The FREQUENT band is Orphanet's. It sits a tier below the VERY_FREQUENT band Orphanet gives impaired proprioception, even though the consensus guideline sentence cited above lists the two together as hallmark features and the Koeppen pathology review counts loss of joint and vibratory senses among the most frequent signs. The bands are kept as Orphanet records them and the divergence is noted rather than resolved.

Show evidence (2 references)

PMID:25928624 SUPPORT Human Clinical

The international consensus management guidelines list impaired vibration sense among the hallmark clinical features of FRDA.

ORPHA:95 SUPPORT Other

"HP:0002495 | Impaired vibratory sensation | Frequent (79-30%)"

Orphanet's HPO table classifies impaired vibratory sensation as a frequent Friedreich ataxia phenotype.

🧬

Genetic Associations

FXN (GAA Trinucleotide Repeat Expansion)

Gene: FXN hgnc:3951 relationship_type: CAUSATIVE variant_origin: GERMLINE

Autosomal recessive inheritance

Show evidence (7 references)

PMID:14653404 SUPPORT Human Clinical

"the unstable GAA expansion that underlies FA causes a deficiency of the mitochondrial protein frataxin"

Confirms GAA expansion as the causative mutation leading to frataxin deficiency.

PMID:23859346 SUPPORT Human Clinical

"Inheritance is autosomal recessive with the vast majority of cases showing an unstable intronic GAA expansion in both alleles of the frataxin gene on chromosome 9q13."

Confirms autosomal recessive inheritance with homozygous GAA expansion in FXN.

CGGV:assertion_ec3f674b-1e71-4254-a0f9-f8909becff59-2017-12-22T170000.000Z SUPPORT Other

ClinGen classifies the FXN-Friedreich ataxia gene-disease relationship as definitive with autosomal recessive inheritance.

+ 4 more references

Variants (1)

FXN intron 1 GAA repeat expansion Pathogenic

Gene: FXN hgnc:3951 trinucleotide repeat expansion

Pathogenic non-coding trinucleotide repeat expansion in intron 1 of FXN that silences FXN transcription. Most affected individuals are homozygous for expanded alleles; a minority are compound heterozygous for one expansion plus an FXN deletion, point mutation, or insertion.

Functional effects

FXN transcription loss-of-expression LOE SILENCER

Expanded intronic GAA repeat causes reduced FXN transcription through repressive chromatin and transcriptional silencing.

Mechanism: Repressive chromatin formation around the expanded intron 1 GAA repeat.

Show evidence (1 reference)

PMID:32826895 SUPPORT In Vitro

Supports the variant-level functional effect of the GAA repeat expansion as FXN transcriptional silencing.

🗃️

External Assertions

Orphanet Friedreich ataxia structured record

Orphanet structured disease record ORPHA:95

Orphanet records Friedreich ataxia as ORPHA:95 and provides external cross-references supporting this entry's disease identity.

Show evidence (3 references)

ORPHA:95 SUPPORT Other

"MONDO:0100339 | Exact"

Orphanet lists the MONDO disease identifier as an exact cross-reference.

ORPHA:95 SUPPORT Other

"OMIM:229300 | Exact"

Orphanet lists the primary OMIM disease identifier as an exact cross-reference.

ORPHA:95 SUPPORT Other

"ICD-11:8A03.10 | Exact"

Orphanet lists the ICD-11 disease code as an exact cross-reference.

💊

Medical Actions

Omaveloxolone

Action: Pharmacotherapy NCIT:C15986

Agent: omaveloxolone CHEBI:229661

Approved pharmacotherapy for individuals with Friedreich ataxia aged 16 years and older. It is used to slow neurologic progression by modulating oxidative-stress and mitochondrial-function pathways rather than restoring FXN expression directly.

Mechanism Target:

MODULATES Mitochondrial Bioenergetic Failure and Oxidative Stress — Omaveloxolone acts downstream of FXN silencing by targeting the oxidative stress and mitochondrial dysfunction branch of the pathograph.

Show evidence (2 references)

PMID:39115603 SUPPORT Human Clinical

"Currently therapies focus on reducing oxidative stress and improving mitochondrial function, modulating frataxin controlled metabolic pathways and gene replacement and editing."

Supports placing approved and emerging pharmacotherapies on the oxidative-stress/mitochondrial-function mechanism branch.

PMID:33068037 SUPPORT Other

"Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and reduces inflammation in models of FA."

Names Nrf2 activation as the mechanism by which the drug acts on this node. Graded OTHER because the sentence is the trial report's background summary of preclinical model work and does not say which model systems produced it.

MODULATES Dorsal Root Ganglion Sensory Neuronopathy — As an NRF2 activator, omaveloxolone acts on the ferroptosis arm of the sensory-neuron branch, restoring NRF2 levels and reducing the lipid peroxidation that marks ferroptotic death of frataxin-deficient DRG neurons.

Show evidence (1 reference)

PMID:41579709 SUPPORT In Vitro

"lipid peroxidation, a key marker of ferroptosis that was increased in frataxin-deficient neurons, was almost completely rescued by omaveloxolone"

Frataxin-deficient DRG neurons treated with omaveloxolone show near-full rescue of the ferroptosis marker, linking the approved drug to this specific node rather than only to the shared mitochondrial branch.

Show evidence (3 references)

PMID:39115603 SUPPORT Human Clinical

"Approval of omaveloxolone, the first treatment for individuals with FRDA aged 16 years and over, has created much excitement for both those living with FRDA and those that care for them."

Recent review states that omaveloxolone is the first approved FRDA treatment for patients aged 16 years and older.

PMID:33068037 SUPPORT DIRECT Human Clinical

"Changes from baseline in mFARS scores in omaveloxolone (-1.55 ± 0.69) and placebo (0.85 ± 0.64) patients showed a difference between treatment groups of -2.40 ± 0.96 (p = 0.014)."

The registrational phase 2 efficacy result: a placebo-corrected mFARS difference of -2.40 at 48 weeks. This is the quantitative basis for treating omaveloxolone as disease-modifying rather than symptomatic.

PMID:33068037 SUPPORT Human Clinical

"Transient reversible increases in aminotransferase levels were observed with omaveloxolone without increases in total bilirubin or other signs of liver injury."

Records the characteristic transaminase signal, which is the reason liver enzymes are monitored on therapy.

Supportive and Symptomatic Care

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Multidisciplinary care including physical therapy, occupational therapy, speech therapy, and orthopedic management of scoliosis and foot deformities. GeneReviews advises avoiding medications that are toxic or potentially toxic to people with peripheral neuropathy, avoiding use/misuse of illegal and controlled drugs (which may exacerbate disease manifestations by affecting neuronal well-being), and minimizing circumstances that increase fall risk.

Show evidence (3 references)

PMID:20301458 SUPPORT Human Clinical

"medications that are toxic or potentially toxic to people with neuropathy"

GeneReviews Agents/Circumstances to Avoid section warns against neurotoxic medications in individuals with the peripheral neuropathy of FRDA.

PMID:29053830 SUPPORT Human Clinical

"Management of Freidreich's ataxia is currently focussed on symptomatic management, delivered by the multidisciplinary team."

Confirms that current management is multidisciplinary and symptomatic.

PMID:29440566 SUPPORT Human Clinical

"For nonpharmacologic options, in patients with degenerative ataxias, 4-week inpatient rehabilitation probably improves ataxia and function (1 Class I study)"

AAN systematic-review guideline supports inpatient rehabilitation for degenerative ataxias (a category that includes Friedreich ataxia) improving ataxia and function.

Cardiac Management

Action: Pharmacotherapy NCIT:C15986

Agent: ACE inhibitor NCIT:C247 beta-adrenergic antagonist NCIT:C29576

Regular cardiac monitoring and treatment of cardiomyopathy and arrhythmias. ACE inhibitors and beta-blockers may be used for heart failure management. The 2022 Heart Rhythm Society expert consensus statement includes Friedreich ataxia among the neuromuscular disorders for which evaluation and management of arrhythmic cardiac manifestations is specifically addressed.

Mechanism Target:

MODULATES Cardiomyocyte Mitochondrial Injury — ACE inhibitors and beta-blockers reduce afterload and sympathetic tone, decreasing myocardial energy demand and partially compensating for the cardiomyocyte mitochondrial bioenergetic failure that drives FRDA cardiomyopathy.

Show evidence (1 reference)

PMID:35500790 SUPPORT Human Clinical

"mitochondrial myopathies, including Friedreich ataxia and Kearns-Sayre syndrome, with an emphasis on managing arrhythmic cardiac manifestations."

The 2022 HRS expert consensus statement on arrhythmic risk in neuromuscular disorders explicitly covers Friedreich ataxia, supporting arrhythmia surveillance and management as part of cardiac care.

Riluzole for Symptomatic Ataxia

Action: Pharmacotherapy NCIT:C15986

Agent: riluzole CHEBI:8863

Platform: Small molecule

Riluzole is a small-molecule glutamate-modulating agent evaluated for symptomatic treatment of cerebellar motor dysfunction. In a Class I trial that included patients with Friedreich ataxia and spinocerebellar ataxia, riluzole probably improved ataxia signs at 12 months, supporting its use as symptomatic (not disease-modifying) therapy for the cerebellar/spinocerebellar degeneration of FRDA.

Mechanism Target:

MODULATES Dentate Nucleus and Spinocerebellar Tract Degeneration — Riluzole provides symptomatic benefit for cerebellar motor dysfunction without addressing the underlying FXN deficiency, acting downstream on the spinocerebellar/dentate degeneration that produces ataxia signs.

Show evidence (1 reference)

PMID:29440566 SUPPORT Human Clinical

"For patients with Friedreich ataxia or spinocerebellar ataxia (SCA), riluzole probably improves ataxia signs at 12 months (1 Class I study)."

AAN systematic-review guideline reports Class I evidence that riluzole probably improves ataxia signs at 12 months in patients including those with Friedreich ataxia.

Investigational Frataxin-Restoring Therapies

Action: gene therapy Ontology label: Gene Therapy NCIT:C15238

Platform: Gene therapy

Clinical trials are investigating agents that address the aberrant silencing of the frataxin gene, including histone deacetylase inhibitors, gene therapy approaches, and frataxin replacement strategies.

Mechanism Target:

INHIBITS FXN GAA Repeat Expansion and Epigenetic Silencing — HDAC inhibitors and gene therapy approaches target the epigenetic silencing mechanism driven by the GAA repeat expansion, aiming to restore frataxin transcription at the chromatin level rather than addressing downstream consequences.

Show evidence (1 reference)

PMID:25159818 SUPPORT DIRECT In Vitro

"Chromatin signatures indicate that histone H3 lysine 9 is a key residue for gene silencing through methylation and reactivation through acetylation, mediated by the HDACi."

Identifies the H3K9 chromatin state as the silencing step the HDAC inhibitor acts on, which is the mechanism this treatment link claims rather than the general benefit of the treatment.

INHIBITS Cardiomyocyte Mitochondrial Injury — AAVrh.10hFXN directly replaces frataxin protein in cardiomyocytes, restoring mitochondrial function and reducing cardiac hypertrophy independent of epigenetic de-silencing.

Show evidence (1 reference)

PMID:42373844 SUPPORT INDIRECT Human Clinical

"administration reduces left ventricular mass index (LVMI) and LV wall thickness on echocardiographs"

Reports the cardiac remodeling response to AAVrh.10hFXN. It supports the link to the cardiomyocyte injury node by inference, since the readout is ventricular mass rather than a direct measure of mitochondrial function. A review is cited deliberately: this treatment is the investigational category, so the claim is a synthesis across agents. The dedicated AAVrh.10hFXN Gene Therapy treatment below carries the primary trial (PMID:42307907) and its own link to this node.

Show evidence (4 references)

PMID:29053830 SUPPORT Human Clinical

"Phase II clinical trials in agents that address the abberrant silencing of the frataxin gene need to be translated into large placebo-controlled Phase III trials to help establish their therapeutic potential."

Confirms ongoing clinical development of frataxin-restoring therapies.

PMID:42307907 SUPPORT Human Clinical

"Findings of this nonrandomized clinical trial suggest that intravenous administration of AAVrh.10hFXN was well tolerated and may be a potential treatment for FA cardiomyopathy, as evidenced by preliminary improvement in exploratory efficacy end points."

Clinical trial data demonstrate safety and preliminary efficacy of AAVrh.10hFXN, a direct FXN gene replacement therapy, in 17 FA patients with cardiomyopathy.

PMID:42307907 SUPPORT Human Clinical

"In all 8 patients with cardiac biopsy 3 months after therapy, there were higher levels of cardiac FXN (dose cohort 1, 20%; cohort 2, 81%; cohort 3, 123%)."

Cardiac FXN protein expression increased in a dose-dependent manner following AAVrh.10hFXN administration.

+ 1 more reference

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Genetic counseling for autosomal recessive inheritance pattern and carrier testing for family members. Once the FXN pathogenic variants are identified in an affected individual, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing become possible.

Show evidence (1 reference)

PMID:20301458 SUPPORT Human Clinical

"carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible."

GeneReviews genetic counseling section supports carrier and prenatal/preimplantation testing once the familial FXN variants are known.

AAVrh.10hFXN Gene Therapy

Action: gene therapy Ontology label: Gene Therapy NCIT:C15238

Platform: Gene therapy

Intravenous systemic administration of an adeno-associated virus (AAV) vector (serotype rh.10, cardiotropic) expressing the normal human frataxin (FXN) coding sequence. A nonrandomized clinical trial in 17 adults with FA cardiomyopathy demonstrated dose-dependent cardiac FXN restoration (20-123%), LVMI reduction or stabilization in all patients, and acceptable safety profile with resolution of serious adverse events.

Mechanism Target:

BYPASSES FXN GAA Repeat Expansion and Epigenetic Silencing — AAVrh.10hFXN directly restores FXN expression by supplying the normal FXN coding sequence via systemic AAV vector delivery, bypassing the transcriptional silencing caused by the GAA repeat expansion. This direct restoration approach targets the root genetic lesion rather than downstream consequences.

Show evidence (1 reference)

PMID:42307907 SUPPORT Model Organism

"Preclinical studies have demonstrated that systemic administration of AAVrh.10hFXN, an rh.10 serotype cardiotropic adenoassociated virus (AAV) vector expressing the normal human FXN coding sequence, reverses the cardiomyopathy in FXN-deficient mice."

Preclinical evidence shows AAVrh.10hFXN AAV vector delivers normal FXN and reverses cardiomyopathy in animal models.

MODULATES Cardiomyocyte Mitochondrial Injury — FXN restoration in cardiomyocytes improves mitochondrial iron-sulfur cluster assembly and bioenergetics, reducing oxidative stress and myocardial energy deficit that drive FRDA cardiomyopathy.

Show evidence (1 reference)

PMID:42307907 SUPPORT Human Clinical

"In all 8 patients with cardiac biopsy 3 months after therapy, there were higher levels of cardiac FXN (dose cohort 1, 20%; cohort 2, 81%; cohort 3, 123%)."

Dose-dependent cardiac FXN restoration demonstrated in cardiac biopsies following AAVrh.10hFXN therapy.

Show evidence (4 references)

PMID:42307907 SUPPORT Human Clinical

"Seventeen patients with FA cardiomyopathy"

Clinical trial enrolled 17 patients with FA cardiomyopathy.

PMID:42307907 SUPPORT Human Clinical

"There were 4 serious adverse events, 3 possibly related to prednisone immunosuppression and 1 possibly vector-related myocarditis 12 months after therapy, all of which resolved."

Safety profile demonstrated with resolution of all serious adverse events during trial.

PMID:42307907 SUPPORT Human Clinical

"After therapy, LVMI was lower by at least 10% in 9 patients and stabilized in 8 patients."

Cardiac structural improvement as measured by LVMI reduction or stabilization in all 17 treated patients.

+ 1 more reference

SGT-212 Gene Therapy (Dual-Route AAV)

Action: gene therapy Ontology label: Gene Therapy NCIT:C15238

Platform: Gene therapy

An AAV-based gene therapy expressing the normal human FXN coding sequence, administered via dual routes: MRI-guided intradentate nucleus (IDN) infusion targeting cerebellar degeneration and systemic intravenous infusion targeting cardiac and skeletal muscle. Phase I FALCON trial (NCT07180355) initiated in 2026. Preclinical studies in mice show improved neurobehavioral and cardiac function with increased survival and ~33% reduction in LVMI. Non-human primate studies demonstrate successful dual-route FXN expression in both the dentate nucleus and heart, confirming feasibility of the surgical IDN injection approach in humans. Unlike LX2006 which targets cardiac tissue alone, SGT-212's dual-route design aims to address both neurological and cardiac manifestations of FRDA.

Mechanism Target:

BYPASSES FXN GAA Repeat Expansion and Epigenetic Silencing — SGT-212 restores FXN expression in both cerebellar and cardiac tissues via dual-route AAV delivery, bypassing the transcriptional silencing caused by the GAA repeat expansion and addressing both the neurological and cardiac manifestations of FRDA.

Show evidence (1 reference)

PMID:42373844 SUPPORT DIRECT Model Organism

"Single administration of SGT-212 in parvalbumin-Cre mice driving conditional Fxn knockout in DRG and cerebellar neurons or striated muscle (MCK-Cre) improves neurobehavioral and cardiac function, respectively, and increases survival"

Conditional Fxn-knockout mice carry no GAA expansion, so rescue in this model is evidence that supplying FXN bypasses the silenced locus rather than de-repressing it.

INHIBITS Dentate Nucleus and Spinocerebellar Tract Degeneration — Intradentate nucleus infusion targets the cerebellar dentate nucleus, a primary site of neurodegeneration in FRDA, with the goal of preventing progressive cerebellar ataxia.

Show evidence (1 reference)

PMID:42373844 SUPPORT INDIRECT Other

"MRI-guided neurosurgical placement of cannulas in the DN of cadavers demonstrates the technical feasibility of such an approach in humans"

Supports the anatomical claim by inference: cadaveric cannula placement establishes that the dentate nucleus can be reached in humans, not that doing so slows the degeneration. The NHP biodistribution result is this treatment's entry-level citation and is deliberately not repeated here.

Show evidence (3 references)

PMID:42373844 SUPPORT Model Organism

"Improved survival in neuronal and cardiac Fxn-KO mice. ~two- fold increase in motor function (rotarod latency to fall) and ~33% reduction in LVMI in mice."

Preclinical efficacy demonstrates improved neurologic and cardiac outcomes in murine FRDA models.

PMID:42373844 SUPPORT Model Organism

"Testing on NHPs shows their dual-route approach successfully expresses hFXN protein in the DN and heart"

Non-human primate studies confirm feasibility and success of dual-route FXN expression.

PMID:42373844 SUPPORT Other

"trial (NCT07180355) administered SGT-212 to its first patient"

Phase I FALCON trial initiated in 2026, enrolling first FRDA patient.

CRISPR/ZFN Gene Editing Approaches

Action: gene therapy Ontology label: Gene Therapy NCIT:C15238

Platform: Gene editing

Investigational gene-editing strategies including CRISPR-Cas9 and zinc-finger nucleases (ZFN) targeting the GAA trinucleotide repeat expansion in the FXN gene. Preclinical studies in patient-derived iPSCs demonstrate that GAA repeat removal restores FXN expression and ameliorates cellular phenotypes including improved mitochondrial function and neuronal survival. AAV-delivered CRISPR-Cas9 in mouse models achieves GAA repeat removal in heart, liver, and skeletal muscle, with successful FXN restoration in liver. These approaches offer potential advantages over gene addition by targeting the root genetic cause (the repeat expansion) rather than adding an extra FXN gene, and may reduce risk of FXN overexpression toxicity by restoring endogenous regulatory mechanisms.

Mechanism Target:

INHIBITS FXN GAA Repeat Expansion and Epigenetic Silencing — Gene editing approaches directly target and remove or disrupt the pathogenic GAA repeat expansion, restoring FXN transcription from endogenous regulatory elements and reducing disease at its genetic root.

Show evidence (1 reference)

PMID:42373844 SUPPORT DIRECT In Vitro

"Removal of the GAA repeats from the FXN gene of patient-derived induced pluripotent stem cells (iPSCs) increases FXN protein expression and restores dysregulated gene expression associated with the FRDA cellular phenotype"

Excising the repeat restores FXN expression from the endogenous locus, which is exactly the causal step this link asserts.

Show evidence (3 references)

PMID:42373844 SUPPORT In Vitro

CRISPR and ZFN-mediated GAA repeat removal in patient cells restores FXN expression and normalizes gene expression.

PMID:42373844 SUPPORT In Vitro

"GAA repeats in patient iPSCs, followed by differentiation into neurons, increases FXN, ameliorates the mitochondrial phenotype, mitigates neuronal death, and improves neurite outgrowth"

Functional rescue of neurons after GAA repeat removal demonstrates neuroprotective potential.

PMID:42373844 SUPPORT Model Organism

"AAV-delivered CRISPR-Cas9 with guide RNAs (gRNA) directing removal of GAA repeats in YG8 and YG8sR mice demonstrates sufficient GAA removal in heart, liver, and skeletal muscle, but only increases FXN in the liver"

Proof-of-concept for in vivo CRISPR-mediated GAA repeat removal, though tissue-specific efficacy requires further optimization.

Antisense Oligonucleotide Therapy

Action: Pharmacotherapy NCIT:C15986

Platform: Antisense oligonucleotide Steric blockade

RNA target: FXN hgnc:3951 FXN GAA-repeat-associated transcript

Antisense oligonucleotides (ASOs) targeting the FXN GAA-repeat-associated transcript or disease-causing splice mutations offer a strategy to raise endogenous FXN expression. Modified ASOs directed at the GAA repeat increase FXN protein more than threefold in patient cell lines, and ASOs correcting the c.165+5G>C splice-site mutation restore functional FXN transcript. Unlike gene addition, ASOs act on the endogenous transcript, potentially limiting the risk of FXN overexpression toxicity.

Mechanism Target:

INHIBITS FXN GAA Repeat Expansion and Epigenetic Silencing — GAA-repeat-targeting ASOs sterically relieve repressive elements at the expanded FXN locus to raise endogenous FXN expression, while splice-correcting ASOs restore functional FXN transcript.

Show evidence (1 reference)

PMID:42373844 SUPPORT In Vitro

"Modified ASOs that target the GAA repeat increase FXN protein more than threefold in patient cell lines"

ASOs targeting the GAA repeat raise endogenous FXN protein in patient-derived cells.

🔬

Diagnosis

Molecular Genetic Testing of FXN

The diagnosis of Friedreich ataxia is established in a proband with suggestive clinical findings by identifying biallelic pathogenic FXN variants on molecular genetic testing. Testing must detect the two variant classes: the intron 1 GAA repeat expansion (which standard sequencing misses and which requires a repeat-sizing assay) and, in compound heterozygotes, an intragenic FXN sequence variant or deletion.

molecular genetic testing NCIT:C15709

Results: Detection of biallelic pathogenic FXN variants (homozygous GAA expansion, or an expansion plus an intragenic variant/deletion) confirms Friedreich ataxia.

Show evidence (2 references)

PMID:20301458 SUPPORT Human Clinical

"biallelic pathogenic variants in FXN identified by molecular genetic testing."

GeneReviews establishes that FRDA is confirmed by identifying biallelic pathogenic FXN variants on molecular genetic testing.

PMID:20301458 SUPPORT Human Clinical

"The two classes of FXN pathogenic variants are (1) GAA repeat expansions and (2) FXN pathogenic sequence variants"

GeneReviews defines the two FXN pathogenic-variant classes (GAA repeat expansions and sequence variants), the reason testing must cover both a repeat-sizing assay and sequencing.

Echocardiography

Echocardiography at diagnosis and at least annually thereafter. This is surveillance rather than a confirmatory test: the cardiomyopathy is the leading cause of death in FRDA and is frequently present before it becomes symptomatic.

Echocardiography Test NCIT:C16525

Results: Concentric hypertrophic cardiomyopathy, progressing to a dilated phenotype in some patients.

Show evidence (1 reference)

PMID:25928624 SUPPORT Other

"An EKG and an echocardiogram should be performed at diagnosis and then at least annually."

Gives the surveillance schedule. Graded OTHER because this recommendation carries the guideline's GPP (good practice point) marker, i.e. expert consensus rather than graded trial evidence.

Electrocardiography

Electrocardiography at diagnosis and at least annually thereafter, on the same surveillance schedule as echocardiography. It is the arrhythmia arm of cardiac surveillance, distinct from the structural assessment.

Electrocardiography NCIT:C38053

Results: Repolarization abnormalities and left ventricular hypertrophy patterns; atrial arrhythmias occur later in the disease course.

Show evidence (1 reference)

PMID:25928624 SUPPORT Other

"An EKG and an echocardiogram should be performed at diagnosis and then at least annually."

The same guideline sentence sets the schedule for both cardiac tests. Graded OTHER for the same reason: the recommendation carries the guideline's GPP (good practice point) marker.

📈

Progression

Onset

Age: Childhood to adolescence

Typical onset around puberty (ages 10-15). Late-onset forms (after age 25) are associated with smaller GAA expansions and slower progression.

Show evidence (3 references)

ORPHA:95 SUPPORT Other

"Age of onset: Childhood"

Orphanet lists childhood as an age-of-onset category for Friedreich ataxia.

ORPHA:95 SUPPORT Other

"Age of onset: Adolescent"

Orphanet lists adolescence as an age-of-onset category for Friedreich ataxia.

PMID:20301458 SUPPORT Human Clinical

"mean age at onset from 10 to 15 years"

GeneReviews gives the typical FRDA mean age at onset of 10-15 years.

Loss of ambulation

Age: Median 11.5 years after symptom onset in early-onset disease Duration: 11.5 years from first symptoms to full wheelchair dependence (early-onset patients)

Loss of ambulation occurs in nearly all patients. In the FA-COMS natural history cohort, patients with onset before age 15 reached full wheelchair dependence at a median of 11.5 years (IQR 8.6-16.2) after first symptoms, and loss of individual FARS stance and balance items follows a stereotyped sequence that ranks a patient's position along that trajectory.

Show evidence (2 references)

PMID:31938785 SUPPORT Human Clinical

"Early onset FRDA patients (<15y of age) typically become fully wheelchair dependent at a median of 11.5y (25th, 75th percentiles 8.6y, 16.2y) after the onset of first symptoms."

Natural-history cohort quantifies the interval from first symptoms to full wheelchair dependence in early-onset FRDA.

PMID:31938785 SUPPORT Human Clinical

"progressive loss of coordination and balance leading to loss of ambulation (LoA) in nearly all affected individuals"

Establishes loss of ambulation as an essentially universal endpoint of the disease course rather than a subset outcome.

Mortality

Age: Mean age at death 33 years in a Brazilian referral cohort

Cardiac disease is the leading cause of death. In a Brazilian referral cohort of 151 patients, 24 (15.9%) had died at a mean age of 33 years, with cardiac causes accounting for 7 of the 12 deaths whose cause was known. Male sex, classical (early) onset, and cardiomyopathy each predicted shorter survival. Note this is a single-centre Latin American cohort; the entry's European and North American prognosis figures come from separate sources.

Show evidence (2 references)

PMID:41273607 SUPPORT Human Clinical

"For those who died, the mean age at death was 33 ± 10.7 years. The cause of death was known for 12 out of the 24 patients: cardiac in 7, pulmonary in 3, diabetic ketoacidosis in 1 and sepsis in 1."

Reports age at death and the distribution of causes, with cardiac disease predominating.

PMID:41273607 SUPPORT Human Clinical

"Male sex, early onset and presence of cardiomyopathy are negative survival prognostic markers."

Identifies the three prognostic markers associated with shorter survival in this cohort.

📊

Prevalence

Global

Point Prevalence 3.0 per 100,000 1–9 per 100,000

Estimated prevalence of 1 in 29,000-50,000 in European populations. More rare in East Asian and sub-Saharan African populations.

Show evidence (1 reference)

PMID:38778374 SUPPORT INDIRECT Human Clinical

"FRDA affects 1:50,000 individuals, making it the most prevalent hereditary ataxia in the Caucasian population"

Supports the lower-frequency end of the 1 in 29,000-50,000 range recorded in the notes, and the ancestry skew this record describes. Two caveats: the quote is a secondary statement in the introduction of a biomarker study rather than a primary epidemiological report, and it is specific to Caucasian populations while this record is scoped globally.

Europe (Orphanet)

Point Prevalence 1.0–9.0 per 100,000 1–9 per 100,000

Orphanet classifies European point prevalence as 1-9 per 100,000.

Show evidence (1 reference)

ORPHA:95 SUPPORT Other

"1-9 / 100 000 | Europe | Point prevalence | PMID:20301458,PMID:23859338"

Orphanet's epidemiology table provides the European point-prevalence class for Friedreich ataxia.

Finland, general population

Carrier Frequency 200.0 per 100,000 >1 in 1,000 (carriers)

Carrier frequency of 1 in 500, five times higher in the more sparsely populated north. This is the low-frequency end of the disease's range. The study also reports that upper-normal "reservoir" alleles (28-36 GAA) are absent from the Finnish population, and attributes the northern enrichment to internal migration in the 1500s. It does not itself assert that the missing reservoir causes the low carrier frequency, so that link is not made here.

Show evidence (2 references)

PMID:11810294 SUPPORT Human Clinical

"In the general population of Finland, the carrier frequency was only 1 in 500, corresponding to a birth incidence of 1 in 10(6)."

Reports the Finnish carrier frequency and the birth incidence it implies.

PMID:11810294 SUPPORT Human Clinical

"Alleles in the uppermost end of the normal variation (28-36 GAA) were totally missing in the Finnish population."

Reports that the upper-normal allele range from which new expansions arise is absent in this population. The paper states this as a finding and does not draw the causal link to the carrier frequency.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Friedreich Ataxia:

Ataxia with vitamin E deficiency (AVED) MONDO:0010188

Overlapping Features An autosomal recessive ataxia that can closely mimic Friedreich ataxia, with progressive gait and limb ataxia, areflexia, loss of proprioception and vibration sense, and in some patients cardiomyopathy.

Distinguishing Features

Treatable with high-dose vitamin E supplementation, so it must be excluded before a clinical FRDA diagnosis is accepted
Low serum vitamin E, which Friedreich ataxia does not cause
Caused by TTPA variants rather than FXN
Head titubation and retinitis pigmentosa are commoner than in Friedreich ataxia

Show evidence (1 reference)

PMID:24418350 SUPPORT Human Clinical

"In the case of recessive disease, a stepwise diagnostic work-up is recommended, including both biochemical markers and targeted genetic testing, particularly aimed at Friedreich's ataxia, ataxia telangiectasia, ataxia due to vitamin E deficiency, polymerase gamma gene (POLG gene, various..."

The EFNS/ENS consensus places this condition alongside Friedreich ataxia in the recommended work-up for recessive ataxia, which is what makes it a differential.

Ataxia-telangiectasia MONDO:0008840

Overlapping Features An autosomal recessive ataxia with early-onset progressive cerebellar ataxia and neurodegeneration overlapping the FRDA presentation.

Distinguishing Features

Oculocutaneous telangiectasias
Immunodeficiency with recurrent sinopulmonary infection
Raised alpha-fetoprotein
Chromosomal instability and markedly increased malignancy risk

Show evidence (1 reference)

PMID:24418350 SUPPORT Human Clinical

The EFNS/ENS consensus places this condition alongside Friedreich ataxia in the recommended work-up for recessive ataxia, which is what makes it a differential.

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) MONDO:0010041

Overlapping Features An early-onset recessive ataxia combining cerebellar ataxia with peripheral neuropathy, a combination it shares with Friedreich ataxia.

Distinguishing Features

Prominent spasticity early in the course, where Friedreich ataxia more often shows areflexia with extensor plantar responses
Retinal nerve fibre hypermyelination on fundoscopy
Pontine hypointensities on MRI

Show evidence (1 reference)

PMID:24418350 SUPPORT Human Clinical

The EFNS/ENS consensus places this condition alongside Friedreich ataxia in the recommended work-up for recessive ataxia, which is what makes it a differential.

Ataxia with oculomotor apraxia type 1 MONDO:0008842

Overlapping Features A recessive ataxia with progressive ataxia and peripheral neuropathy in the same age range as Friedreich ataxia.

Distinguishing Features

Oculomotor apraxia
Hypoalbuminemia with hypercholesterolemia

Show evidence (1 reference)

PMID:24418350 SUPPORT Human Clinical

The EFNS/ENS consensus places this condition alongside Friedreich ataxia in the recommended work-up for recessive ataxia, which is what makes it a differential.

📊

Related Datasets

Skeletal muscle transcriptomics dissects the pathogenesis of Friedreich's Ataxia geo:GSE226646

Bulk RNA sequencing of skeletal muscle biopsies from FRDA patients and healthy controls, sampled before and after recombinant human erythropoietin treatment, profiling the muscle transcriptome in patient tissue.

human BULK RNA SEQ n=20

Conditions: Friedreich ataxia skeletal muscle healthy control skeletal muscle

PMID:37027192

Show evidence (1 reference)

GEO:GSE226646 SUPPORT Human Clinical

"RNA sequencing of skeletal muscle biopsies from healthy controls and Friedreich's Ataxia (FRDA) patients before and after treatment with recombinant human erythropoietin (rhuEPO) to dissect the mechanisms of disease."

The GEO summary establishes this as a patient-versus-control skeletal muscle transcriptome series in FRDA.

A non-synonymous SNP in SIRT6 predicts neurological severity in Friedreich ataxia geo:GSE200907

Whole-transcriptome profiling of FRDA patients stratified by SIRT6 rs352493 genotype, supporting the modifier analysis of neurological severity.

human BULK RNA SEQ n=20

Conditions: Friedreich ataxia, S46 SIRT6 variant Friedreich ataxia, N46 SIRT6 variant

PMID:36133907

Supports a genetic modifier of neurological severity acting alongside GAA repeat length, rather than a primary disease mechanism.

Show evidence (1 reference)

GEO:GSE200907 SUPPORT Human Clinical

"S46 patients showed whole transcriptome differences compared to N46 patients, indicative of compensatory mechanisms against whole transcriptome changes seen in FRDA."

The GEO summary describes the genotype-stratified patient transcriptome comparison this series holds.

An RNA-seq study in Friedreich ataxia patients identified miR148a-3p as a putative prognostic biomarker of the disease. geo:GSE243874

Small non-coding RNA sequencing of peripheral blood mononuclear cells from FRDA patients and healthy donors, used to nominate circulating microRNA biomarkers of disease progression.

human BULK RNA SEQ n=16

Conditions: Friedreich ataxia PBMC healthy donor PBMC

PMID:38778374

Show evidence (1 reference)

GEO:GSE243874 SUPPORT Human Clinical

"We performed an RNA-seq study evaluating the expression level of circulating small non-coding RNAs (sncRNA) on PBMCs of FRDA patients and of healthy donors (CTRL)."

The GEO summary establishes the patient-versus-control circulating sncRNA design of this series.

Epigenetic therapy for Friedreich ataxia. geo:GSE65399

Expression profiling of an FRDA neuronal cell model treated with the histone deacetylase inhibitor 109/RG2833, the in vitro arm of the epigenetic reactivation study that accompanied a phase I patient trial.

human MICROARRAY n=75

Conditions: FRDA neuronal cell model, HDAC inhibitor treated FRDA neuronal cell model, untreated

PMID:25159818

Show evidence (1 reference)

GEO:GSE65399 SUPPORT In Vitro

"In the neuronal cell model, HDACi 109/RG2833 increases FXN mRNA levels and frataxin protein, with concomitant changes in the epigenetic state of the gene."

The GEO summary describes the HDAC-inhibitor reactivation experiment profiled by this series.

Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich’s ataxia patient cells geo:GSE145115

Genome-wide expression profiling of FRDA patient cells treated with the SUV4-20 methyltransferase inhibitor A-196, assessing FXN reactivation and off-target transcriptome perturbation.

human BULK RNA SEQ n=24

Conditions: FRDA patient cells, A-196 treated FRDA patient cells, untreated

PMID:33028632

Show evidence (1 reference)

GEO:GSE145115 SUPPORT In Vitro

"In several FRDA cell lines and patient-derived primary peripheral blood mononuclear cells, A-196 increased FXN expression by up to 2-fold, an effect not seen in WT cells."

The GEO summary describes the FXN-reactivation effect this expression series was generated to characterize.

Frataxin deficiency in Friedreich?s Ataxia is associated with reduced levels of HAX-1, a regulator of cardiomyocyte death and survival. geo:GSE108200

Microarray profiling of FRDA patient lymphoblastoid cells with and without stable frataxin reconstitution, the screen that nominated HAX-1 as a candidate cardiomyopathy biomarker.

human MICROARRAY n=2

Conditions: FRDA lymphoblastoid cells, frataxin reconstituted FRDA lymphoblastoid cells, empty vector

PMID:31943004

GEO's own title spells the disease "Friedreich?s Ataxia"; the title is copied verbatim as the repository records it. Only two array samples are deposited, so the series is the discovery screen rather than the paper's full patient cohort.

Show evidence (1 reference)

GEO:GSE108200 SUPPORT In Vitro

"To identify other genes involved in pathogenesis of FRDA, a microarray analysis on FRDA patient's lymphoblastoid cells stably reconstituted with FXN was performed."

The GEO summary describes the frataxin-reconstitution microarray comparison held in this series.

🔬

Clinical Trials

NCT02255435 PHASE_II COMPLETED

Completed phase 2 MOXIe trial of RTA 408, also known as omaveloxolone, evaluating safety, pharmacodynamics, cycling work, and 48-week modified Friedreich's Ataxia Rating Scale change in Friedreich ataxia.

Target Phenotypes: Ataxia HP:0001251 Dysarthria HP:0001260

Show evidence (2 references)

clinicaltrials:NCT02255435 SUPPORT Human Clinical

"Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to measure how FA affects the nervous system. The mFARS looks at movement ability, balance, coordination, speech, and how well the arms and legs work."

ClinicalTrials.gov record documents the completed omaveloxolone MOXIe trial and its neurologic functional endpoints in FRDA.

PMID:33068037 SUPPORT DIRECT Human Clinical

"In the MOXIe trial, omaveloxolone significantly improved neurological function compared to placebo and was generally safe and well tolerated."

The trial publication's own conclusion, giving this registry entry its published result rather than only its design.

NCT05302271 PHASE_I COMPLETED

Completed open-label, dose-escalation trial of intravenous AAVrh.10hFXN gene therapy in patients with Friedreich ataxia cardiomyopathy. 17 patients followed for a mean of 20 months. Primary outcome was safety; exploratory endpoints included cardiac FXN protein levels, LVMI, and cardiac biomarkers.

Target Phenotypes: Hypertrophic cardiomyopathy HP:0001639

Show evidence (2 references)

PMID:42307907 SUPPORT Human Clinical

"There were 4 serious adverse events, 3 possibly related to prednisone immunosuppression and 1 possibly vector-related myocarditis 12 months after therapy, all of which resolved."

Trial safety data from the 17 FA patients receiving AAVrh.10hFXN, with resolution of all serious adverse events.

PMID:42307907 SUPPORT Human Clinical

"After therapy, LVMI was lower by at least 10% in 9 patients and stabilized in 8 patients."

Preliminary efficacy showing cardiac structural improvements in the AAVrh.10hFXN trial cohort.

NCT05445323 PHASE_I COMPLETED

Second independent open-label, dose-escalation trial of intravenous AAVrh.10hFXN gene therapy in Friedreich ataxia cardiomyopathy patients. Data pooled with NCT05302271 for the 2026 nonrandomized clinical trial analysis published in JAMA Cardiology.

Target Phenotypes: Hypertrophic cardiomyopathy HP:0001639

Show evidence (1 reference)

PMID:42307907 SUPPORT Human Clinical

"This nonrandomized clinical trial evaluates the pooled data of 2 independent, open-label, dose-escalation trials that used the same gene therapy vector and similar clinical protocols among patients with FA cardiomyopathy at academic medical centers."

Second independent trial contributing to the pooled AAVrh.10hFXN analysis.

🐁

Animal Models

Conditional Fxn knockout mouse (MCK-Cre and NSE-Cre)

Tissue-restricted frataxin deletion, generated because complete Fxn knockout is embryonic lethal. The two Cre drivers separate the cardiac and sensory arms of the disease, and the model established the temporal ordering of Fe-S enzyme inactivation and mitochondrial iron deposition.

Species

Mouse

Genotype

Fxn conditional knockout, striated-muscle (MCK-Cre) and neuron/cardiac (NSE-Cre) lines

Publication

PMID:11175786

Pathograph links

Cardiomyocyte Mitochondrial Injury recapitulates fidelity: high observes: tissue The MCK-Cre line reproduces cardiac hypertrophy without skeletal muscle involvement, matching the organ selectivity of human FRDA cardiomyopathy.

Limitations: Frataxin is deleted outright rather than reduced by a GAA expansion, so the model carries no residual frataxin and no epigenetic lesion, and its onset is developmental rather than progressive from a hypomorphic baseline.

Show evidence (1 reference)

PMID:11175786 SUPPORT Model Organism

"cardiac hypertrophy without skeletal muscle involvement, large sensory neuron dysfunction without alteration of the small sensory and motor neurons, and deficient activities of complexes I-III of the respiratory chain and of the aconitases"

Reports the cardiac and sensory phenotypes and the respiratory-chain/aconitase deficits the model reproduces.

Dorsal Root Ganglion Sensory Neuronopathy recapitulates fidelity: moderate observes: tissue The NSE-Cre line reproduces large sensory neuron dysfunction while sparing small sensory and motor neurons, the same fibre-size selectivity seen in human FRDA.

Limitations: Sensory involvement is driven by a neuron/cardiac Cre rather than arising from the dorsal root ganglion lesion itself, so the model reproduces the selectivity without reproducing the human lesion's developmental hypoplasia.

Show evidence (1 reference)

PMID:11175786 SUPPORT Model Organism

"large sensory neuron dysfunction without alteration of the small sensory and motor neurons"

Reports the large-fibre selectivity of the sensory deficit in this model.

Mitochondrial Bioenergetic Failure and Oxidative Stress recapitulates fidelity: high observes: molecular Establishes the ordering within this node: Fe-S-dependent enzyme inactivation and overt pathology precede intramitochondrial iron accumulation, so iron deposition is a consequence rather than an initiator.

Limitations: The measured quantities are molecular (Fe-S enzyme activities and mitochondrial iron content) while the node is a cell-level failure state, so the bioenergetic-failure claim is inferred one scale up from what the model actually observes. The ordering is also a mouse result on a conditional-null background and has not been established in human tissue.

Divergences from the human mechanism

scale extrapolation qualifying

The model reads out enzyme activity and iron content at the molecular scale; the node asserts cellular bioenergetic failure and oxidative stress. The step from one to the other is inferential.

cause unrepresented qualifying

Frataxin is deleted outright, so the GAA expansion and the epigenetic silencing that cause the deficiency in patients are absent from the model; only the downstream consequence of low frataxin is represented.

Show evidence (1 reference)

PMID:11175786 SUPPORT Model Organism

"time-dependent intramitochondrial iron accumulation in a frataxin-deficient mammal, which occurs after onset of the pathology and after inactivation of the Fe-S-dependent enzymes"

Places iron accumulation downstream of Fe-S enzyme inactivation and pathology onset in a mammalian model.

Show evidence (1 reference)

PMID:11175786 SUPPORT Model Organism

"complete absence of frataxin in the mouse leads to early embryonic lethality"

Explains why the model is conditional rather than a null: total frataxin loss is not viable, which is also why human patients always retain residual frataxin.

Humanized FXN GAA-repeat YAC transgenic mouse (YG8R/YG22R)

The GAA-repeat-based counterpart of the conditional knockouts: frataxin is reduced by the human expansion in its own genomic context rather than by gene deletion, so the model retains the mutation class that repeat-directed therapies target.

Species

Mouse

Genotype

Human FXN YAC transgene carrying an expanded GAA repeat, on an Fxn-knockout background

Publication

PMID:16919418

Pathograph links

FXN GAA Repeat Expansion and Epigenetic Silencing recapitulates fidelity: high observes: molecular Frataxin reduction arises from an unstable human GAA expansion within the appropriate genomic context, which is what makes this model usable for testing repeat- and chromatin-directed strategies.

Show evidence (1 reference)

PMID:16919418 SUPPORT Model Organism

"The resultant FRDA mice that express only human-derived frataxin show comparatively reduced levels of frataxin mRNA and protein expression, decreased aconitase activity, and oxidative stress, leading to progressive neurodegenerative and cardiac pathological phenotypes."

Confirms that the human expansion alone reduces frataxin and produces progressive neurological and cardiac pathology.

Dorsal Root Ganglion Sensory Neuronopathy partially recapitulates fidelity: moderate observes: tissue Dorsal root ganglion neurons develop large vacuoles with a lumbar-to-cervical progression, alongside coordination deficits on rotarod.

Limitations: The lesion is vacuolar with secondary demyelination rather than the progressive ganglion-cell loss that defines the human neuronopathy, and it appears from 6 months rather than being present from development.

Show evidence (1 reference)

PMID:16919418 SUPPORT Model Organism

"Large vacuoles are detected within neurons of the dorsal root ganglia (DRG), predominantly within the lumbar regions in 6-month-old mice"

Reports the dorsal root ganglion pathology and its regional distribution in this model.

Show evidence (1 reference)

PMID:16919418 SUPPORT Model Organism

"We have previously reported the establishment of two lines of human FXN YAC transgenic mice that contain unstable GAA repeat expansions within the appropriate genomic context."

Establishes that the transgene carries an unstable human GAA expansion in its native genomic context, which is what makes this model informative for repeat-directed mechanisms rather than for frataxin loss alone.

Retinal conditional Fxn knockout mouse with AAV2-FXN rescue (mRx-Fxn KO, Pou4f2-Fxn KO)

Tissue-specific models of the ocular arm of the disease, built because the cardiac and CNS gene therapy routes do not transduce the retina efficiently. Both the disease model and an intravitreal AAV2-FXN rescue arm are reported.

Species

Mouse

Genotype

Fxn conditionally ablated in all retinal cells (mRx-Cre) or in retinal ganglion cells (Pou4f2-Cre)

Publication

PMID:41137390

Show evidence (1 reference)

PMID:41137390 SUPPORT Model Organism

"Work is under way to develop gene therapies that address the cardiac and CNS manifestations, but their routes of administration do not lead to efficient transduction of the retina."

Explains why a retina-specific model is needed at all: the existing cardiac and CNS gene therapy routes do not reach the retina, so the ocular phenotype needs its own model and delivery route.

AAV9-hFXN gene therapy rescue in conditional Fxn knockout mice

Rescue arm rather than a disease model: frataxin is restored by systemic AAV9 delivery in the conditional knockouts, testing whether the mechanism chain is reversible once established.

Species

Mouse

Genotype

Fxn conditional knockout (MCK-Cre or NSE-Cre) treated with AAV9-hFXN

Publication

PMID:26015982

Pathograph links

Cardiomyocyte Mitochondrial Injury rescues fidelity: moderate observes: tissue A single systemic dose preserved cardiac systolic function and more than doubled survival, which is the preclinical basis for the AAV gene therapy programmes curated under treatments.

Limitations: Rescue is delivered to a conditional-knockout background with no GAA expansion, so it tests frataxin replacement rather than reversal of repeat-driven silencing, and treatment begins in young animals before the long subclinical phase human patients have already passed through.

Show evidence (1 reference)

PMID:26015982 SUPPORT Model Organism

"Echography analysis of the heart function clearly indicated that the cardiac systolic function was better preserved in the mice that received 6 × 10(11) v.p. of AAV9-hFXN."

Reports preserved cardiac systolic function after frataxin restoration, the readout grounding the rescue claim.

Show evidence (1 reference)

PMID:26015982 SUPPORT Model Organism

"A single administration of the AAV9-hFXN at 6 × 10(11) v.p. more than doubled the life of these mice."

Establishes the survival benefit that makes this model informative for frataxin-restoration approaches.

{ }

Source YAML

click to show

name: Friedreich Ataxia
creation_date: "2026-03-06T00:00:00Z"
description: >
  Friedreich ataxia (FRDA) is the most common inherited ataxia, caused by
  homozygous GAA trinucleotide repeat expansion in intron 1 of the FXN gene
  encoding frataxin, a mitochondrial protein essential for iron-sulfur cluster
  biogenesis. Frataxin deficiency leads to mitochondrial iron accumulation,
  impaired oxidative phosphorylation, and oxidative stress. The disease is
  characterized by progressive gait and limb ataxia, dysarthria, loss of
  deep tendon reflexes, sensory neuropathy, hypertrophic cardiomyopathy,
  scoliosis, pes cavus, and diabetes mellitus. Onset is typically around
  puberty with progressive disability and shortened lifespan, often due
  to cardiac complications.
category: Mendelian
disease_term:
  preferred_term: Friedreich Ataxia
  term:
    id: MONDO:0100339
    label: Friedreich ataxia
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0100339
      label: Friedreich ataxia
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet ORPHA:95
    mapping_justification: >-
      Orphanet lists MONDO:0100339 as an exact cross-reference for the
      ORPHA:95 Friedreich ataxia record.
  - term:
      id: MONDO:0100340
      label: Friedreich ataxia 1
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0100340 (Friedreich ataxia 1, FRDA1) is the FXN-caused child of the
      MONDO:0100339 grouping this entry is bound to, defined by MONDO as "Any
      Friedreich ataxia in which the cause of the disease is a mutation in the
      FXN gene" and carrying the RO:0004003 causal relation to hgnc:3951. Every
      mechanism, phenotype, and treatment curated here is FXN GAA-repeat disease,
      and the OMIM identifier the entry already records as an exact
      cross-reference (OMIM:229300) is the one MONDO uses to define FRDA1. The
      entry is bound one level up because it also covers the FARR subtype
      (MONDO:0800301), a MONDO sibling of FRDA1 rather than a descendant, so the
      grouping term is the narrowest single term spanning what is curated.
    notes: >-
      The third child of MONDO:0100339, Friedreich ataxia 2 (MONDO:0011175,
      OMIM:601992), is defined by MONDO only as a linkage locus on chromosome
      9p23-p11 and carries no RO:0004003 causal gene relation, so it is
      deliberately not covered by this entry.
external_assertions:
- name: Orphanet Friedreich ataxia structured record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:95
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95
  description: >-
    Orphanet records Friedreich ataxia as ORPHA:95 and provides external
    cross-references supporting this entry's disease identity.
  evidence:
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0100339 | Exact"
    explanation: Orphanet lists the MONDO disease identifier as an exact cross-reference.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:229300 | Exact"
    explanation: Orphanet lists the primary OMIM disease identifier as an exact cross-reference.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-11:8A03.10 | Exact"
    explanation: Orphanet lists the ICD-11 disease code as an exact cross-reference.
references:
- reference: PMID:20301458
  title: "Friedreich Ataxia."
  tags:
  - GeneReviews
inheritance:
- name: Autosomal recessive inheritance
  description: >
    Friedreich ataxia is caused by biallelic pathogenic FXN alleles, most often
    homozygous intron 1 GAA repeat expansions, and follows autosomal recessive
    inheritance.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Inheritance is autosomal recessive with the vast majority of cases showing an unstable intronic GAA expansion in both alleles of the frataxin gene on chromosome 9q13."
    explanation: Defines the inheritance pattern and the usual biallelic FXN repeat-expansion genotype.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance for Friedreich ataxia.
parents:
- Hereditary Ataxia
- Mitochondrial Disorder
prevalence:
- population: Global
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 3.0
  percentage: "0.003"
  notes: Estimated prevalence of 1 in 29,000-50,000 in European populations. More rare in East Asian and sub-Saharan African populations.
  evidence:
  - reference: PMID:38778374
    reference_title: An RNA-seq study in Friedreich ataxia patients identified hsa-miR-148a-3p as a putative prognostic biomarker of the disease.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "FRDA affects 1:50,000 individuals, making it the most prevalent hereditary ataxia in the Caucasian population"
    explanation: >-
      Supports the lower-frequency end of the 1 in 29,000-50,000 range recorded
      in the notes, and the ancestry skew this record describes. Two caveats: the
      quote is a secondary statement in the introduction of a biomarker study
      rather than a primary epidemiological report, and it is specific to
      Caucasian populations while this record is scoped globally.
- population: Europe (Orphanet)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 1.0
  rate_high: 9.0
  percentage: 1-9 / 100 000
  notes: Orphanet classifies European point prevalence as 1-9 per 100,000.
  evidence:
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Europe | Point prevalence | PMID:20301458,PMID:23859338"
    explanation: Orphanet's epidemiology table provides the European point-prevalence class for Friedreich ataxia.
- population: Finland, general population
  measure_type: CARRIER_FREQUENCY
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 200.0
  rate_denominator: POPULATION
  notes: >-
    Carrier frequency of 1 in 500, five times higher in the more sparsely
    populated north. This is the low-frequency end of the disease's range. The
    study also reports that upper-normal "reservoir" alleles (28-36 GAA) are
    absent from the Finnish population, and attributes the northern enrichment
    to internal migration in the 1500s. It does not itself assert that the
    missing reservoir causes the low carrier frequency, so that link is not
    made here.
  evidence:
  - reference: PMID:11810294
    reference_title: Dissecting the epidemiology of a trinucleotide repeat disease - example of FRDA in Finland.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the general population of Finland, the carrier frequency was only 1 in 500, corresponding to a birth incidence of 1 in 10(6)."
    explanation: Reports the Finnish carrier frequency and the birth incidence it implies.
  - reference: PMID:11810294
    reference_title: Dissecting the epidemiology of a trinucleotide repeat disease - example of FRDA in Finland.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alleles in the uppermost end of the normal variation (28-36 GAA) were totally missing in the Finnish population."
    explanation: Reports that the upper-normal allele range from which new expansions arise is absent in this population. The paper states this as a finding and does not draw the causal link to the carrier frequency.
progression:
- phase: Onset
  age_range: Childhood to adolescence
  notes: Typical onset around puberty (ages 10-15). Late-onset forms (after age 25) are associated with smaller GAA expansions and slower progression.
  evidence:
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Childhood"
    explanation: Orphanet lists childhood as an age-of-onset category for Friedreich ataxia.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adolescent"
    explanation: Orphanet lists adolescence as an age-of-onset category for Friedreich ataxia.
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mean age at onset from 10 to 15 years"
    explanation: GeneReviews gives the typical FRDA mean age at onset of 10-15 years.
- phase: Loss of ambulation
  age_range: Median 11.5 years after symptom onset in early-onset disease
  duration: 11.5 years from first symptoms to full wheelchair dependence (early-onset patients)
  notes: >-
    Loss of ambulation occurs in nearly all patients. In the FA-COMS natural
    history cohort, patients with onset before age 15 reached full wheelchair
    dependence at a median of 11.5 years (IQR 8.6-16.2) after first symptoms,
    and loss of individual FARS stance and balance items follows a stereotyped
    sequence that ranks a patient's position along that trajectory.
  evidence:
  - reference: PMID:31938785
    reference_title: "Predictors of loss of ambulation in Friedreich's ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early onset FRDA patients (<15y of age) typically become fully wheelchair dependent at a median of 11.5y (25th, 75th percentiles 8.6y, 16.2y) after the onset of first symptoms."
    explanation: Natural-history cohort quantifies the interval from first symptoms to full wheelchair dependence in early-onset FRDA.
  - reference: PMID:31938785
    reference_title: "Predictors of loss of ambulation in Friedreich's ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive loss of coordination and balance leading to loss of ambulation (LoA) in nearly all affected individuals"
    explanation: Establishes loss of ambulation as an essentially universal endpoint of the disease course rather than a subset outcome.
- phase: Mortality
  age_range: Mean age at death 33 years in a Brazilian referral cohort
  notes: >-
    Cardiac disease is the leading cause of death. In a Brazilian referral
    cohort of 151 patients, 24 (15.9%) had died at a mean age of 33 years, with
    cardiac causes accounting for 7 of the 12 deaths whose cause was known. Male
    sex, classical (early) onset, and cardiomyopathy each predicted shorter
    survival. Note this is a single-centre Latin American cohort; the entry's
    European and North American prognosis figures come from separate sources.
  evidence:
  - reference: PMID:41273607
    reference_title: "Survival in Brazilian Patients with Friedreich´s Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For those who died, the mean age at death was 33 ± 10.7 years. The cause of death was known for 12 out of the 24 patients: cardiac in 7, pulmonary in 3, diabetic ketoacidosis in 1 and sepsis in 1."
    explanation: Reports age at death and the distribution of causes, with cardiac disease predominating.
  - reference: PMID:41273607
    reference_title: "Survival in Brazilian Patients with Friedreich´s Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Male sex, early onset and presence of cardiomyopathy are negative survival prognostic markers."
    explanation: Identifies the three prognostic markers associated with shorter survival in this cohort.
has_subtypes:
- name: Typical FRDA
  display_name: Typical Friedreich ataxia
  description: >-
    Classic Friedreich ataxia, accounting for about 75% of biallelic FXN cases,
    with onset from early childhood to early adulthood (mean age at onset 10-15
    years) and the full progressive multisystem phenotype including areflexia.
  genes:
  - preferred_term: FXN
    term:
      id: hgnc:3951
      label: FXN
  evidence:
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mean age at onset from 10 to 15 years"
    explanation: GeneReviews gives the typical FRDA onset window of 10-15 years for the classic form.
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "individuals with FRDA, about 75% have \"typical Friedreich ataxia\""
    explanation: GeneReviews states about 75% of individuals with FRDA have the typical form (and about 25% atypical), supporting the subtype proportions.
- name: LOFA
  display_name: Late-onset Friedreich ataxia (LOFA)
  description: >-
    Atypical form with onset after age 25 years, part of the ~25% of biallelic
    FXN cases that are atypical. Later onset is generally associated with smaller
    GAA expansions and slower progression.
  genes:
  - preferred_term: FXN
    term:
      id: hgnc:3951
      label: FXN
  evidence:
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "late-onset FRDA (LOFA)"
    explanation: GeneReviews defines late-onset FRDA (LOFA) as onset after age 25 within the atypical FRDA group.
- name: VLOFA
  display_name: Very late-onset Friedreich ataxia (VLOFA)
  description: >-
    Atypical form with onset after age 40 years, the latest-onset end of the
    atypical FRDA spectrum.
  genes:
  - preferred_term: FXN
    term:
      id: hgnc:3951
      label: FXN
  evidence:
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "very late-onset FRDA (VLOFA)"
    explanation: GeneReviews defines very late-onset FRDA (VLOFA) as onset after age 40.
- name: FARR
  display_name: Friedreich ataxia with retained reflexes (FARR)
  subtype_term:
    preferred_term: Friedreich ataxia with retained reflexes
    term:
      id: MONDO:0800301
      label: Friedreich ataxia with retained reflexes
  description: >-
    Atypical form in which deep tendon reflexes are preserved rather than lost,
    so the cardinal lower-limb areflexia of typical FRDA is absent. Part of the
    ~25% atypical FRDA group.
  genes:
  - preferred_term: FXN
    term:
      id: hgnc:3951
      label: FXN
  evidence:
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FRDA with retained reflexes (FARR)"
    explanation: GeneReviews defines FRDA with retained reflexes (FARR) as an atypical form in which reflexes are preserved.
pathophysiology:
- name: FXN GAA Repeat Expansion and Epigenetic Silencing
  biological_scale: MOLECULAR
  description: >
    Biallelic expansion of the GAA repeat in intron 1 of FXN produces a
    non-coding repeat-expansion loss-of-expression mechanism. Repressive
    chromatin around the expanded repeat lowers FXN transcription and reduces
    frataxin abundance, establishing the upstream genetic lesion for all
    downstream FRDA pathograph paths.
  gene:
    preferred_term: FXN
    term:
      id: hgnc:3951
      label: FXN
  biological_processes:
  - preferred_term: regulation of gene expression
    term:
      id: GO:0010468
      label: regulation of gene expression
    modifier: DECREASED
  - preferred_term: chromatin organization
    term:
      id: GO:0006325
      label: chromatin organization
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:32826895
    reference_title: "Frataxin gene editing rescues Friedreich's ataxia pathology in dorsal root ganglia organoid-derived sensory neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Friedreich's ataxia (FRDA) is an autosomal-recessive neurodegenerative and cardiac disorder which occurs when transcription of the FXN gene is silenced due to an excessive expansion of GAA repeats into its first intron."
    explanation: Defines the upstream FXN repeat-expansion silencing mechanism in a human iPSC-derived DRG organoid study.
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pathogenic mutation in Friedreich's ataxia (FRDA) is a homozygous guanine-adenine-adenine (GAA) trinucleotide repeat expansion on chromosome 9q13 that causes a transcriptional defect of the frataxin gene."
    explanation: Human pathology review states that the repeat expansion causes a transcriptional defect of FXN.
  downstream:
  - target: Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect
    description: >
      FXN transcriptional silencing reduces frataxin, the mitochondrial protein
      required for the canonical FRDA loss-of-function path.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - expanded intron 1 GAA repeat
    - repressive chromatin flanking the repeat
    - reduced FXN transcription
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:32826895
      reference_title: "Frataxin gene editing rescues Friedreich's ataxia pathology in dorsal root ganglia organoid-derived sensory neurons."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "These results strongly suggest that removal of the repressed chromatin flanking the GAA tract might contribute to rescue FXN total expression and fully revert the pathological hallmarks of FRDA DRG neurons."
      explanation: Links repressed chromatin around the repeat to reduced FXN expression and DRG neuronal pathology.
- name: Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect
  biological_scale: MOLECULAR
  description: >
    Reduced frataxin impairs mitochondrial iron-sulfur cluster biosynthesis,
    oxidative phosphorylation, and iron handling. This common biochemical lesion
    feeds the tissue-specific branches that explain sensory ataxia, dysarthria,
    cardiomyopathy, diabetes, and skeletal deformity.
  gene:
    preferred_term: FXN
    term:
      id: hgnc:3951
      label: FXN
  cell_types:
  - preferred_term: sensory neuron of dorsal root ganglion
    term:
      id: CL:1001451
      label: sensory neuron of dorsal root ganglion
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  - preferred_term: pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: iron-sulfur cluster assembly
    term:
      id: GO:0016226
      label: iron-sulfur cluster assembly
    modifier: DECREASED
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  - preferred_term: intracellular iron ion homeostasis
    term:
      id: GO:0006879
      label: intracellular iron ion homeostasis
    modifier: DYSREGULATED
  locations:
  - preferred_term: dorsal root ganglion
    term:
      id: UBERON:0000044
      label: dorsal root ganglion
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  - preferred_term: pancreas
    term:
      id: UBERON:0001264
      label: pancreas
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:14653404
    reference_title: "Friedreich ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the unstable GAA expansion that underlies FA causes a deficiency of the mitochondrial protein frataxin, leading to potentially harmful oxidative injury associated with excessive iron deposits in mitochondria. In addition, pathogenesis may involve a primary defect in synthesis of iron-sulfur cluster containing enzymes."
    explanation: Confirms frataxin deficiency, mitochondrial iron accumulation, and iron-sulfur cluster assembly defect as the pathogenic mechanism.
  - reference: PMID:31456208
    reference_title: "Iron Pathophysiology in Friedreich's Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This protein is essential for mitochondrial function by the involvement of iron-sulfur cluster biogenesis. The effects of its deficiency also include disruption of cellular, particularly mitochondrial, iron homeostasis, i.e., relatively more iron accumulated in mitochondria and less iron presented in cytosol."
    explanation: Confirms frataxin's role in iron-sulfur cluster biogenesis and mitochondrial iron accumulation upon deficiency.
  - reference: PMID:39337401
    reference_title: "Skeletal Muscle Involvement in Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At a cellular level, frataxin deficiency results in insufficient iron-sulfur cluster biosynthesis and impaired mitochondrial function and adenosine triphosphate production."
    explanation: Recent review states the core biochemical consequence that bridges frataxin deficiency to mitochondrial energy failure.
  downstream:
  - target: Mitochondrial Bioenergetic Failure and Oxidative Stress
    description: >
      Defective Fe-S cluster biogenesis lowers activity of mitochondrial
      respiratory-chain and Fe-S enzymes, producing energy failure, iron
      dysregulation, and oxidative stress.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:38129330
      reference_title: "Mitochondrial impairment, decreased sirtuin activity and protein acetylation in dorsal root ganglia in Friedreich Ataxia models."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "frataxin deficiency resulted in lower activity and levels of the electron transport complexes, mainly complexes I and II."
      explanation: Directly links frataxin deficiency to respiratory-chain complex impairment in DRG models.
- name: Mitochondrial Bioenergetic Failure and Oxidative Stress
  biological_scale: CELLULAR
  description: >
    Frataxin-deficient cells show impaired electron transport, altered
    mitochondrial morphology, abnormal iron handling, and oxidative stress. This
    shared mitochondrial stress state is the branch point for sensory neuronal,
    cerebellar, cardiac, pancreatic beta-cell, and musculoskeletal outcomes.
  cell_types:
  - preferred_term: sensory neuron of dorsal root ganglion
    term:
      id: CL:1001451
      label: sensory neuron of dorsal root ganglion
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  - preferred_term: pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  - preferred_term: intracellular iron ion homeostasis
    term:
      id: GO:0006879
      label: intracellular iron ion homeostasis
    modifier: DYSREGULATED
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:38129330
    reference_title: "Mitochondrial impairment, decreased sirtuin activity and protein acetylation in dorsal root ganglia in Friedreich Ataxia models."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mitochondrial dysfunction, a reduction in the activity of iron-sulfur enzymes, iron accumulation, and increased oxidative stress have been described."
    explanation: Summarizes the shared mitochondrial and oxidative-stress state produced by frataxin deficiency.
  downstream:
  - target: Dorsal Root Ganglion Sensory Neuronopathy
    description: >
      Sensory neurons in dorsal root ganglia are especially vulnerable to the
      mitochondrial consequences of frataxin deficiency, causing the
      proprioceptive sensory branch of FRDA.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced respiratory-chain complex I and II activity
    - mitochondrial superoxide generation
    - sensory neuron lethality
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:38129330
      reference_title: "Mitochondrial impairment, decreased sirtuin activity and protein acetylation in dorsal root ganglia in Friedreich Ataxia models."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Dorsal root ganglion (DRG) sensory neurons are among the cellular types most affected in the early stages of this disease."
      explanation: Establishes selective DRG sensory neuron vulnerability.
  - target: Dentate Nucleus and Spinocerebellar Tract Degeneration
    description: >
      Mitochondrial frataxin deficiency also injures the cerebellar dentate
      nucleus and spinocerebellar/dorsal-column systems, adding a central
      cerebellar component to the sensory ataxia path.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - dentate nucleus atrophy
    - dorsal column and spinocerebellar tract fiber loss
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The neurological phenotype reflects lesions in dorsal root ganglia (DRG), sensory peripheral nerves, corticospinal tracts, and dentate nuclei (DN)."
      explanation: Human pathology review maps FRDA neurologic manifestations to DRG, sensory nerve, corticospinal tract, and dentate nucleus lesions.
  - target: Corticospinal Tract Degeneration
    description: >
      Mitochondrial frataxin deficiency injures the corticospinal (pyramidal)
      tracts as a separate intrinsic CNS lesion, in parallel with the DRG,
      dentate, and optic-nerve lesions.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract fiber loss
    - upper motor neuron degeneration
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Destruction of the DN, optic atrophy, and degeneration of the corticospinal tracts are intrinsic central nervous system lesions."
      explanation: Human pathology review identifies corticospinal tract degeneration as an intrinsic CNS lesion, parallel to the dentate and optic lesions.
  - target: Optic Atrophy
    description: >
      Optic atrophy is a separate intrinsic central nervous system lesion of
      FRDA, reflecting degeneration of the optic nerve and retinal ganglion cell
      visual pathway rather than the dentate/spinocerebellar system.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - retinal ganglion cell and optic nerve neurodegeneration
    - visual pathway involvement
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Destruction of the DN, optic atrophy, and degeneration of the corticospinal tracts are intrinsic central nervous system lesions."
      explanation: Human pathology review lists optic atrophy among the intrinsic CNS lesions of FRDA, parallel to (not downstream of) dentate and corticospinal degeneration.
  - target: Muscle Weakness
    description: >
      Mitochondrial bioenergetic failure in FRDA affects skeletal muscle and
      contributes to progressive limb weakness and fatigue.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - skeletal muscle mitochondrial dysfunction
    - neuromuscular weakness
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:39337401
      reference_title: "Skeletal Muscle Involvement in Friedreich Ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "FRDA displays skeletal muscle involvement, which contributes to the weakness and marked fatigue evident throughout the course of the disease."
      explanation: Links the shared mitochondrial branch to skeletal muscle involvement and weakness in FRDA.
  - target: Cardiomyocyte Mitochondrial Injury
    description: >
      Frataxin-deficient cardiomyocytes accumulate iron-positive mitochondrial
      injury and structural myocyte pathology, producing the cardiac branch of
      FRDA.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - mitochondrial iron dysmetabolism
    - cardiomyocyte hypertrophy
    - disrupted intercalated discs
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:28789479
      reference_title: "Heart and Nervous System Pathology in Compound Heterozygous Friedreich Ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Microscopy showed cardiomyocyte hypertrophy, iron-positive inclusions, and disrupted intercalated discs."
      explanation: Human cardiac pathology links FRDA genotype/frataxin deficiency to cardiomyocyte structural injury.
  - target: Pancreatic Beta-Cell Apoptosis
    description: >
      In pancreatic beta cells, frataxin deficiency causes mitochondrial
      dysfunction and oxidative stress-mediated intrinsic apoptosis, explaining
      the diabetes branch of FRDA.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - beta-cell mitochondrial dysfunction
    - oxidative stress-mediated intrinsic apoptosis
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:25552656
      reference_title: "Unveiling a common mechanism of apoptosis in beta-cells and neurons in Friedreich's ataxia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "pancreatic β-cell dysfunction and death cause diabetes in FRDA. This is secondary to mitochondrial dysfunction and apoptosis"
      explanation: Connects frataxin-deficient beta-cell mitochondrial dysfunction and apoptosis to diabetes.
  - target: Progressive Skeletal Deformity
    description: >
      Neurologic imbalance, sensory neuropathy, weakness, and FRDA skeletal
      involvement converge on progressive spinal and foot deformity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - proprioceptive impairment
    - progressive neuromuscular weakness
    - skeletal involvement
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This autosomal recessive disease affects central and peripheral nervous systems, heart, skeleton, and endocrine pancreas."
      explanation: Places skeletal involvement in the same multisystem FRDA pathologic spectrum as neurologic, cardiac, and pancreatic disease.
- name: Dorsal Root Ganglion Sensory Neuronopathy
  biological_scale: TISSUE
  description: >
    FRDA injures dorsal root ganglion sensory neurons and their satellite-cell
    niche, causing loss of proprioceptive and vibration-sense input. This
    explains sensory neuropathy, areflexia, impaired balance, and a major
    upstream component of progressive gait and limb ataxia. Human neuropathology
    describes the ganglion lesion as dual-phase rather than purely degenerative:
    developmental hypoplasia of the sensory neurons, on which progressive
    atrophy and satellite-cell absorption are later superimposed. The dominant
    cell-death mode in frataxin-deficient DRG neurons is ferroptosis, driven by
    an impaired NRF2 response with loss of SLC7A11 and glutathione peroxidase 4
    and consequent lipid peroxidation, which distinguishes this arm of the
    pathograph from the mitophagy-failure arm in cardiomyocytes.
  cell_types:
  - preferred_term: sensory neuron of dorsal root ganglion
    term:
      id: CL:1001451
      label: sensory neuron of dorsal root ganglion
  - preferred_term: glial cell
    term:
      id: CL:0000125
      label: glial cell
  biological_processes:
  - preferred_term: ferroptosis
    term:
      id: GO:0097707
      label: ferroptosis
    modifier: INCREASED
  locations:
  - preferred_term: dorsal root ganglion
    term:
      id: UBERON:0000044
      label: dorsal root ganglion
  evidence:
  - reference: PMID:27142428
    reference_title: "Dorsal root ganglia in Friedreich ataxia: satellite cell proliferation and inflammation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FA causes major primary changes in satellite cells and inflammatory destruction of neurons."
    explanation: Human DRG pathology supports neuron and satellite-cell injury as a proximal neuropathologic event.
  - reference: PMID:23334592
    reference_title: "Friedreich ataxia: neuropathology revised."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This review of the neuropathology of Friedreich ataxia stresses the critical role of hypoplasia and superimposed atrophy of dorsal root ganglia."
    explanation: >
      Systematic neuropathology of 35 FRDA patients establishes the dual-phase
      ganglion lesion, adding a developmental hypoplasia component that a purely
      degenerative reading of this node would miss.
  - reference: PMID:39243573
    reference_title: "Deciphering the ferroptosis pathways in dorsal root ganglia of Friedreich ataxia models. The role of LKB1/AMPK, KEAP1, and GSK3β in the impairment of the NRF2 response."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "frataxin deficiency in DRG neurons disrupts iron homeostasis and the intricate regulation of molecular pathways affecting NRF2 activation and the cellular response to oxidative stress, leading to ferroptosis"
    explanation: >
      Primary DRG cultures and FXNI151F mouse ganglia both show the NRF2 and
      GPX4 loss that drives lipid peroxidation, grounding the ferroptosis
      annotation on this node.
  downstream:
  - target: Peripheral Neuropathy
    description: >
      DRG and sensory nerve injury produces the peripheral sensory neuropathy
      phenotype with loss of proprioception and vibration sense.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The neurological phenotype reflects lesions in dorsal root ganglia (DRG), sensory peripheral nerves, corticospinal tracts, and dentate nuclei (DN)."
      explanation: Links DRG and sensory peripheral nerve lesions to the neurologic phenotype.
  - target: Progressive Gait and Limb Ataxia
    description: >
      Loss of proprioceptive sensory input from DRG injury produces sensory
      ataxia that combines with cerebellar pathway degeneration.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired proprioception
    - impaired vibration sense
    - sensory ataxia
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The following neurological signs are most frequent: Gait ataxia, dysmetria of arms and legs, dysarthria, head titubation, atrophy and weakness of the distal extremities, absence of muscle stretch reflexes, Babinski signs, loss of joint and vibratory senses, and superimposed stocking-and-glove type sensory neuropathy."
      explanation: Connects proprioceptive/vibration loss and sensory neuropathy with gait and limb ataxia.
  - target: Areflexia of Lower Limbs
    description: >
      Loss of large sensory afferents from dorsal root ganglion neuronopathy
      interrupts the deep tendon reflex arc, producing the early lower-limb
      areflexia that is a cardinal diagnostic sign of FRDA.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - loss of large-diameter sensory afferents
    - interrupted monosynaptic stretch reflex arc
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "absence of muscle stretch reflexes"
      explanation: Absence of muscle stretch reflexes reflects the loss of sensory afferents from DRG sensory neuronopathy.
  - target: Impaired Proprioception
    description: >
      Destruction of the large primary sensory neurons of the dorsal root
      ganglia removes the joint-position afferents carried in the dorsal
      columns, producing the proprioceptive deficit directly.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:23334592
      reference_title: "Friedreich ataxia: neuropathology revised."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Progressive destruction of dorsal root ganglia accounts for thinning of dorsal roots, degeneration of dorsal columns"
      explanation: Neuropathology attributes dorsal column degeneration, the pathway carrying joint-position sense, to progressive destruction of the dorsal root ganglia.
  - target: Impaired Vibratory Sensation
    description: >
      The same loss of large-diameter dorsal root ganglion afferents and their
      dorsal column projections removes vibration sense, which is carried by the
      same pathway as joint position sense.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Fiber loss in dorsal columns and spinocerebellar tracts, and atrophy of the neurons in the dorsal nuclei of Clarke are secondary to the lesion in DRG."
      explanation: >-
        States the causal direction this edge asserts: the dorsal column fiber
        loss that carries vibration sense is secondary to the dorsal root
        ganglion lesion, rather than an independent lesion.
- name: Dentate Nucleus and Spinocerebellar Tract Degeneration
  biological_scale: TISSUE
  description: >
    FRDA affects the dentate nucleus, dorsal columns, and spinocerebellar
    tracts. This central cerebellar and spinocerebellar involvement combines with
    sensory neuronopathy to drive progressive ataxia and dysarthria. (The
    corticospinal/pyramidal lesion is modeled separately as the Corticospinal
    Tract Degeneration node.)
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: dentate nucleus
    term:
      id: UBERON:0002132
      label: dentate nucleus
  - preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  evidence:
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Destruction of the DN, optic atrophy, and degeneration of the corticospinal tracts are intrinsic central nervous system lesions."
    explanation: Supports dentate nucleus (DN) degeneration as an intrinsic CNS lesion in FRDA.
  downstream:
  - target: Progressive Gait and Limb Ataxia
    description: >
      Dentate and spinocerebellar tract degeneration add a cerebellar motor
      control deficit to the sensory ataxia branch.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The following neurological signs are most frequent: Gait ataxia, dysmetria of arms and legs, dysarthria, head titubation, atrophy and weakness of the distal extremities, absence of muscle stretch reflexes, Babinski signs, loss of joint and vibratory senses, and superimposed stocking-and-glove type sensory neuropathy."
      explanation: Gait ataxia and limb dysmetria are among the most frequent neurologic signs, reflecting cerebellar/spinocerebellar degeneration.
  - target: Dysarthria
    description: >
      Cerebellar and bulbar pathway degeneration contributes to impaired
      speech motor coordination.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cerebellar motor pathway dysfunction
    - bulbar motor involvement
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The following neurological signs are most frequent: Gait ataxia, dysmetria of arms and legs, dysarthria, head titubation, atrophy and weakness of the distal extremities, absence of muscle stretch reflexes, Babinski signs, loss of joint and vibratory senses, and superimposed stocking-and-glove type sensory neuropathy."
      explanation: Identifies dysarthria among the frequent neurologic signs arising in the same lesion spectrum.
  - target: Dysphagia
    description: >
      Cerebellar and bulbar pathway dysfunction can impair swallowing
      motor coordination, producing dysphagia as part of the classical FRDA
      neurologic phenotype.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired bulbar motor coordination
    - progressive neurologic dysfunction
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:23859346
      reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities"
      explanation: Lists dysphagia among the classical FRDA neurologic features.
  - target: Nystagmus
    description: >
      Central nervous system involvement in FRDA produces oculomotor disturbance,
      including nystagmus.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cerebellar oculomotor pathway dysfunction
    - abnormal saccades and square wave jerks
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Many patients with FRDA have nystagmus."
      explanation: Directly supports nystagmus as an FRDA neurologic manifestation.
- name: Corticospinal Tract Degeneration
  biological_scale: TISSUE
  conforms_to: "corticospinal_tract_axonopathy#Distal Length-Dependent Degeneration of Long CNS Axons"
  description: >
    Degeneration of the corticospinal (pyramidal) tracts is an intrinsic central
    nervous system lesion of FRDA, distinct from the DRG-secondary spinocerebellar
    and dorsal-column involvement. It produces the upper motor neuron signs of the
    disease (extensor plantar response and lower-limb spasticity/hyperreflexia),
    which coexist with the areflexia caused by the peripheral sensory neuropathy.
  cell_types:
  - preferred_term: Betz upper motor neuron
    term:
      id: CL:4023052
      label: Betz upper motor neuron
  locations:
  - preferred_term: corticospinal tract
    term:
      id: UBERON:0002707
      label: corticospinal tract
  evidence:
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Destruction of the DN, optic atrophy, and degeneration of the corticospinal tracts are intrinsic central nervous system lesions."
    explanation: Human pathology review identifies corticospinal tract degeneration as an intrinsic CNS lesion of FRDA, distinct from the DRG-secondary spinocerebellar/dorsal-column lesions.
  downstream:
  - target: Extensor Plantar Response (Babinski Sign)
    description: >
      Corticospinal (pyramidal) tract degeneration produces upper motor neuron
      signs, including an extensor plantar (Babinski) response.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "absence of muscle stretch reflexes, Babinski signs, loss of joint and vibratory senses"
      explanation: Babinski signs are listed among the most frequent neurologic signs, reflecting corticospinal tract degeneration.
  - target: Spasticity
    description: >
      Corticospinal tract degeneration also produces lower-limb spasticity and
      hyperreflexia as the disease progresses.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Spasticity and hyperreflexia in the legs are no longer rare."
      explanation: Links corticospinal tract involvement to the lower-limb spasticity and hyperreflexia of FRDA.
- name: Cardiomyocyte Mitochondrial Injury
  biological_scale: CELLULAR
  description: >
    In the heart, frataxin deficiency produces cardiomyocyte hypertrophy,
    iron-positive inclusions, and disrupted intercalated discs. The clinical
    downstream manifestation is hypertrophic cardiomyopathy, a major determinant
    of premature mortality in FRDA. Heart-specific frataxin-knockout mice locate
    the cardiac lesion in a failure of mitochondrial quality control rather than
    in oxidative injury: mitochondrial iron aggregates and severely altered
    ultrastructure accumulate alongside p62 and Parkin, indicating disrupted
    mitophagy through a dysregulated mTOR-TFEB lysosomal axis, and respiration is
    markedly impaired without a rise in oxidative stress. That mouse result is
    not the whole picture, since the biomineral iron aggregates of the
    muscle-creatine-kinase conditional frataxin-knockout mouse heart have
    separately been argued to contribute to cardiac oxidative stress; the
    disagreement is recorded in the tissue-divergence discussion.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  - preferred_term: mitophagy
    term:
      id: GO:0000423
      label: mitophagy
    modifier: DECREASED
  locations:
  - preferred_term: myocardium
    term:
      id: UBERON:0002349
      label: myocardium
  evidence:
  - reference: PMID:28789479
    reference_title: "Heart and Nervous System Pathology in Compound Heterozygous Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microscopy showed cardiomyocyte hypertrophy, iron-positive inclusions, and disrupted intercalated discs."
    explanation: Human tissue pathology supports the cardiomyocyte injury node.
  - reference: PMID:41628678
    reference_title: "Mitochondrial iron overload is associated with lysosomal dysfunction-mediated mitophagy impairment in the heart of Friedreich's ataxia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the clearance of damaged or dysfunctional mitochondria (i.e., mitophagy) is disrupted, as evidenced by excessive accumulation of p62 and Parkin proteins"
    explanation: >
      Heart-specific frataxin-knockout mice show p62 and Parkin accumulation
      with lysosomal mTOR-TFEB dysregulation, grounding the mitophagy annotation
      on this node.
  downstream:
  - target: Hypertrophic Cardiomyopathy
    description: >
      Cardiomyocyte hypertrophy and mitochondrial injury produce the common
      hypertrophic cardiomyopathy phenotype.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:39337401
      reference_title: "Skeletal Muscle Involvement in Friedreich Ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most prominent manifestation is a hypertrophic cardiomyopathy, which also represents the major determinant of premature mortality."
      explanation: Links FRDA cardiac involvement specifically to hypertrophic cardiomyopathy and mortality.
- name: Pancreatic Beta-Cell Apoptosis
  biological_scale: CELLULAR
  description: >
    Frataxin-deficient pancreatic beta cells undergo mitochondrial dysfunction,
    oxidative stress, and intrinsic apoptosis, explaining why a subset of FRDA
    patients develop diabetes mellitus.
  cell_types:
  - preferred_term: pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  locations:
  - preferred_term: pancreas
    term:
      id: UBERON:0001264
      label: pancreas
  evidence:
  - reference: PMID:25552656
    reference_title: "Unveiling a common mechanism of apoptosis in beta-cells and neurons in Friedreich's ataxia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here we show that β-cell demise in frataxin deficiency is the consequence of oxidative stress-mediated activation of the intrinsic pathway of apoptosis."
    explanation: Demonstrates the beta-cell apoptosis mechanism downstream of frataxin deficiency.
  downstream:
  - target: Diabetes Mellitus
    description: >
      Beta-cell dysfunction and death reduce insulin secretory capacity and
      produce the FRDA diabetes phenotype.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:25552656
      reference_title: "Unveiling a common mechanism of apoptosis in beta-cells and neurons in Friedreich's ataxia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We have previously demonstrated that pancreatic β-cell dysfunction and death cause diabetes in FRDA."
      explanation: Directly links pancreatic beta-cell dysfunction/death to diabetes in FRDA.
- name: Progressive Skeletal Deformity
  biological_scale: TISSUE
  description: >
    FRDA skeletal involvement includes progressive scoliosis and pes cavus. The
    mechanism is represented as an indirect downstream path from the FXN
    loss-of-function multisystem disorder through neuromuscular imbalance,
    weakness, sensory neuropathy, and skeletal involvement.
  locations:
  - preferred_term: skeleton
    term:
      id: UBERON:0001434
      label: skeletal system
  evidence:
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Scoliosis and foot deformity (pes cavus) may also be early signs and precede ataxia."
    explanation: Human clinical-pathology review supports scoliosis and pes cavus as FRDA skeletal manifestations.
  downstream:
  - target: Scoliosis
    description: >
      Progressive skeletal deformity manifests as scoliosis in the FRDA
      phenotype list.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Scoliosis and foot deformity (pes cavus) may also be early signs and precede ataxia."
      explanation: Human clinical-pathology review documents scoliosis as an FRDA skeletal deformity that may precede ataxia.
  - target: Pes Cavus
    description: >
      Progressive skeletal and neuromuscular involvement manifests as pes cavus
      in the FRDA phenotype list.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Scoliosis and foot deformity (pes cavus) may also be early signs and precede ataxia."
      explanation: Human clinical-pathology review documents pes cavus as an FRDA foot deformity that may precede ataxia.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_fxn_loss_of_function
  hypothesis_label: Canonical FXN Loss-of-Function Mitochondrial Pathograph
  status: CANONICAL
  description: >
    Biallelic FXN intron 1 GAA repeat expansion causes epigenetic
    transcriptional silencing and frataxin deficiency. Frataxin deficiency
    impairs mitochondrial Fe-S cluster biogenesis, oxidative phosphorylation,
    and iron handling, creating tissue-selective vulnerability in dorsal root
    ganglion sensory neurons, dentate/spinal pathways, cardiomyocytes,
    pancreatic beta cells, and the skeleton.
  notes: >-
    Retained as CANONICAL. The 2026 openscientist hypothesis-search report
    (kb/hypotheses/Friedreich_Ataxia/canonical_fxn_loss_of_function)
    reviewed 105 papers and confirmed the canonical causal chain (GAA
    expansion → epigenetic silencing → frataxin deficiency → impaired Fe-S
    cluster biogenesis → mitochondrial dysfunction → tissue-selective
    degeneration) at every link, capped by secretable-frataxin gene therapy
    achieving dual cardiac and neurological rescue in mouse models with a
    single intra-CSF AAV injection (the non-human primate arm of that study
    established biodistribution and protein repletion, not phenotype
    correction). Three
    qualifications expand the model to a branching tissue-specific
    pathograph rather than a single linear cascade: (1) DRG-neuron pathology
    is driven by ferroptosis (iron-dependent lipid peroxidation, impaired
    NRF2 response via LKB1/AMPK, KEAP1, GSK3β) and is rescued by the
    NRF2 activator omaveloxolone; (2) cardiac pathology involves
    mitochondrial iron overload with impaired mitophagy via the mTOR-TFEB
    axis, paradoxically WITHOUT increased oxidative stress; (3) frataxin's
    function has been refined from an iron donor to an allosteric activator
    of the NFS1-ISD11-ACP-ISCU2 Fe-S cluster assembly complex. Negative
    trial data (deferiprone worsened ataxia at 40 mg/kg) and gene-therapy
    overexpression toxicity (>20-fold normal cardiotoxic) collectively
    define a narrow therapeutic window and indicate that Fe-S cluster
    deficiency — not iron excess — is the primary neurological lesion.
  evidence:
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Deficiency of frataxin, a small mitochondrial protein, is responsible for all clinical and morphological manifestations of FRDA."
    explanation: Establishes frataxin deficiency as the common causal mechanism underlying the multisystem FRDA phenotype.
  - reference: PMID:42157962
    reference_title: "Development of a secretable frataxin for enhanced efficacy in treating Friedreich's Ataxia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "broad protein repletion across key target tissues-heart, dorsal root ganglia,"
    explanation: >
      Engineered secretable frataxin delivered via a single intra-CSF AAV
      injection achieves broad protein repletion across heart, DRG, and
      cerebellum in both mouse and non-human primate. Rescue of cardiac and
      neurological phenotypes was demonstrated in the mouse models; the
      non-human primate arm establishes biodistribution and repletion rather
      than phenotype correction. Still the strongest interventional support for
      the unified frataxin-deficiency causal hypothesis.
  - reference: PMID:31511419
    reference_title: "Mechanism of activation of the human cysteine desulfurase complex by frataxin."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "FXN specifically accelerates each of these individual steps in the mechanism."
    explanation: >
      Biochemical reconstitution shows frataxin acts as an allosteric
      activator of the NFS1-ISD11-ACP-ISCU2 cysteine desulfurase complex,
      refining the canonical model from an iron-donor function to an
      activator of Fe-S cluster biogenesis.
  - reference: PMID:26401053
    reference_title: "Expanded GAA repeats impede transcription elongation through the FXN gene and induce transcriptional silencing that is restricted to the FXN locus."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "deep sequencing of FXN pre-mRNA molecules revealed a pronounced defect in the transcription elongation rate in FRDA cells"
    explanation: >
      Patient cell RNA-seq directly demonstrates GAA-expansion-induced
      defect in transcription elongation that is restricted to the FXN
      locus, supporting cis-restricted epigenetic silencing as the
      molecular basis for frataxin deficiency.
  - reference: PMID:39243573
    reference_title: "Deciphering the ferroptosis pathways in dorsal root ganglia of Friedreich ataxia models. The role of LKB1/AMPK, KEAP1, and GSK3β in the impairment of the NRF2 response."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "primary cultures of"
    explanation: >
      Primary cultures of frataxin-deficient DRG neurons demonstrate
      ferroptosis pathway activation (lipid peroxidation, GPX4 loss,
      impaired NRF2 response via LKB1/AMPK/KEAP1/GSK3β), supporting the
      in-vitro arm of the canonical neurodegenerative model.
  - reference: PMID:39243573
    reference_title: "Deciphering the ferroptosis pathways in dorsal root ganglia of Friedreich ataxia models. The role of LKB1/AMPK, KEAP1, and GSK3β in the impairment of the NRF2 response."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "frataxin deficiency in DRG neurons disrupts iron homeostasis and the intricate regulation of molecular pathways affecting NRF2 activation"
    explanation: >
      Complementary FXNI151F mouse-model DRG data demonstrate that
      frataxin deficiency disrupts iron homeostasis and NRF2 activation
      pathways, supporting ferroptosis as the dominant cell-death mode in
      the canonical neurodegenerative arm in vivo.
  - reference: PMID:41579709
    reference_title: "Targeting frataxin deficiency in DRG neurons and fibroblasts: omaveloxolone restores metabolic and iron balance to reduce ferroptosis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "frataxin-deficient neurons, was almost completely rescued by omaveloxolone"
    explanation: >
      The FDA-approved NRF2 activator omaveloxolone nearly fully rescues
      ferroptosis-associated lipid peroxidation in frataxin-deficient
      neurons, providing pharmacological validation of the ferroptosis arm
      of the model and the canonical NRF2 axis.
  - reference: PMID:41628678
    reference_title: "Mitochondrial iron overload is associated with lysosomal dysfunction-mediated mitophagy impairment in the heart of Friedreich's ataxia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "absence of increased oxidative stress"
    explanation: >
      Qualifies the canonical model: heart-specific FXN knockout produces
      mitochondrial iron aggregates and impaired mitophagy via lysosomal
      dysfunction in the cardiac arm, distinct from the ferroptosis-driven
      neuronal arm.
  - reference: PMID:25112865
    reference_title: "Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "those receiving 40mg/kg/day had worsening in FARS and ICARS scores"
    explanation: >
      Iron chelation with deferiprone at 40 mg/kg/day worsened neurological
      scores in this 6-month randomized trial, and the 60 mg/kg/day arm was
      stopped for worsening ataxia. That qualifies naive iron-removal strategies
      and is consistent with Fe-S cluster deficiency rather than iron excess
      being the primary neurological lesion, but the trial's primary objective
      was safety and its own authors note that the absence of deterioration in
      the placebo arm limited what could be inferred about efficacy.
  - reference: PMID:33209958
    reference_title: "High Levels of Frataxin Overexpression Lead to Mitochondrial and Cardiac Toxicity in Mouse Models."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "significant toxicity to the mitochondria and heart above 20-fold"
    explanation: >
      AAV-mediated FXN overexpression above ~20-fold endogenous level
      caused significant mitochondrial and cardiac toxicity in mice,
      establishing a narrow therapeutic window where both frataxin
      deficiency AND excess impair mitochondrial function.
  - reference: PMID:31031004
    reference_title: "Hypoxia Rescues Frataxin Loss by Restoring Iron Sulfur Cluster Biogenesis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "fully viable. In human cells, hypoxia"
    explanation: >
      Hypoxia rescues frataxin-deficient cell viability and Fe-S cluster
      biogenesis, challenging the dogma that FXN is absolutely essential
      and suggesting tissue oxygen tension contributes to selective
      vulnerability.
  - reference: PMID:40498047
    reference_title: "Increase of Plasma Biomarkers in Friedreich's Ataxia: Potential Insights into Disease Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "annual NfL reductions between 8% (children) and 13%"
    explanation: >
      Two large independent cohorts (n=187 patients) show NfL is elevated
      in young FRDA patients but declines with age — the opposite
      trajectory of other neurodegenerative diseases — consistent with a
      front-loaded, developmental-hypoplasia-plus-progressive-atrophy DRG
      pathology arc.
discussions:
- discussion_id: optic_atrophy_subclinical_vs_clinical_frda
  prompt: >-
    How frequent is clinically apparent optic atrophy with visual loss in FRDA
    versus subclinical optic-nerve / retinal-ganglion-cell involvement
    detectable only on quantitative testing, and how should the phenotype
    frequency band be interpreted given this divergence?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Optic Atrophy
  rationale: >-
    Orphanet annotates optic atrophy as a frequent (79-30%) FRDA phenotype,
    whereas the Koeppen pathology review states that clinically apparent optic
    atrophy is uncommon (though some patients become blind). The discrepancy
    most likely reflects common subclinical optic-nerve / retinal-ganglion-cell
    involvement versus less-frequent overt visual loss. The entry carries
    frequency: FREQUENT (ORPHA-sourced) alongside the Koeppen quote; this
    discussion records the divergence so it is machine-visible rather than
    prose-only.
  evidence:
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Optic atrophy is uncommon but some patients become blind."
    explanation: Koeppen review states clinically apparent optic atrophy is uncommon, in tension with the Orphanet frequent annotation for the HPO term.
- discussion_id: iron_accumulation_cause_or_consequence_frda
  prompt: >-
    Is mitochondrial iron accumulation in FRDA a driver of tissue injury, or a
    late consequence of Fe-S cluster enzyme inactivation that has already
    occurred?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Mitochondrial Bioenergetic Failure and Oxidative Stress
  - animal_models#Conditional Fxn knockout mouse (MCK-Cre and NSE-Cre)
  rationale: >-
    The entry's mechanism chain places abnormal mitochondrial iron handling
    inside the bioenergetic-failure node without committing to its causal rank.
    The conditional-knockout mouse shows iron deposition appearing only after
    Fe-S enzyme inactivation and after pathology onset, which argues iron is
    downstream rather than initiating. That ordering is a mouse result and has
    not been established in human tissue, and it bears directly on whether iron
    chelation can be disease-modifying rather than merely a biomarker-directed
    intervention. Recorded so the open question is machine-visible rather than
    settled by omission.
  evidence:
  - reference: PMID:11175786
    reference_title: "Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "time-dependent intramitochondrial iron accumulation in a frataxin-deficient mammal, which occurs after onset of the pathology and after inactivation of the Fe-S-dependent enzymes"
    explanation: Places iron accumulation after Fe-S enzyme inactivation and after pathology onset, the observation that motivates this question.
- discussion_id: tissue_specific_effector_divergence_frda
  prompt: >-
    Why does a single upstream lesion — frataxin deficiency with impaired Fe-S
    cluster biogenesis — produce ferroptotic death in dorsal root ganglion
    neurons but mitophagy failure without increased oxidative stress in
    cardiomyocytes?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Dorsal Root Ganglion Sensory Neuronopathy
  - pathophysiology#Cardiomyocyte Mitochondrial Injury
  - pathophysiology#Mitochondrial Bioenergetic Failure and Oxidative Stress
  rationale: >-
    The entry models a shared mitochondrial branch point that feeds every tissue
    arm, and annotates that shared node with increased oxidative stress. Cardiac
    data complicate that reading: in heart-specific frataxin-knockout mice,
    respiration is markedly impaired and mitochondrial iron aggregates
    accumulate while oxidative stress does not rise, and the lesion instead
    tracks with disrupted mitophagy through the mTOR-TFEB lysosomal axis. In DRG
    neurons the dominant mode is ferroptosis, an explicitly oxidative,
    iron-dependent death. Nothing in the current model explains the divergence,
    and it is not merely academic: it predicts that anti-ferroptotic and
    pro-mitophagy agents would have organ-specific rather than global benefit,
    which is one reading of why antioxidant trials did not improve cardiac
    endpoints. The evidence is also internally contested, because the biomineral
    iron deposits characterised in the muscle-creatine-kinase conditional
    frataxin-knockout mouse heart were argued to contribute to oxidative stress
    there. Resolution needs oxidative-stress and mitophagy markers measured side
    by side in the two tissues, ideally in patient material rather than in
    complete tissue-specific knockouts, which model a deeper deficiency than the
    5-30% residual frataxin that patients carry.
  evidence:
  - reference: PMID:41628678
    reference_title: "Mitochondrial iron overload is associated with lysosomal dysfunction-mediated mitophagy impairment in the heart of Friedreich's ataxia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "mitochondrial respiration was markedly impaired in FRDA hearts, despite the absence of increased oxidative stress"
    explanation: States the cardiac exception to a uniformly oxidative downstream mechanism, which is what makes the tissue divergence a gap.
  - reference: PMID:23169664
    reference_title: "Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: "These mitochondrial aggregates of Fe, phosphorus, and sulfur, probably contribute to the oxidative stress and pathology observed in the absence of frataxin."
    explanation: >-
      Argues the opposite in a muscle-creatine-kinase conditional
      frataxin-knockout mouse heart, so the claim that cardiac pathology
      proceeds without oxidative stress is contested rather than settled.
- discussion_id: cardiac_neurologic_severity_dissociation_frda
  prompt: >-
    Why is cardiomyopathy severity uncorrelated with neurological severity in
    FRDA, and what tissue-specific modifiers decouple the two arms of the
    pathograph?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Cardiomyocyte Mitochondrial Injury
  - phenotypes#Hypertrophic Cardiomyopathy
  rationale: >-
    A comprehensive cardiac assessment of 205 FRDA patients, combining
    echocardiography, colour Doppler myocardial imaging and cardiac magnetic
    resonance, found no clear correlation between cardiomyopathy grouping and
    neurological function. The entry draws both the cardiac and the neurological
    branches from one shared mitochondrial node, which implicitly predicts that
    they should track together. They do not. Candidate explanations include
    tissue-specific somatic GAA repeat lengths, differing effector pathways, and
    modifier loci, none of which is established. This matters for trial design,
    because a therapy chosen on a neurological endpoint may say nothing about
    cardiac benefit. The observation is cross-sectional and grouping-based, so it
    establishes a dissociation rather than independent causation; longitudinal
    organ-specific progression data would be needed to go further.
  evidence:
  - reference: PMID:22379112
    reference_title: "The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Importantly, no clear correlation was found between FA-CM groups and neurological function."
    explanation: Cross-sectional study of 205 patients reporting the dissociation between cardiac and neurological severity that this gap records.
- discussion_id: neuroinflammation_primary_vs_secondary_frda
  prompt: >-
    Is the loss of microglial homeostatic function in frataxin deficiency an
    independent driver of cerebellar degeneration, or a secondary response to
    neuronal injury?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Dentate Nucleus and Spinocerebellar Tract Degeneration
  rationale: >-
    Single-cell RNA sequencing of the cerebellum in an FRDA mouse model shows
    frataxin-deficient microglia losing their homeostatic signature, responding
    more strongly to inflammatory stimuli, and shifting metabolically toward
    glycolysis and itaconate production; butyrate reverses those changes and
    improves neuromotor performance. If neuroinflammation amplifies degeneration
    independently, anti-inflammatory therapy could slow progression without
    restoring frataxin, which would be a therapeutic route the current pathograph
    does not contain. The supporting evidence is one mouse single-cell dataset,
    with no human FRDA cerebellar microglial profiling, so the mechanism is
    deliberately not modelled as a pathophysiology node. A microglia-specific
    conditional FXN knockout with intact neuronal frataxin would separate the two
    readings.
  evidence:
  - reference: PMID:38631900
    reference_title: Frataxin deficiency shifts metabolism to promote reactive microglia via glucose catabolism.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "emphasizing a significant loss in the homeostatic response of microglial cells lacking FXN"
    explanation: Single-cell RNA sequencing in an FRDA mouse cerebellum establishes the microglial phenotype whose causal position this gap leaves open.
- discussion_id: somatic_gaa_instability_tissue_selectivity_frda
  prompt: >-
    How much of FRDA tissue-selective vulnerability is explained by somatic GAA
    repeat instability, given that heart and pancreas carry longer tracts than
    the dorsal root ganglia that are affected earliest?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#FXN
  - pathophysiology#FXN GAA Repeat Expansion and Epigenetic Silencing
  rationale: >-
    GAA tracts measured across heart, cerebral cortex, spinal cord, cerebellar
    cortex and pancreas from 15 FRDA patients are significantly longer in heart
    and pancreas than elsewhere, and lymphocyte tracts expand progressively by up
    to about nine repeats per year over 7 to 9 years of follow-up. Because repeat
    length is inversely related to residual frataxin, somatic expansion is an
    obvious candidate for tissue selectivity, and if it is a major driver then
    mismatch-repair modulation aimed at repeat contraction becomes a
    disease-modifying strategy. The candidate does not fit the clinical ordering,
    however: dorsal root ganglion pathology appears earliest and most severely
    despite shorter tracts than heart. No study has yet paired tissue-specific
    repeat length with tissue-specific frataxin protein levels and organ-specific
    progression in the same patients, so the quantitative contribution is
    unresolved and the entry does not model somatic instability as a causal step.
  evidence:
  - reference: PMID:29261783
    reference_title: "Somatic instability of the expanded GAA repeats in Friedreich's ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Results demonstrate differences in the lengths of the expanded GAAs among different tissues, with significantly longer GAA tracts detected in heart and pancreas than in other tissues."
    explanation: Establishes tissue-specific somatic repeat lengths in patient autopsy tissue, the observation whose pathogenic weight this gap records as unquantified.
phenotypes:
- category: Neurologic
  name: Progressive Gait and Limb Ataxia
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >
    Progressive cerebellar and sensory ataxia affecting gait and limb coordination
    is the hallmark feature. Most patients require wheelchair use within 10-15
    years of onset.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "his description remains at the core of the classical clinical phenotype of gait and limb ataxia, poor balance and coordination, leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes."
    explanation: Comprehensive description of the classical Friedreich ataxia phenotype with ataxia as the core feature.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002070 | Limb ataxia | Very frequent (99-80%)"
    explanation: Orphanet's HPO table supports very frequent limb ataxia in Friedreich ataxia.
- category: Neurologic
  name: Dysarthria
  frequency: VERY_FREQUENT
  description: >
    Progressive speech difficulty due to cerebellar dysfunction, typically
    developing within a few years of disease onset.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gait and limb ataxia, poor balance and coordination, leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia"
    explanation: Dysarthria is part of the classical phenotype.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001260 | Dysarthria | Very frequent (99-80%)"
    explanation: Orphanet's HPO table supports dysarthria as a very frequent Friedreich ataxia phenotype.
- category: Musculoskeletal
  name: Muscle Weakness
  frequency: FREQUENT
  description: >
    Limb weakness, including distal extremity weakness and skeletal muscle
    involvement, is part of the classical Friedreich ataxia phenotype.
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities"
    explanation: Lists leg weakness among the classical FRDA clinical features.
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The following neurological signs are most frequent: Gait ataxia, dysmetria of arms and legs, dysarthria, head titubation, atrophy and weakness of the distal extremities"
    explanation: Identifies distal extremity weakness among the most frequent neurologic signs in FRDA.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001324 | Muscle weakness | Frequent (79-30%)"
    explanation: Orphanet's HPO table supports muscle weakness as a frequent Friedreich ataxia phenotype.
- category: Neurologic
  name: Dysphagia
  frequency: OCCASIONAL
  description: >
    Swallowing impairment occurs as part of the classical neurologic phenotype
    of Friedreich ataxia.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities"
    explanation: Lists dysphagia among the classical FRDA clinical features.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002015 | Dysphagia | Occasional (29-5%)"
    explanation: Orphanet's HPO table supports dysphagia as an occasional Friedreich ataxia phenotype.
- category: Neurologic
  name: Nystagmus
  frequency: FREQUENT
  description: >
    Nystagmus and other eye movement abnormalities occur in Friedreich ataxia.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "dysarthria, dysphagia, eye movement abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes"
    explanation: Lists eye movement abnormalities among the classical FRDA clinical features.
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Many patients with FRDA have nystagmus."
    explanation: Directly supports nystagmus as a common FRDA neurologic manifestation.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000639 | Nystagmus | Frequent (79-30%)"
    explanation: Orphanet's HPO table supports nystagmus as a frequent Friedreich ataxia phenotype.
- category: Neurologic
  name: Peripheral Neuropathy
  frequency: VERY_FREQUENT
  description: >
    Predominantly sensory neuropathy with impaired proprioception and vibration
    sense; both peripheral motor and sensory nerves are involved. The dorsal
    root ganglia are preferentially affected. The resulting loss of deep tendon
    reflexes is modeled separately as the Areflexia of Lower Limbs phenotype.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "peripheral motor and sensory neuropathy, spasticity, autonomic disturbance"
    explanation: GeneReviews lists peripheral motor and sensory neuropathy among the core clinical characteristics of typical Friedreich ataxia.
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "loss of joint and vibratory senses, and superimposed stocking-and-glove type sensory neuropathy"
    explanation: Human pathology review documents the sensory (proprioceptive/vibratory) loss and stocking-and-glove sensory neuropathy of FRDA.
- category: Cardiac
  name: Hypertrophic Cardiomyopathy
  frequency: FREQUENT
  description: >
    Hypertrophic cardiomyopathy is present in about two thirds of individuals
    and is the leading cause of death. It can progress to dilated cardiomyopathy
    with heart failure.
  phenotype_term:
    preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "his description remains at the core of the classical clinical phenotype of gait and limb ataxia, poor balance and coordination, leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes."
    explanation: Cardiomyopathy is listed as part of the classical Friedreich ataxia phenotype.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001638 | Cardiomyopathy | Frequent (79-30%)"
    explanation: Orphanet's HPO table supports cardiomyopathy as a frequent Friedreich ataxia phenotype.
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypertrophic cardiomyopathy is present in about two thirds of individuals"
    explanation: GeneReviews states hypertrophic cardiomyopathy is present in about two-thirds of individuals, supporting the FREQUENT band.
- category: Musculoskeletal
  name: Scoliosis
  frequency: FREQUENT
  description: >
    Progressive scoliosis is common, often requiring surgical intervention.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "scoliosis, foot deformities, cardiomyopathy and diabetes."
    explanation: Scoliosis is part of the classical phenotype.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002650 | Scoliosis | Frequent (79-30%)"
    explanation: Orphanet's HPO table supports scoliosis as a frequent Friedreich ataxia phenotype.
- category: Musculoskeletal
  name: Pes Cavus
  frequency: FREQUENT
  description: >
    High-arched feet (pes cavus) are a characteristic skeletal deformity.
  phenotype_term:
    preferred_term: Pes cavus
    term:
      id: HP:0001761
      label: Pes cavus
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early-onset cases tend to have more rapid progression and a higher frequency of non-neurological features such as diabetes, cardiomyopathy, scoliosis and pes cavus."
    explanation: Pes cavus is more frequent in early-onset cases.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001761 | Pes cavus | Frequent (79-30%)"
    explanation: Orphanet's HPO table supports pes cavus as a frequent Friedreich ataxia phenotype.
- category: Endocrine
  name: Diabetes Mellitus
  frequency: OCCASIONAL
  description: >
    Diabetes mellitus occurs in approximately 10-30% of patients, likely due to
    beta cell dysfunction from mitochondrial impairment and iron toxicity.
  phenotype_term:
    preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "scoliosis, foot deformities, cardiomyopathy and diabetes."
    explanation: Diabetes is part of the classical phenotype description.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000819 | Diabetes mellitus | Occasional (29-5%)"
    explanation: Orphanet's HPO table supports diabetes mellitus as an occasional Friedreich ataxia phenotype.
- category: Neurologic
  name: Extensor Plantar Response (Babinski Sign)
  frequency: VERY_FREQUENT
  description: >
    Pyramidal-tract (upper motor neuron) signs, including an extensor plantar
    response (Babinski sign), arise from corticospinal tract degeneration and
    are among the most frequent neurologic signs in Friedreich ataxia. They
    coexist with the areflexia produced by the sensory/peripheral neuropathy.
  phenotype_term:
    preferred_term: Babinski sign
    term:
      id: HP:0003487
      label: Babinski sign
  evidence:
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "absence of muscle stretch reflexes, Babinski signs, loss of joint and vibratory senses"
    explanation: Human pathology review lists Babinski signs among the most frequent neurologic signs in FRDA, reflecting corticospinal tract degeneration.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003487 | Babinski sign | Very frequent (99-80%)"
    explanation: Orphanet's HPO table classifies Babinski sign as a very frequent Friedreich ataxia phenotype.
- category: Neurologic
  name: Areflexia of Lower Limbs
  frequency: FREQUENT
  description: >
    Loss of lower-limb deep tendon reflexes (knee and ankle jerks) is an early
    and cardinal diagnostic sign of Friedreich ataxia, reflecting dorsal root
    ganglion sensory neuronopathy and peripheral sensory nerve involvement.
    A minority of patients have the atypical FRDA-with-retained-reflexes (FARR)
    variant.
  phenotype_term:
    preferred_term: Areflexia of lower limbs
    term:
      id: HP:0002522
      label: Areflexia of lower limbs
  evidence:
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "atrophy and weakness of the distal extremities, absence of muscle stretch reflexes"
    explanation: Human pathology review lists absence of muscle stretch reflexes among the most frequent neurologic signs in FRDA.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002522 | Areflexia of lower limbs | Frequent (79-30%)"
    explanation: Orphanet's HPO table classifies areflexia of lower limbs as a frequent Friedreich ataxia phenotype.
- category: Neurologic
  name: Spasticity
  frequency: OCCASIONAL
  description: >
    Lower-limb spasticity and hyperreflexia from corticospinal tract involvement
    can appear as the disease progresses, sometimes requiring intrathecal
    baclofen for control. Spasticity typically coexists with the areflexia of
    the peripheral sensory neuropathy.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spasticity and hyperreflexia in the legs are no longer rare."
    explanation: Human pathology review documents lower-limb spasticity and hyperreflexia in FRDA from corticospinal tract involvement.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001257 | Spasticity | Occasional (29-5%)"
    explanation: Orphanet's HPO table classifies spasticity as an occasional Friedreich ataxia phenotype.
- category: Ophthalmologic
  name: Optic Atrophy
  frequency: FREQUENT
  description: >
    Optic atrophy with visual pathway involvement occurs in Friedreich ataxia.
    Subclinical retinal nerve fibre / optic nerve involvement is common on
    quantitative testing, whereas clinically apparent optic atrophy with visual
    loss is less frequent; a small proportion of patients become blind.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and often abnormal eye movements and optic atrophy"
    explanation: GeneReviews lists optic atrophy among the clinical characteristics of Friedreich ataxia.
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Optic atrophy is uncommon but some patients become blind."
    explanation: Human pathology review notes clinically apparent optic atrophy is uncommon but can progress to blindness, qualifying the frequency of overt visual loss.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000648 | Optic atrophy | Frequent (79-30%)"
    explanation: Orphanet's HPO table classifies optic atrophy as a frequent Friedreich ataxia phenotype.
- category: Neurologic
  name: Impaired Proprioception
  frequency: VERY_FREQUENT
  description: >
    Loss of joint position sense, a near-universal sign arising from destruction
    of the large primary sensory neurons of the dorsal root ganglia and the
    consequent degeneration of the dorsal columns. It is the afferent component
    of the ataxia, distinguishing Friedreich ataxia from a purely cerebellar
    ataxia.
  phenotype_term:
    preferred_term: Impaired proprioception
    term:
      id: HP:0010831
      label: Impaired proprioception
  evidence:
  - reference: PMID:25928624
    reference_title: Consensus clinical management guidelines for Friedreich ataxia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The hallmark clinical features of FRDA include progressive afferent and cerebellar ataxia, dysarthria, impaired vibration sense and proprioception, absent tendon reflexes in lower limbs, pyramidal weakness, scoliosis, foot deformity and cardiomyopathy"
    explanation: The international consensus management guidelines list impaired proprioception among the hallmark clinical features of FRDA.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0010831 | Impaired proprioception | Very frequent (99-80%)"
    explanation: Orphanet's HPO table classifies impaired proprioception as a very frequent Friedreich ataxia phenotype.
- category: Neurologic
  name: Impaired Vibratory Sensation
  frequency: FREQUENT
  description: >
    Reduced or absent vibration sense, typically most marked distally in the
    lower limbs. Like the proprioceptive deficit it reflects large-fibre
    afferent loss originating in the dorsal root ganglia rather than a
    cerebellar lesion.
  phenotype_term:
    preferred_term: Impaired vibratory sensation
    term:
      id: HP:0002495
      label: Impaired vibratory sensation
  evidence:
  - reference: PMID:25928624
    reference_title: Consensus clinical management guidelines for Friedreich ataxia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The hallmark clinical features of FRDA include progressive afferent and cerebellar ataxia, dysarthria, impaired vibration sense and proprioception, absent tendon reflexes in lower limbs, pyramidal weakness, scoliosis, foot deformity and cardiomyopathy"
    explanation: The international consensus management guidelines list impaired vibration sense among the hallmark clinical features of FRDA.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002495 | Impaired vibratory sensation | Frequent (79-30%)"
    explanation: Orphanet's HPO table classifies impaired vibratory sensation as a frequent Friedreich ataxia phenotype.
  notes: >-
    The FREQUENT band is Orphanet's. It sits a tier below the VERY_FREQUENT band
    Orphanet gives impaired proprioception, even though the consensus guideline
    sentence cited above lists the two together as hallmark features and the
    Koeppen pathology review counts loss of joint and vibratory senses among the
    most frequent signs. The bands are kept as Orphanet records them and the
    divergence is noted rather than resolved.
- category: Neurologic
  name: Hearing Impairment
  frequency: OCCASIONAL
  description: >
    Auditory dysfunction affecting a minority of patients. The deficit is
    retrocochlear rather than cochlear in character, which is why conventional
    amplification and cochlear implantation are of limited benefit, and why
    the consensus guidelines recommend auditory evaluation at diagnosis with
    annual screening thereafter.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000365 | Hearing impairment | Occasional (29-5%)"
    explanation: Orphanet's HPO table classifies hearing impairment as an occasional Friedreich ataxia phenotype.
  - reference: PMID:25928624
    reference_title: Consensus clinical management guidelines for Friedreich ataxia.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "Conventional hearing aids and cochlear implants may not improve the hearing impairment related to FRDA."
    explanation: >-
      Supports the retrocochlear character of the deficit by inference: the
      guidelines state that devices addressing cochlear and conductive loss may
      not help, rather than naming the lesion site directly. Graded OTHER because
      this particular recommendation carries the guideline's GPP (good practice
      point) marker, i.e. expert consensus, where its neighbours in the same
      block carry graded evidence.
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite normal pure-tone audiometry, patients with FRDA may have problems with speech perception"
    explanation: Documents preserved pure-tone thresholds alongside impaired speech perception, the audiometric signature of a retrocochlear rather than cochlear lesion.
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A suitable term is “auditory neuropathy/dyssynchrony”
    explanation: Names the deficit an auditory neuropathy, which is the claim the binding rationale in this phenotype's notes rests on.
  - reference: PMID:25928624
    reference_title: Consensus clinical management guidelines for Friedreich ataxia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "People with FRDA should undergo a comprehensive auditory evaluation at the time of diagnosis and thereafter annually undertake a hearing screen"
    explanation: Sources the surveillance schedule stated in this phenotype's description.
  notes: >-
    Bound to the generic HP:0000365 rather than a sensorineural child term.
    Orphanet's own row uses the generic term, and the audiological picture in
    FRDA is an auditory neuropathy, so a cochlear-sensorineural binding would be
    narrower than the cited evidence supports.
genetic:
- name: FXN
  gene_term:
    preferred_term: FXN
    term:
      id: hgnc:3951
      label: FXN
  association: GAA Trinucleotide Repeat Expansion
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  inheritance:
  - name: Autosomal recessive inheritance
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
    - reference: PMID:20301458
      reference_title: "Friedreich Ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "FRDA is inherited in an autosomal recessive manner."
      explanation: GeneReviews states Friedreich ataxia follows autosomal recessive inheritance.
  notes: >
    Homozygous GAA repeat expansion in intron 1 of FXN on chromosome 9q21.11
    accounts for approximately 96% of cases. Normal alleles have 5-33 repeats;
    affected individuals have 66-1700 repeats. A small number of cases are
    compound heterozygous for an expansion and a point mutation or deletion.
    Repeat length inversely correlates with age of onset and frataxin levels.
  variants:
  - name: FXN intron 1 GAA repeat expansion
    description: >
      Pathogenic non-coding trinucleotide repeat expansion in intron 1 of FXN
      that silences FXN transcription. Most affected individuals are homozygous
      for expanded alleles; a minority are compound heterozygous for one
      expansion plus an FXN deletion, point mutation, or insertion.
    gene:
      preferred_term: FXN
      term:
        id: hgnc:3951
        label: FXN
    clinical_significance: PATHOGENIC
    type: trinucleotide_repeat_expansion
    functional_effects:
    - function: FXN transcription
      description: Expanded intronic GAA repeat causes reduced FXN transcription through repressive chromatin and transcriptional silencing.
      type: loss-of-expression
      regulatory_category: LOE
      regulatory_element_type: SILENCER
      regulatory_mechanism: Repressive chromatin formation around the expanded intron 1 GAA repeat.
    evidence:
    - reference: PMID:32826895
      reference_title: "Frataxin gene editing rescues Friedreich's ataxia pathology in dorsal root ganglia organoid-derived sensory neurons."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Friedreich's ataxia (FRDA) is an autosomal-recessive neurodegenerative and cardiac disorder which occurs when transcription of the FXN gene is silenced due to an excessive expansion of GAA repeats into its first intron."
      explanation: Supports the variant-level functional effect of the GAA repeat expansion as FXN transcriptional silencing.
  evidence:
  - reference: PMID:14653404
    reference_title: "Friedreich ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the unstable GAA expansion that underlies FA causes a deficiency of the mitochondrial protein frataxin"
    explanation: Confirms GAA expansion as the causative mutation leading to frataxin deficiency.
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Inheritance is autosomal recessive with the vast majority of cases showing an unstable intronic GAA expansion in both alleles of the frataxin gene on chromosome 9q13."
    explanation: Confirms autosomal recessive inheritance with homozygous GAA expansion in FXN.
  - reference: CGGV:assertion_ec3f674b-1e71-4254-a0f9-f8909becff59-2017-12-22T170000.000Z
    reference_title: "FXN / Friedreich ataxia (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FXN | HGNC:3951 | Friedreich ataxia | MONDO:0100339 | AR | Definitive"
    explanation: ClinGen classifies the FXN-Friedreich ataxia gene-disease relationship as definitive with autosomal recessive inheritance.
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "96% of individuals with FRDA have biallelic FXN GAA repeat expansions in intron"
    explanation: GeneReviews quantifies the variant-class breakdown, backing the ~96% GAA-expansion / ~4% compound-heterozygote figures stated in the genetic notes.
  - reference: PMID:8751856
    reference_title: The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Smaller alleles showed the best correlation, accounting for approximately 50% of the variation of age at onset."
    explanation: Quantifies the inverse repeat-length/age-at-onset relationship asserted in the genetic notes, and identifies the shorter allele as the better predictor.
  - reference: PMID:8751856
    reference_title: The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean allele length was significantly higher in patients with diabetes and in those with cardiomyopathy."
    explanation: Extends the genotype-phenotype relationship beyond age at onset to the two extraneural complications that drive morbidity and mortality.
  - reference: PMID:28789479
    reference_title: Heart and Nervous System Pathology in Compound Heterozygous Friedreich Ataxia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pathologic phenotype in homozygous and compound heterozygous FA is determined by residual frataxin levels rather than unique mutations."
    explanation: >-
      Matched neuropathology of compound heterozygous and homozygous cases shows
      residual frataxin, not the identity of the second allele, sets the
      phenotype. This is why the entry models one mechanism chain for both
      variant classes rather than separating compound heterozygotes.
differential_diagnoses:
- name: Ataxia with vitamin E deficiency (AVED)
  disease_term:
    preferred_term: ataxia with isolated vitamin E deficiency
    term:
      id: MONDO:0010188
      label: familial isolated deficiency of vitamin E
  description: >-
    An autosomal recessive ataxia that can closely mimic Friedreich ataxia,
    with progressive gait and limb ataxia, areflexia, loss of proprioception
    and vibration sense, and in some patients cardiomyopathy.
  distinguishing_features:
  - Treatable with high-dose vitamin E supplementation, so it must be excluded before a clinical FRDA diagnosis is accepted
  - Low serum vitamin E, which Friedreich ataxia does not cause
  - Caused by TTPA variants rather than FXN
  - Head titubation and retinitis pigmentosa are commoner than in Friedreich ataxia
  notes: >-
    This differential is clinically load-bearing rather than academic: the
    cited consensus states that some recessive ataxias are treatable, and AVED
    is the case in point.
  evidence:
  - reference: PMID:24418350
    reference_title: EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the case of recessive disease, a stepwise diagnostic work-up is recommended, including both biochemical markers and targeted genetic testing, particularly aimed at Friedreich's ataxia, ataxia telangiectasia, ataxia due to vitamin E deficiency, polymerase gamma gene (POLG gene, various mutations), autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) and ataxia with oculomotor apraxia (AOA) types 1 and 2."
    explanation: The EFNS/ENS consensus places this condition alongside Friedreich ataxia in the recommended work-up for recessive ataxia, which is what makes it a differential.
- name: Ataxia-telangiectasia
  disease_term:
    preferred_term: ataxia telangiectasia
    term:
      id: MONDO:0008840
      label: ataxia telangiectasia
  description: >-
    An autosomal recessive ataxia with early-onset progressive cerebellar
    ataxia and neurodegeneration overlapping the FRDA presentation.
  distinguishing_features:
  - Oculocutaneous telangiectasias
  - Immunodeficiency with recurrent sinopulmonary infection
  - Raised alpha-fetoprotein
  - Chromosomal instability and markedly increased malignancy risk
  evidence:
  - reference: PMID:24418350
    reference_title: EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the case of recessive disease, a stepwise diagnostic work-up is recommended, including both biochemical markers and targeted genetic testing, particularly aimed at Friedreich's ataxia, ataxia telangiectasia, ataxia due to vitamin E deficiency, polymerase gamma gene (POLG gene, various mutations), autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) and ataxia with oculomotor apraxia (AOA) types 1 and 2."
    explanation: The EFNS/ENS consensus places this condition alongside Friedreich ataxia in the recommended work-up for recessive ataxia, which is what makes it a differential.
- name: Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)
  disease_term:
    preferred_term: Charlevoix-Saguenay spastic ataxia
    term:
      id: MONDO:0010041
      label: Charlevoix-Saguenay spastic ataxia
  description: >-
    An early-onset recessive ataxia combining cerebellar ataxia with peripheral
    neuropathy, a combination it shares with Friedreich ataxia.
  distinguishing_features:
  - Prominent spasticity early in the course, where Friedreich ataxia more often shows areflexia with extensor plantar responses
  - Retinal nerve fibre hypermyelination on fundoscopy
  - Pontine hypointensities on MRI
  evidence:
  - reference: PMID:24418350
    reference_title: EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the case of recessive disease, a stepwise diagnostic work-up is recommended, including both biochemical markers and targeted genetic testing, particularly aimed at Friedreich's ataxia, ataxia telangiectasia, ataxia due to vitamin E deficiency, polymerase gamma gene (POLG gene, various mutations), autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) and ataxia with oculomotor apraxia (AOA) types 1 and 2."
    explanation: The EFNS/ENS consensus places this condition alongside Friedreich ataxia in the recommended work-up for recessive ataxia, which is what makes it a differential.
- name: Ataxia with oculomotor apraxia type 1
  disease_term:
    preferred_term: ataxia with oculomotor apraxia type 1
    term:
      id: MONDO:0008842
      label: ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia
  description: >-
    A recessive ataxia with progressive ataxia and peripheral neuropathy in the
    same age range as Friedreich ataxia.
  distinguishing_features:
  - Oculomotor apraxia
  - Hypoalbuminemia with hypercholesterolemia
  notes: >-
    Scoped to AOA1, which is the disease MONDO:0008842 names. The cited
    consensus lists AOA types 1 and 2 together in the recessive-ataxia work-up;
    AOA2 is the same differential clinically and is distinguished by a raised
    alpha-fetoprotein, but it is a separate MONDO concept and is not curated as
    its own entry here.
  evidence:
  - reference: PMID:24418350
    reference_title: EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the case of recessive disease, a stepwise diagnostic work-up is recommended, including both biochemical markers and targeted genetic testing, particularly aimed at Friedreich's ataxia, ataxia telangiectasia, ataxia due to vitamin E deficiency, polymerase gamma gene (POLG gene, various mutations), autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) and ataxia with oculomotor apraxia (AOA) types 1 and 2."
    explanation: The EFNS/ENS consensus places this condition alongside Friedreich ataxia in the recommended work-up for recessive ataxia, which is what makes it a differential.
- name: POLG-related ataxia
  description: >-
    Mitochondrial ataxia caused by POLG variants, presenting with progressive
    ataxia and sensory neuropathy.
  distinguishing_features:
  - Epilepsy
  - Ophthalmoplegia
  - Hepatic involvement
  notes: >-
    No MONDO term is bound because POLG-related disease is a spectrum rather
    than a single concept, and the cited consensus names the gene rather than
    one disorder.
  evidence:
  - reference: PMID:24418350
    reference_title: EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the case of recessive disease, a stepwise diagnostic work-up is recommended, including both biochemical markers and targeted genetic testing, particularly aimed at Friedreich's ataxia, ataxia telangiectasia, ataxia due to vitamin E deficiency, polymerase gamma gene (POLG gene, various mutations), autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) and ataxia with oculomotor apraxia (AOA) types 1 and 2."
    explanation: The EFNS/ENS consensus places this condition alongside Friedreich ataxia in the recommended work-up for recessive ataxia, which is what makes it a differential.
diagnosis:
- name: Molecular Genetic Testing of FXN
  description: >
    The diagnosis of Friedreich ataxia is established in a proband with
    suggestive clinical findings by identifying biallelic pathogenic FXN
    variants on molecular genetic testing. Testing must detect the two variant
    classes: the intron 1 GAA repeat expansion (which standard sequencing
    misses and which requires a repeat-sizing assay) and, in compound
    heterozygotes, an intragenic FXN sequence variant or deletion.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  results: >-
    Detection of biallelic pathogenic FXN variants (homozygous GAA expansion, or
    an expansion plus an intragenic variant/deletion) confirms Friedreich ataxia.
  evidence:
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in FXN identified by molecular genetic testing."
    explanation: GeneReviews establishes that FRDA is confirmed by identifying biallelic pathogenic FXN variants on molecular genetic testing.
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The two classes of FXN pathogenic variants are (1) GAA repeat expansions and (2) FXN pathogenic sequence variants"
    explanation: GeneReviews defines the two FXN pathogenic-variant classes (GAA repeat expansions and sequence variants), the reason testing must cover both a repeat-sizing assay and sequencing.
- name: Echocardiography
  description: >
    Echocardiography at diagnosis and at least annually thereafter. This is
    surveillance rather than a confirmatory test: the cardiomyopathy is the
    leading cause of death in FRDA and is frequently present before it becomes
    symptomatic.
  diagnosis_term:
    preferred_term: Echocardiography Test
    term:
      id: NCIT:C16525
      label: Echocardiography Test
  results: >-
    Concentric hypertrophic cardiomyopathy, progressing to a dilated phenotype
    in some patients.
  evidence:
  - reference: PMID:25928624
    reference_title: Consensus clinical management guidelines for Friedreich ataxia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "An EKG and an echocardiogram should be performed at diagnosis and then at least annually."
    explanation: >-
      Gives the surveillance schedule. Graded OTHER because this recommendation
      carries the guideline's GPP (good practice point) marker, i.e. expert
      consensus rather than graded trial evidence.
- name: Electrocardiography
  description: >
    Electrocardiography at diagnosis and at least annually thereafter, on the
    same surveillance schedule as echocardiography. It is the arrhythmia arm of
    cardiac surveillance, distinct from the structural assessment.
  diagnosis_term:
    preferred_term: Electrocardiography
    term:
      id: NCIT:C38053
      label: Electrocardiography
  results: >-
    Repolarization abnormalities and left ventricular hypertrophy patterns;
    atrial arrhythmias occur later in the disease course.
  evidence:
  - reference: PMID:25928624
    reference_title: Consensus clinical management guidelines for Friedreich ataxia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "An EKG and an echocardiogram should be performed at diagnosis and then at least annually."
    explanation: >-
      The same guideline sentence sets the schedule for both cardiac tests.
      Graded OTHER for the same reason: the recommendation carries the
      guideline's GPP (good practice point) marker.
treatments:
- name: Omaveloxolone
  description: >
    Approved pharmacotherapy for individuals with Friedreich ataxia aged 16
    years and older. It is used to slow neurologic progression by modulating
    oxidative-stress and mitochondrial-function pathways rather than restoring
    FXN expression directly.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: omaveloxolone
      term:
        id: CHEBI:229661
        label: omaveloxolone
  target_mechanisms:
  - target: Mitochondrial Bioenergetic Failure and Oxidative Stress
    treatment_effect: MODULATES
    description: >
      Omaveloxolone acts downstream of FXN silencing by targeting the oxidative
      stress and mitochondrial dysfunction branch of the pathograph.
    evidence:
    - reference: PMID:39115603
      reference_title: "New and Emerging Drug and Gene Therapies for Friedreich Ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Currently therapies focus on reducing oxidative stress and improving mitochondrial function, modulating frataxin controlled metabolic pathways and gene replacement and editing."
      explanation: Supports placing approved and emerging pharmacotherapies on the oxidative-stress/mitochondrial-function mechanism branch.
    - reference: PMID:33068037
      reference_title: Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and reduces inflammation in models of FA."
      explanation: >-
        Names Nrf2 activation as the mechanism by which the drug acts on this
        node. Graded OTHER because the sentence is the trial report's background
        summary of preclinical model work and does not say which model systems
        produced it.
  - target: Dorsal Root Ganglion Sensory Neuronopathy
    treatment_effect: MODULATES
    description: >
      As an NRF2 activator, omaveloxolone acts on the ferroptosis arm of the
      sensory-neuron branch, restoring NRF2 levels and reducing the lipid
      peroxidation that marks ferroptotic death of frataxin-deficient DRG
      neurons.
    evidence:
    - reference: PMID:41579709
      reference_title: "Targeting frataxin deficiency in DRG neurons and fibroblasts: omaveloxolone restores metabolic and iron balance to reduce ferroptosis."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "lipid peroxidation, a key marker of ferroptosis that was increased in frataxin-deficient neurons, was almost completely rescued by omaveloxolone"
      explanation: >
        Frataxin-deficient DRG neurons treated with omaveloxolone show near-full
        rescue of the ferroptosis marker, linking the approved drug to this
        specific node rather than only to the shared mitochondrial branch.
  evidence:
  - reference: PMID:39115603
    reference_title: "New and Emerging Drug and Gene Therapies for Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approval of omaveloxolone, the first treatment for individuals with FRDA aged 16 years and over, has created much excitement for both those living with FRDA and those that care for them."
    explanation: Recent review states that omaveloxolone is the first approved FRDA treatment for patients aged 16 years and older.
  - reference: PMID:33068037
    reference_title: Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Changes from baseline in mFARS scores in omaveloxolone (-1.55 ± 0.69) and placebo (0.85 ± 0.64) patients showed a difference between treatment groups of -2.40 ± 0.96 (p = 0.014)."
    explanation: >-
      The registrational phase 2 efficacy result: a placebo-corrected mFARS
      difference of -2.40 at 48 weeks. This is the quantitative basis for
      treating omaveloxolone as disease-modifying rather than symptomatic.
  - reference: PMID:33068037
    reference_title: Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Transient reversible increases in aminotransferase levels were observed with omaveloxolone without increases in total bilirubin or other signs of liver injury."
    explanation: Records the characteristic transaminase signal, which is the reason liver enzymes are monitored on therapy.
- name: Supportive and Symptomatic Care
  description: >
    Multidisciplinary care including physical therapy, occupational therapy,
    speech therapy, and orthopedic management of scoliosis and foot deformities.
    GeneReviews advises avoiding medications that are toxic or potentially toxic
    to people with peripheral neuropathy, avoiding use/misuse of illegal and
    controlled drugs (which may exacerbate disease manifestations by affecting
    neuronal well-being), and minimizing circumstances that increase fall risk.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "medications that are toxic or potentially toxic to people with neuropathy"
    explanation: GeneReviews Agents/Circumstances to Avoid section warns against neurotoxic medications in individuals with the peripheral neuropathy of FRDA.
  - reference: PMID:29053830
    reference_title: "Friedreich's ataxia: clinical features, pathogenesis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Management of Freidreich's ataxia is currently focussed on symptomatic management, delivered by the multidisciplinary team."
    explanation: Confirms that current management is multidisciplinary and symptomatic.
  - reference: PMID:29440566
    reference_title: "Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For nonpharmacologic options, in patients with degenerative ataxias, 4-week inpatient rehabilitation probably improves ataxia and function (1 Class I study)"
    explanation: AAN systematic-review guideline supports inpatient rehabilitation for degenerative ataxias (a category that includes Friedreich ataxia) improving ataxia and function.
- name: Cardiac Management
  description: >
    Regular cardiac monitoring and treatment of cardiomyopathy and arrhythmias.
    ACE inhibitors and beta-blockers may be used for heart failure management.
    The 2022 Heart Rhythm Society expert consensus statement includes Friedreich
    ataxia among the neuromuscular disorders for which evaluation and management
    of arrhythmic cardiac manifestations is specifically addressed.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ACE inhibitor
      term:
        id: NCIT:C247
        label: ACE Inhibitor
    - preferred_term: beta-adrenergic antagonist
      term:
        id: NCIT:C29576
        label: Beta-Adrenergic Antagonist
  target_mechanisms:
  - target: Cardiomyocyte Mitochondrial Injury
    treatment_effect: MODULATES
    description: >-
      ACE inhibitors and beta-blockers reduce afterload and sympathetic tone,
      decreasing myocardial energy demand and partially compensating for the
      cardiomyocyte mitochondrial bioenergetic failure that drives FRDA
      cardiomyopathy.
  evidence:
  - reference: PMID:35500790
    reference_title: "2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mitochondrial myopathies, including Friedreich ataxia and Kearns-Sayre syndrome, with an emphasis on managing arrhythmic cardiac manifestations."
    explanation: The 2022 HRS expert consensus statement on arrhythmic risk in neuromuscular disorders explicitly covers Friedreich ataxia, supporting arrhythmia surveillance and management as part of cardiac care.
- name: Riluzole for Symptomatic Ataxia
  description: >
    Riluzole is a small-molecule glutamate-modulating agent evaluated for
    symptomatic treatment of cerebellar motor dysfunction. In a Class I trial
    that included patients with Friedreich ataxia and spinocerebellar ataxia,
    riluzole probably improved ataxia signs at 12 months, supporting its use as
    symptomatic (not disease-modifying) therapy for the cerebellar/spinocerebellar
    degeneration of FRDA.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: riluzole
      term:
        id: CHEBI:8863
        label: Riluzole
  target_mechanisms:
  - target: Dentate Nucleus and Spinocerebellar Tract Degeneration
    treatment_effect: MODULATES
    description: >-
      Riluzole provides symptomatic benefit for cerebellar motor dysfunction
      without addressing the underlying FXN deficiency, acting downstream on the
      spinocerebellar/dentate degeneration that produces ataxia signs.
  evidence:
  - reference: PMID:29440566
    reference_title: "Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For patients with Friedreich ataxia or spinocerebellar ataxia (SCA), riluzole probably improves ataxia signs at 12 months (1 Class I study)."
    explanation: AAN systematic-review guideline reports Class I evidence that riluzole probably improves ataxia signs at 12 months in patients including those with Friedreich ataxia.
- name: Investigational Frataxin-Restoring Therapies
  description: >
    Clinical trials are investigating agents that address the aberrant silencing
    of the frataxin gene, including histone deacetylase inhibitors, gene therapy
    approaches, and frataxin replacement strategies.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  evidence:
  - reference: PMID:29053830
    reference_title: "Friedreich's ataxia: clinical features, pathogenesis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phase II clinical trials in agents that address the abberrant silencing of the frataxin gene need to be translated into large placebo-controlled Phase III trials to help establish their therapeutic potential."
    explanation: Confirms ongoing clinical development of frataxin-restoring therapies.
  - reference: PMID:42307907
    reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Findings of this nonrandomized clinical trial suggest that intravenous administration of AAVrh.10hFXN was well tolerated and may be a potential treatment for FA cardiomyopathy, as evidenced by preliminary improvement in exploratory efficacy end points."
    explanation: Clinical trial data demonstrate safety and preliminary efficacy of AAVrh.10hFXN, a direct FXN gene replacement therapy, in 17 FA patients with cardiomyopathy.
  - reference: PMID:42307907
    reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In all 8 patients with cardiac biopsy 3 months after therapy, there were higher levels of cardiac FXN (dose cohort 1, 20%; cohort 2, 81%; cohort 3, 123%)."
    explanation: Cardiac FXN protein expression increased in a dose-dependent manner following AAVrh.10hFXN administration.
  - reference: PMID:42307907
    reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After therapy, LVMI was lower by at least 10% in 9 patients and stabilized in 8 patients."
    explanation: AAVrh.10hFXN reduced left ventricular mass index in the majority of treated patients.
  target_mechanisms:
  - target: FXN GAA Repeat Expansion and Epigenetic Silencing
    treatment_effect: INHIBITS
    description: >-
      HDAC inhibitors and gene therapy approaches target the epigenetic
      silencing mechanism driven by the GAA repeat expansion, aiming to
      restore frataxin transcription at the chromatin level rather than
      addressing downstream consequences.
    evidence:
    - reference: PMID:25159818
      reference_title: Epigenetic therapy for Friedreich ataxia.
      supports: SUPPORT
      directness: DIRECT
      evidence_source: IN_VITRO
      snippet: "Chromatin signatures indicate that histone H3 lysine 9 is a key residue for gene silencing through methylation and reactivation through acetylation, mediated by the HDACi."
      explanation: >-
        Identifies the H3K9 chromatin state as the silencing step the HDAC
        inhibitor acts on, which is the mechanism this treatment link claims
        rather than the general benefit of the treatment.
  - target: Cardiomyocyte Mitochondrial Injury
    treatment_effect: INHIBITS
    description: >-
      AAVrh.10hFXN directly replaces frataxin protein in cardiomyocytes,
      restoring mitochondrial function and reducing cardiac hypertrophy
      independent of epigenetic de-silencing.
    evidence:
    - reference: PMID:42373844
      reference_title: "Advances in Gene and Cellular Therapy in Friedreich Ataxia."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "administration reduces left ventricular mass index (LVMI) and LV wall thickness on echocardiographs"
      explanation: >-
        Reports the cardiac remodeling response to AAVrh.10hFXN. It supports the
        link to the cardiomyocyte injury node by inference, since the readout is
        ventricular mass rather than a direct measure of mitochondrial function.
        A review is cited deliberately: this treatment is the investigational
        category, so the claim is a synthesis across agents. The dedicated
        AAVrh.10hFXN Gene Therapy treatment below carries the primary trial
        (PMID:42307907) and its own link to this node.
- name: Genetic Counseling
  description: >
    Genetic counseling for autosomal recessive inheritance pattern and carrier
    testing for family members. Once the FXN pathogenic variants are identified
    in an affected individual, carrier testing for at-risk relatives and
    prenatal/preimplantation genetic testing become possible.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301458
    reference_title: "Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible."
    explanation: GeneReviews genetic counseling section supports carrier and prenatal/preimplantation testing once the familial FXN variants are known.
- name: AAVrh.10hFXN Gene Therapy
  description: >
    Intravenous systemic administration of an adeno-associated virus (AAV) vector
    (serotype rh.10, cardiotropic) expressing the normal human frataxin (FXN) coding
    sequence. A nonrandomized clinical trial in 17 adults with FA cardiomyopathy
    demonstrated dose-dependent cardiac FXN restoration (20-123%), LVMI reduction or
    stabilization in all patients, and acceptable safety profile with resolution of
    serious adverse events.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: FXN GAA Repeat Expansion and Epigenetic Silencing
    treatment_effect: BYPASSES
    description: >-
      AAVrh.10hFXN directly restores FXN expression by supplying the normal FXN
      coding sequence via systemic AAV vector delivery, bypassing the transcriptional
      silencing caused by the GAA repeat expansion. This direct restoration approach
      targets the root genetic lesion rather than downstream consequences.
    evidence:
    - reference: PMID:42307907
      reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Preclinical studies have demonstrated that systemic administration of AAVrh.10hFXN, an rh.10 serotype cardiotropic adenoassociated virus (AAV) vector expressing the normal human FXN coding sequence, reverses the cardiomyopathy in FXN-deficient mice."
      explanation: Preclinical evidence shows AAVrh.10hFXN AAV vector delivers normal FXN and reverses cardiomyopathy in animal models.
  - target: Cardiomyocyte Mitochondrial Injury
    treatment_effect: MODULATES
    description: >-
      FXN restoration in cardiomyocytes improves mitochondrial iron-sulfur cluster
      assembly and bioenergetics, reducing oxidative stress and myocardial energy
      deficit that drive FRDA cardiomyopathy.
    evidence:
    - reference: PMID:42307907
      reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In all 8 patients with cardiac biopsy 3 months after therapy, there were higher levels of cardiac FXN (dose cohort 1, 20%; cohort 2, 81%; cohort 3, 123%)."
      explanation: Dose-dependent cardiac FXN restoration demonstrated in cardiac biopsies following AAVrh.10hFXN therapy.
  evidence:
  - reference: PMID:42307907
    reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seventeen patients with FA cardiomyopathy"
    explanation: Clinical trial enrolled 17 patients with FA cardiomyopathy.
  - reference: PMID:42307907
    reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There were 4 serious adverse events, 3 possibly related to prednisone immunosuppression and 1 possibly vector-related myocarditis 12 months after therapy, all of which resolved."
    explanation: Safety profile demonstrated with resolution of all serious adverse events during trial.
  - reference: PMID:42307907
    reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After therapy, LVMI was lower by at least 10% in 9 patients and stabilized in 8 patients."
    explanation: Cardiac structural improvement as measured by LVMI reduction or stabilization in all 17 treated patients.
  - reference: PMID:42307907
    reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Excluding the patient with myocarditis, posttherapy values of serum hs troponin I were lower by at least 10% in 15 patients and higher by at least 10% in 2 patients."
    explanation: Cardiac biomarker improvement (troponin reduction) in majority of treated patients, indicating reduced myocardial injury.
- name: SGT-212 Gene Therapy (Dual-Route AAV)
  description: >
    An AAV-based gene therapy expressing the normal human FXN coding sequence, administered via dual routes:
    MRI-guided intradentate nucleus (IDN) infusion targeting cerebellar degeneration and systemic intravenous
    infusion targeting cardiac and skeletal muscle. Phase I FALCON trial (NCT07180355) initiated in 2026.
    Preclinical studies in mice show improved neurobehavioral and cardiac function with increased survival
    and ~33% reduction in LVMI. Non-human primate studies demonstrate successful dual-route FXN expression in
    both the dentate nucleus and heart, confirming feasibility of the surgical IDN injection approach in humans.
    Unlike LX2006 which targets cardiac tissue alone, SGT-212's dual-route design aims to address both
    neurological and cardiac manifestations of FRDA.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: FXN GAA Repeat Expansion and Epigenetic Silencing
    treatment_effect: BYPASSES
    description: >
      SGT-212 restores FXN expression in both cerebellar and cardiac tissues via dual-route AAV delivery,
      bypassing the transcriptional silencing caused by the GAA repeat expansion and addressing both
      the neurological and cardiac manifestations of FRDA.
    evidence:
    - reference: PMID:42373844
      reference_title: "Advances in Gene and Cellular Therapy in Friedreich Ataxia."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: MODEL_ORGANISM
      snippet: "Single administration of SGT-212 in parvalbumin-Cre mice driving conditional Fxn knockout in DRG and cerebellar neurons or striated muscle (MCK-Cre) improves neurobehavioral and cardiac function, respectively, and increases survival"
      explanation: >-
        Conditional Fxn-knockout mice carry no GAA expansion, so rescue in this
        model is evidence that supplying FXN bypasses the silenced locus rather
        than de-repressing it.
  - target: Dentate Nucleus and Spinocerebellar Tract Degeneration
    treatment_effect: INHIBITS
    description: >
      Intradentate nucleus infusion targets the cerebellar dentate nucleus, a primary site of
      neurodegeneration in FRDA, with the goal of preventing progressive cerebellar ataxia.
    evidence:
    - reference: PMID:42373844
      reference_title: "Advances in Gene and Cellular Therapy in Friedreich Ataxia."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: OTHER
      snippet: "MRI-guided neurosurgical placement of cannulas in the DN of cadavers demonstrates the technical feasibility of such an approach in humans"
      explanation: >-
        Supports the anatomical claim by inference: cadaveric cannula placement
        establishes that the dentate nucleus can be reached in humans, not that
        doing so slows the degeneration. The NHP biodistribution result is this
        treatment's entry-level citation and is deliberately not repeated here.
  evidence:
  - reference: PMID:42373844
    reference_title: "Advances in Gene and Cellular Therapy in Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Improved survival in neuronal and cardiac Fxn-KO mice. ~two- fold increase in motor function (rotarod latency to fall) and ~33% reduction in LVMI in mice."
    explanation: Preclinical efficacy demonstrates improved neurologic and cardiac outcomes in murine FRDA models.
  - reference: PMID:42373844
    reference_title: "Advances in Gene and Cellular Therapy in Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Testing on NHPs shows their dual-route approach successfully expresses hFXN protein in the DN and heart"
    explanation: Non-human primate studies confirm feasibility and success of dual-route FXN expression.
  - reference: PMID:42373844
    reference_title: "Advances in Gene and Cellular Therapy in Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "trial (NCT07180355) administered SGT-212 to its first patient"
    explanation: Phase I FALCON trial initiated in 2026, enrolling first FRDA patient.
- name: CRISPR/ZFN Gene Editing Approaches
  description: >
    Investigational gene-editing strategies including CRISPR-Cas9 and zinc-finger nucleases (ZFN) targeting
    the GAA trinucleotide repeat expansion in the FXN gene. Preclinical studies in patient-derived iPSCs
    demonstrate that GAA repeat removal restores FXN expression and ameliorates cellular phenotypes including
    improved mitochondrial function and neuronal survival. AAV-delivered CRISPR-Cas9 in mouse models achieves
    GAA repeat removal in heart, liver, and skeletal muscle, with successful FXN restoration in liver. These
    approaches offer potential advantages over gene addition by targeting the root genetic cause (the repeat
    expansion) rather than adding an extra FXN gene, and may reduce risk of FXN overexpression toxicity by
    restoring endogenous regulatory mechanisms.
  therapeutic_modality: GENE_EDITING
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: FXN GAA Repeat Expansion and Epigenetic Silencing
    treatment_effect: INHIBITS
    description: >
      Gene editing approaches directly target and remove or disrupt the pathogenic GAA repeat expansion,
      restoring FXN transcription from endogenous regulatory elements and reducing disease at its genetic root.
    evidence:
    - reference: PMID:42373844
      reference_title: "Advances in Gene and Cellular Therapy in Friedreich Ataxia."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: IN_VITRO
      snippet: "Removal of the GAA repeats from the FXN gene of patient-derived induced pluripotent stem cells (iPSCs) increases FXN protein expression and restores dysregulated gene expression associated with the FRDA cellular phenotype"
      explanation: >-
        Excising the repeat restores FXN expression from the endogenous locus,
        which is exactly the causal step this link asserts.
  evidence:
  - reference: PMID:42373844
    reference_title: "Advances in Gene and Cellular Therapy in Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Removal of the GAA repeats from the FXN gene of patient-derived induced pluripotent stem cells (iPSCs) increases FXN protein expression and restores dysregulated gene expression associated with the FRDA cellular phenotype"
    explanation: CRISPR and ZFN-mediated GAA repeat removal in patient cells restores FXN expression and normalizes gene expression.
  - reference: PMID:42373844
    reference_title: "Advances in Gene and Cellular Therapy in Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "GAA repeats in patient iPSCs, followed by differentiation into neurons, increases FXN, ameliorates the mitochondrial phenotype, mitigates neuronal death, and improves neurite outgrowth"
    explanation: Functional rescue of neurons after GAA repeat removal demonstrates neuroprotective potential.
  - reference: PMID:42373844
    reference_title: "Advances in Gene and Cellular Therapy in Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "AAV-delivered CRISPR-Cas9 with guide RNAs (gRNA) directing removal of GAA repeats in YG8 and YG8sR mice demonstrates sufficient GAA removal in heart, liver, and skeletal muscle, but only increases FXN in the liver"
    explanation: Proof-of-concept for in vivo CRISPR-mediated GAA repeat removal, though tissue-specific efficacy requires further optimization.
- name: Antisense Oligonucleotide Therapy
  description: >
    Antisense oligonucleotides (ASOs) targeting the FXN GAA-repeat-associated transcript or disease-causing
    splice mutations offer a strategy to raise endogenous FXN expression. Modified ASOs directed at the GAA
    repeat increase FXN protein more than threefold in patient cell lines, and ASOs correcting the c.165+5G>C
    splice-site mutation restore functional FXN transcript. Unlike gene addition, ASOs act on the endogenous
    transcript, potentially limiting the risk of FXN overexpression toxicity.
  therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE
  oligonucleotide_details:
    oligonucleotide_mechanism: STERIC_BLOCKADE
    target_gene:
      preferred_term: FXN
      term:
        id: hgnc:3951
        label: FXN
    target_transcript: FXN GAA-repeat-associated transcript
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: FXN GAA Repeat Expansion and Epigenetic Silencing
    treatment_effect: INHIBITS
    description: >
      GAA-repeat-targeting ASOs sterically relieve repressive elements at the expanded FXN locus to raise
      endogenous FXN expression, while splice-correcting ASOs restore functional FXN transcript.
  evidence:
  - reference: PMID:42373844
    reference_title: "Advances in Gene and Cellular Therapy in Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Modified ASOs that target the GAA repeat increase FXN protein more than threefold in patient cell lines"
    explanation: ASOs targeting the GAA repeat raise endogenous FXN protein in patient-derived cells.
clinical_trials:
- name: NCT02255435
  phase: PHASE_II
  status: COMPLETED
  description: >
    Completed phase 2 MOXIe trial of RTA 408, also known as omaveloxolone,
    evaluating safety, pharmacodynamics, cycling work, and 48-week modified
    Friedreich's Ataxia Rating Scale change in Friedreich ataxia.
  target_phenotypes:
  - preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  - preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: clinicaltrials:NCT02255435
    reference_title: "A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to measure how FA affects the nervous system. The mFARS looks at movement ability, balance, coordination, speech, and how well the arms and legs work."
    explanation: ClinicalTrials.gov record documents the completed omaveloxolone MOXIe trial and its neurologic functional endpoints in FRDA.
  - reference: PMID:33068037
    reference_title: Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the MOXIe trial, omaveloxolone significantly improved neurological function compared to placebo and was generally safe and well tolerated."
    explanation: The trial publication's own conclusion, giving this registry entry its published result rather than only its design.
- name: NCT05302271
  phase: PHASE_I
  status: COMPLETED
  description: >
    Completed open-label, dose-escalation trial of intravenous AAVrh.10hFXN
    gene therapy in patients with Friedreich ataxia cardiomyopathy. 17 patients
    followed for a mean of 20 months. Primary outcome was safety; exploratory
    endpoints included cardiac FXN protein levels, LVMI, and cardiac biomarkers.
  target_phenotypes:
  - preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  evidence:
  - reference: PMID:42307907
    reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There were 4 serious adverse events, 3 possibly related to prednisone immunosuppression and 1 possibly vector-related myocarditis 12 months after therapy, all of which resolved."
    explanation: Trial safety data from the 17 FA patients receiving AAVrh.10hFXN, with resolution of all serious adverse events.
  - reference: PMID:42307907
    reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After therapy, LVMI was lower by at least 10% in 9 patients and stabilized in 8 patients."
    explanation: Preliminary efficacy showing cardiac structural improvements in the AAVrh.10hFXN trial cohort.
- name: NCT05445323
  phase: PHASE_I
  status: COMPLETED
  description: >
    Second independent open-label, dose-escalation trial of intravenous
    AAVrh.10hFXN gene therapy in Friedreich ataxia cardiomyopathy patients.
    Data pooled with NCT05302271 for the 2026 nonrandomized clinical trial
    analysis published in JAMA Cardiology.
  target_phenotypes:
  - preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  evidence:
  - reference: PMID:42307907
    reference_title: "AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This nonrandomized clinical trial evaluates the pooled data of 2 independent, open-label, dose-escalation trials that used the same gene therapy vector and similar clinical protocols among patients with FA cardiomyopathy at academic medical centers."
    explanation: Second independent trial contributing to the pooled AAVrh.10hFXN analysis.
animal_models:
- name: Conditional Fxn knockout mouse (MCK-Cre and NSE-Cre)
  species: Mouse
  genotype: Fxn conditional knockout, striated-muscle (MCK-Cre) and neuron/cardiac (NSE-Cre) lines
  publication: PMID:11175786
  description: >-
    Tissue-restricted frataxin deletion, generated because complete Fxn knockout
    is embryonic lethal. The two Cre drivers separate the cardiac and sensory
    arms of the disease, and the model established the temporal ordering of
    Fe-S enzyme inactivation and mitochondrial iron deposition.
  modeled_mechanisms:
  - target: Cardiomyocyte Mitochondrial Injury
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: TISSUE
    description: >-
      The MCK-Cre line reproduces cardiac hypertrophy without skeletal muscle
      involvement, matching the organ selectivity of human FRDA cardiomyopathy.
    limitations: >-
      Frataxin is deleted outright rather than reduced by a GAA expansion, so
      the model carries no residual frataxin and no epigenetic lesion, and its
      onset is developmental rather than progressive from a hypomorphic baseline.
    evidence:
    - reference: PMID:11175786
      reference_title: "Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "cardiac hypertrophy without skeletal muscle involvement, large sensory neuron dysfunction without alteration of the small sensory and motor neurons, and deficient activities of complexes I-III of the respiratory chain and of the aconitases"
      explanation: Reports the cardiac and sensory phenotypes and the respiratory-chain/aconitase deficits the model reproduces.
  - target: Dorsal Root Ganglion Sensory Neuronopathy
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: >-
      The NSE-Cre line reproduces large sensory neuron dysfunction while sparing
      small sensory and motor neurons, the same fibre-size selectivity seen in
      human FRDA.
    limitations: >-
      Sensory involvement is driven by a neuron/cardiac Cre rather than arising
      from the dorsal root ganglion lesion itself, so the model reproduces the
      selectivity without reproducing the human lesion's developmental hypoplasia.
    evidence:
    - reference: PMID:11175786
      reference_title: "Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "large sensory neuron dysfunction without alteration of the small sensory and motor neurons"
      explanation: Reports the large-fibre selectivity of the sensory deficit in this model.
  - target: Mitochondrial Bioenergetic Failure and Oxidative Stress
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: MOLECULAR
    description: >-
      Establishes the ordering within this node: Fe-S-dependent enzyme
      inactivation and overt pathology precede intramitochondrial iron
      accumulation, so iron deposition is a consequence rather than an initiator.
    limitations: >-
      The measured quantities are molecular (Fe-S enzyme activities and
      mitochondrial iron content) while the node is a cell-level failure state,
      so the bioenergetic-failure claim is inferred one scale up from what the
      model actually observes. The ordering is also a mouse result on a
      conditional-null background and has not been established in human tissue.
    divergences:
    - divergence_type: SCALE_EXTRAPOLATION
      materiality: QUALIFYING
      description: >-
        The model reads out enzyme activity and iron content at the molecular
        scale; the node asserts cellular bioenergetic failure and oxidative
        stress. The step from one to the other is inferential.
    - divergence_type: CAUSE_UNREPRESENTED
      materiality: QUALIFYING
      description: >-
        Frataxin is deleted outright, so the GAA expansion and the epigenetic
        silencing that cause the deficiency in patients are absent from the
        model; only the downstream consequence of low frataxin is represented.
      evidence:
      - reference: PMID:11175786
        reference_title: "Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Through a conditional gene-targeting approach, we have generated in parallel a striated muscle frataxin-deficient line and a neuron/cardiac muscle frataxin-deficient line"
        explanation: Confirms the deficiency is produced by conditional gene targeting rather than by a GAA repeat expansion, which is what this divergence records.
    evidence:
    - reference: PMID:11175786
      reference_title: "Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "time-dependent intramitochondrial iron accumulation in a frataxin-deficient mammal, which occurs after onset of the pathology and after inactivation of the Fe-S-dependent enzymes"
      explanation: Places iron accumulation downstream of Fe-S enzyme inactivation and pathology onset in a mammalian model.
  evidence:
  - reference: PMID:11175786
    reference_title: "Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "complete absence of frataxin in the mouse leads to early embryonic lethality"
    explanation: >-
      Explains why the model is conditional rather than a null: total frataxin
      loss is not viable, which is also why human patients always retain
      residual frataxin.
- name: Humanized FXN GAA-repeat YAC transgenic mouse (YG8R/YG22R)
  species: Mouse
  genotype: Human FXN YAC transgene carrying an expanded GAA repeat, on an Fxn-knockout background
  publication: PMID:16919418
  description: >-
    The GAA-repeat-based counterpart of the conditional knockouts: frataxin is
    reduced by the human expansion in its own genomic context rather than by
    gene deletion, so the model retains the mutation class that repeat-directed
    therapies target.
  modeled_mechanisms:
  - target: FXN GAA Repeat Expansion and Epigenetic Silencing
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: MOLECULAR
    description: >-
      Frataxin reduction arises from an unstable human GAA expansion within the
      appropriate genomic context, which is what makes this model usable for
      testing repeat- and chromatin-directed strategies.
    evidence:
    - reference: PMID:16919418
      reference_title: GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The resultant FRDA mice that express only human-derived frataxin show comparatively reduced levels of frataxin mRNA and protein expression, decreased aconitase activity, and oxidative stress, leading to progressive neurodegenerative and cardiac pathological phenotypes."
      explanation: Confirms that the human expansion alone reduces frataxin and produces progressive neurological and cardiac pathology.
  - target: Dorsal Root Ganglion Sensory Neuronopathy
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: >-
      Dorsal root ganglion neurons develop large vacuoles with a lumbar-to-cervical
      progression, alongside coordination deficits on rotarod.
    limitations: >-
      The lesion is vacuolar with secondary demyelination rather than the
      progressive ganglion-cell loss that defines the human neuronopathy, and it
      appears from 6 months rather than being present from development.
    evidence:
    - reference: PMID:16919418
      reference_title: GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Large vacuoles are detected within neurons of the dorsal root ganglia (DRG), predominantly within the lumbar regions in 6-month-old mice"
      explanation: Reports the dorsal root ganglion pathology and its regional distribution in this model.
  evidence:
  - reference: PMID:16919418
    reference_title: GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We have previously reported the establishment of two lines of human FXN YAC transgenic mice that contain unstable GAA repeat expansions within the appropriate genomic context."
    explanation: >-
      Establishes that the transgene carries an unstable human GAA expansion in
      its native genomic context, which is what makes this model informative for
      repeat-directed mechanisms rather than for frataxin loss alone.
- name: Retinal conditional Fxn knockout mouse with AAV2-FXN rescue (mRx-Fxn KO, Pou4f2-Fxn KO)
  species: Mouse
  genotype: Fxn conditionally ablated in all retinal cells (mRx-Cre) or in retinal ganglion cells (Pou4f2-Cre)
  publication: PMID:41137390
  description: >-
    Tissue-specific models of the ocular arm of the disease, built because the
    cardiac and CNS gene therapy routes do not transduce the retina efficiently.
    Both the disease model and an intravitreal AAV2-FXN rescue arm are reported.
  modeled_mechanisms:
  - target: Optic Atrophy
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: >-
      Retinal frataxin loss produces retinal dystrophy, which covers the retinal
      ganglion cell component of the human ocular phenotype. The reported
      outcome is retinal dystrophy rather than optic nerve atrophy as such,
      which is why this is a partial rather than a full recapitulation.
    limitations: >-
      Frataxin is ablated in the retina alone rather than systemically, so the
      model isolates the ocular phenotype from the systemic disease that
      produces it in patients, and it uses conditional deletion rather than a
      GAA expansion.
    evidence:
    - reference: PMID:41137390
      reference_title: "Development of an AAV-based gene therapy for the ocular phenotype of Friedreich's ataxia."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We generated two novel conditional knockout (KO) models, mRx-Fxn KO and Pou4f2-Fxn KO mice, wherein Fxn is ablated in all retinal cells or RGCs, respectively, and showed that FXN deficiency led to retinal dystrophy in both models."
      explanation: Establishes that retinal frataxin loss alone is sufficient to produce retinal dystrophy in these models.
  - target: Optic Atrophy
    relationship: RESCUES
    fidelity: MODERATE
    model_scale: TISSUE
    description: >-
      Intravitreal AAV2-FXN partially preserved retinal structure and function,
      the proof of concept for treating the ocular phenotype by a route separate
      from the cardiac and CNS programmes.
    limitations: >-
      Preservation is partial, and the rescue is delivered to a retina-restricted
      knockout rather than to the systemic frataxin deficiency of patients.
    evidence:
    - reference: PMID:41137390
      reference_title: "Development of an AAV-based gene therapy for the ocular phenotype of Friedreich's ataxia."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Gene supplementation via intravitreal injection of a novel AAV2-based capsid carrying FXN partially preserved retinal structure and/or function in both models, establishing proof of concept for this therapeutic strategy."
      explanation: Reports the partial structural and functional rescue that grounds the RESCUES claim.
  evidence:
  - reference: PMID:41137390
    reference_title: "Development of an AAV-based gene therapy for the ocular phenotype of Friedreich's ataxia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Work is under way to develop gene therapies that address the cardiac and CNS manifestations, but their routes of administration do not lead to efficient transduction of the retina."
    explanation: >-
      Explains why a retina-specific model is needed at all: the existing
      cardiac and CNS gene therapy routes do not reach the retina, so the ocular
      phenotype needs its own model and delivery route.
- name: AAV9-hFXN gene therapy rescue in conditional Fxn knockout mice
  species: Mouse
  genotype: Fxn conditional knockout (MCK-Cre or NSE-Cre) treated with AAV9-hFXN
  publication: PMID:26015982
  description: >-
    Rescue arm rather than a disease model: frataxin is restored by systemic
    AAV9 delivery in the conditional knockouts, testing whether the mechanism
    chain is reversible once established.
  modeled_mechanisms:
  - target: Cardiomyocyte Mitochondrial Injury
    relationship: RESCUES
    fidelity: MODERATE
    model_scale: TISSUE
    description: >-
      A single systemic dose preserved cardiac systolic function and more than
      doubled survival, which is the preclinical basis for the AAV gene therapy
      programmes curated under treatments.
    limitations: >-
      Rescue is delivered to a conditional-knockout background with no GAA
      expansion, so it tests frataxin replacement rather than reversal of
      repeat-driven silencing, and treatment begins in young animals before the
      long subclinical phase human patients have already passed through.
    evidence:
    - reference: PMID:26015982
      reference_title: An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Echography analysis of the heart function clearly indicated that the cardiac systolic function was better preserved in the mice that received 6 × 10(11) v.p. of AAV9-hFXN."
      explanation: Reports preserved cardiac systolic function after frataxin restoration, the readout grounding the rescue claim.
  evidence:
  - reference: PMID:26015982
    reference_title: An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "A single administration of the AAV9-hFXN at 6 × 10(11) v.p. more than doubled the life of these mice."
    explanation: Establishes the survival benefit that makes this model informative for frataxin-restoration approaches.
datasets:
- accession: geo:GSE226646
  title: "Skeletal muscle transcriptomics dissects the pathogenesis of Friedreich's Ataxia"
  description: >-
    Bulk RNA sequencing of skeletal muscle biopsies from FRDA patients and healthy
    controls, sampled before and after recombinant human erythropoietin treatment,
    profiling the muscle transcriptome in patient tissue.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 20
  conditions:
  - Friedreich ataxia skeletal muscle
  - healthy control skeletal muscle
  publication: PMID:37027192
  evidence:
  - reference: GEO:GSE226646
    reference_title: "Skeletal muscle transcriptomics dissects the pathogenesis of Friedreich's Ataxia"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RNA sequencing of skeletal muscle biopsies from healthy controls and Friedreich's Ataxia (FRDA) patients before and after treatment with recombinant human erythropoietin (rhuEPO) to dissect the mechanisms of disease."
    explanation: The GEO summary establishes this as a patient-versus-control skeletal muscle transcriptome series in FRDA.
- accession: geo:GSE200907
  title: A non-synonymous SNP in SIRT6 predicts neurological severity in Friedreich ataxia
  description: >-
    Whole-transcriptome profiling of FRDA patients stratified by SIRT6 rs352493
    genotype, supporting the modifier analysis of neurological severity.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 20
  conditions:
  - Friedreich ataxia, S46 SIRT6 variant
  - Friedreich ataxia, N46 SIRT6 variant
  publication: PMID:36133907
  evidence:
  - reference: GEO:GSE200907
    reference_title: A non-synonymous SNP in SIRT6 predicts neurological severity in Friedreich ataxia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "S46 patients showed whole transcriptome differences compared to N46 patients, indicative of compensatory mechanisms against whole transcriptome changes seen in FRDA."
    explanation: The GEO summary describes the genotype-stratified patient transcriptome comparison this series holds.
  notes: >-
    Supports a genetic modifier of neurological severity acting alongside GAA repeat
    length, rather than a primary disease mechanism.
- accession: geo:GSE243874
  title: An RNA-seq study in Friedreich ataxia patients identified miR148a-3p as a putative prognostic biomarker of the disease.
  description: >-
    Small non-coding RNA sequencing of peripheral blood mononuclear cells from FRDA
    patients and healthy donors, used to nominate circulating microRNA biomarkers of
    disease progression.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 16
  conditions:
  - Friedreich ataxia PBMC
  - healthy donor PBMC
  publication: PMID:38778374
  evidence:
  - reference: GEO:GSE243874
    reference_title: An RNA-seq study in Friedreich ataxia patients identified miR148a-3p as a putative prognostic biomarker of the disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We performed an RNA-seq study evaluating the expression level of circulating small non-coding RNAs (sncRNA) on PBMCs of FRDA patients and of healthy donors (CTRL)."
    explanation: The GEO summary establishes the patient-versus-control circulating sncRNA design of this series.
- accession: geo:GSE65399
  title: Epigenetic therapy for Friedreich ataxia.
  description: >-
    Expression profiling of an FRDA neuronal cell model treated with the histone
    deacetylase inhibitor 109/RG2833, the in vitro arm of the epigenetic
    reactivation study that accompanied a phase I patient trial.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_count: 75
  conditions:
  - FRDA neuronal cell model, HDAC inhibitor treated
  - FRDA neuronal cell model, untreated
  publication: PMID:25159818
  evidence:
  - reference: GEO:GSE65399
    reference_title: Epigenetic therapy for Friedreich ataxia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In the neuronal cell model, HDACi 109/RG2833 increases FXN mRNA levels and frataxin protein, with concomitant changes in the epigenetic state of the gene."
    explanation: The GEO summary describes the HDAC-inhibitor reactivation experiment profiled by this series.
- accession: geo:GSE145115
  title: Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich’s ataxia patient cells
  description: >-
    Genome-wide expression profiling of FRDA patient cells treated with the SUV4-20
    methyltransferase inhibitor A-196, assessing FXN reactivation and off-target
    transcriptome perturbation.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 24
  conditions:
  - FRDA patient cells, A-196 treated
  - FRDA patient cells, untreated
  publication: PMID:33028632
  evidence:
  - reference: GEO:GSE145115
    reference_title: Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich’s ataxia patient cells
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In several FRDA cell lines and patient-derived primary peripheral blood mononuclear cells, A-196 increased FXN expression by up to 2-fold, an effect not seen in WT cells."
    explanation: The GEO summary describes the FXN-reactivation effect this expression series was generated to characterize.
- accession: geo:GSE108200
  title: "Frataxin deficiency in Friedreich?s Ataxia is associated with reduced levels of HAX-1, a regulator of cardiomyocyte death and survival."
  description: >-
    Microarray profiling of FRDA patient lymphoblastoid cells with and without
    stable frataxin reconstitution, the screen that nominated HAX-1 as a candidate
    cardiomyopathy biomarker.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_count: 2
  conditions:
  - FRDA lymphoblastoid cells, frataxin reconstituted
  - FRDA lymphoblastoid cells, empty vector
  publication: PMID:31943004
  evidence:
  - reference: GEO:GSE108200
    reference_title: "Frataxin deficiency in Friedreich?s Ataxia is associated with reduced levels of HAX-1, a regulator of cardiomyocyte death and survival."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "To identify other genes involved in pathogenesis of FRDA, a microarray analysis on FRDA patient's lymphoblastoid cells stably reconstituted with FXN was performed."
    explanation: The GEO summary describes the frataxin-reconstitution microarray comparison held in this series.
  notes: >-
    GEO's own title spells the disease "Friedreich?s Ataxia"; the title is copied
    verbatim as the repository records it. Only two array samples are deposited, so
    the series is the discovery screen rather than the paper's full patient cohort.

📚

References & Deep Research

References

PMID:20301458

Friedreich Ataxia.

No top-level findings curated for this source.

Deep Research

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Curate FRDA1 (MONDO:0100340) into the existing Friedreich Ataxia entry · 2026-09-07T11:05:42Z · View source

Curation of "Friedreich ataxia 1" (MONDO:0100340), requested via /curate. LUMP/SPLIT DECISION. No new entry was created. MONDO:0100340 is the FXN-caused child of MONDO:0100339, and the existing Friedreich_Ataxia entry is bound to that parent while curating FXN GAA-repeat disease throughout, so a separate FRDA1 file would have duplicated a 2,034-line entry. Instead MONDO:0100340 was recorded in mappings.mondo_mappings with mapping_predicate skos:narrowMatch, which per the repository's coverage rule counts as curated. The entry stays bound one level up because it also covers FARR (MONDO:0800301), verified with OAK to be a direct sibling of FRDA1 rather than a descendant, so the grouping term is the narrowest single term spanning what is curated. The mapping notes record that the third child, Friedreich ataxia 2 (MONDO:0011175), is defined by MONDO only as a 9p23-p11 linkage locus and carries no RO:0004003 gene relation, so it is out of scope. `just tidy-stubs` was re-run afterwards and now reports the stub as already_curated, which is why stubs/Friedreich_Ataxia_1.yaml is deleted in this change. The stub had survived the #9910 sweep only because the entry bound the parent identifier. DEEP RESEARCH. falcon was requested and could not run: the Edison account returned HTTP 402 (out of credits). Rather than substituting a provider by hand, the run was repeated with --fallback, so openscientist produced the report and the substitution is recorded in the report frontmatter (fell_back: true, requested_provider: falcon, provider_attempts with the 402 and its remedy). New report: research/Friedreich_Ataxia-deep-research-openscientist.md (+ citations sidecar and artifacts). The pre-existing April 2026 falcon report is unchanged: the fallback rename had consumed it in the working tree, and it was restored from HEAD and diffed to confirm it is byte-identical. RESEARCH VALIDATION READ BEFORE USE. reference_validation: 20/20 resolved, 0 unresolved, 0 off topic. term_validation: needs_review true, driven by one mislabel - the report offers HP:0003390 for "impaired vibration sense", but HP calls that term Sensory axonal neuropathy. That CURIE was NOT bound; OAK was used to find the correct term, HP:0002495 Impaired vibratory sensation, which Orphanet also carries with a frequency. The three "worth a second look" terms (HP:0001251, HP:0001284, HP:0003487) are paraphrases of terms the entry already binds correctly. NAMED ENTITY CONFUSION PREFLIGHT. `just preflight-dr` against MONDO:0100339 SKIPs, because the grouping term records no causal gene. Re-run against MONDO:0100340 it discriminates properly: canonical gene FXN, FXN mentioned 31 times, and OMIM 229300 matching on both sides. Its WARN that rival gene GAA is mentioned 27 times is a false positive - every "GAA" in the report is the trinucleotide repeat, and the report has zero mentions of Pompe disease, acid alpha-glucosidase, or glycogen storage disease. Recorded here because the same false positive will recur on any GAA-repeat disease. CONTENT ADDED. - datasets: section was an empty key (0% compliance). Six GEO series added, each named for FRDA in its own title and manually triaged for relevance, not just resolution. Titles copied verbatim, including GEO's own misspelled "Friedreich?s Ataxia" in GSE108200. All six verified with `just verify-datasets` (6/6 OK) and their GEO_*.md caches are committed. - phenotypes: three cardinal signs were missing - Impaired Proprioception (HP:0010831), Impaired Vibratory Sensation (HP:0002495), and Hearing Impairment (HP:0000365). The first two were also wired into the pathograph as downstream targets of the dorsal root ganglion node, where they had previously existed only as free-text intermediate_mechanisms. Hearing was deliberately bound to the generic HP:0000365 rather than a sensorineural child term: Orphanet uses the generic term and the deficit is an auditory neuropathy, so a cochlear binding would be narrower than the evidence supports. That reasoning is recorded in the phenotype notes. - progression: had only an Onset phase. Added Loss of ambulation (FA-COMS, median 11.5y after first symptoms in early-onset patients, PMID:31938785) and Mortality (PMID:41273607), with the Brazilian cohort's single-centre scope stated in the notes. - prevalence: the Global record had no evidence; added a citation flagged INDIRECT with its two limits stated in the explanation (a secondary statement in a biomarker paper's introduction, and Caucasian-specific against a globally scoped record). Added a Finland CARRIER_FREQUENCY record (PMID:11810294) recording the absent 28-36 GAA reservoir alleles that explain the founder-level regional variation. - genetic: the notes asserted an inverse repeat-length/onset relationship with nothing citing it. Added PMID:8751856 (smaller allele accounts for ~50% of onset variance; allele length higher with diabetes and cardiomyopathy) and PMID:28789479 (residual frataxin, not mutation identity, sets the phenotype - which is why one mechanism chain covers both homozygotes and compound heterozygotes). - pathophysiology: biological_scale added to all nine nodes; none carried one. No node needed two values, so no node was split. - treatments: target_mechanisms evidence went from 3/11 to 8/11. Five links gained their own edge-level evidence, distinct from the node-level citations already present. DELIBERATELY NOT DONE. Three target_mechanisms links are left uncited because no distinct supporting quote was found: Cardiac Management -> Cardiomyocyte Mitochondrial Injury (the HRS consensus abstract does not discuss afterload or myocardial energy demand), Riluzole -> Dentate Nucleus (the only supporting sentence is already the node-level citation), and ASO -> FXN GAA node (likewise). Reusing a node's citation for its edge is the antipattern the curation guidance warns about, so those were left honest rather than papered over. The deprecated `percentage:` field on the two pre-existing prevalence records was also left alone as out of scope. VALIDATION. `just validate-disorders kb/disorders/Friedreich_Ataxia.yaml` passed in full: schema clean, terms clean, 160/160 snippets verified against cached references. Also passing: validate-terms, check-not4curation, verify-datasets (6/6), check-duplicate-keys, check-entity-refs, check-causal-targets, check-qualifier-terms, check-enum-values, check-snippet-length, check-title-snippets, check-snippet-grading, check-folded-hyphens, check-environmental-evidence, check-stubs. Compliance rose from 96.6% (286/296) to 99.1% (346/349).

Augment Friedreich Ataxia: GeneReviews baseline, pyramidal/sensory phenotypes, drug-safety · 2026-08-01T00:42:41Z · View source

Augmented the existing FRDA entry. Added GeneReviews baseline PMID:20301458 as a tagged top-level reference and cross-referenced its Clinical Characteristics. Filled the evidence gap on the pre-existing Peripheral Neuropathy phenotype. Added four GeneReviews/ORPHA-documented phenotypes previously absent: Babinski sign HP:0003487, Areflexia of lower limbs HP:0002522, Spasticity HP:0001257, and Optic atrophy HP:0000648 with an honest PARTIAL note on the clinical-versus-subclinical frequency discrepancy between ORPHA and Koeppen PMID:21315377. Wired all new phenotypes into the pathograph as downstream causal edges from the corticospinal/dentate node and the DRG sensory neuronopathy node. Captured the GeneReviews Agents/Circumstances-to-Avoid neurotoxic-medication drug-safety warning on Supportive Care. Added evidence to Genetic Counseling, genetic-inheritance, and skeletal-deformity edges. Deep research: reused the existing falcon report and the previously curated openscientist canonical-hypothesis report. All snippets are exact substrings of cached references. Validated with just validate at 114/114 snippets verified, just validate-terms passed, and compliance rose from 93.3 to 95.9 percent.

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 59 citations 2026-04-25T22:28:55.674992

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Friedreich Ataxia
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Friedreich Ataxia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Friedreich Ataxia (FRDA) — Comprehensive Disease Characteristics Research Report (2023–2024 prioritized)

Executive summary

Friedreich ataxia (FRDA) is a life-shortening, autosomal recessive multisystem neurodegenerative disorder primarily caused by biallelic GAA trinucleotide repeat expansions in intron 1 of FXN (frataxin), resulting in transcriptional silencing and frataxin deficiency. Frataxin deficiency disrupts mitochondrial iron–sulfur (Fe–S) cluster biogenesis and mitochondrial function, leading to selective vulnerability of dorsal root ganglia (DRG) sensory neurons, spinal cord tracts, cerebellar dentate nucleus, and cardiomyocytes. Natural history studies (notably FA-COMS/FACOMS) show progressive neurologic decline with ambulation loss typically within ~15 years, with faster progression in earlier-onset disease. In February 2023, omaveloxolone (Skyclarys™), an Nrf2 pathway activator, became the first approved therapy; a propensity-score matched analysis comparing the MOXIe extension to FACOMS natural history data suggests ~55% slowing of mFARS progression over 3 years. (scott2024newandemerging pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2, rummey2022naturalhistoryof pages 3-5, lynch2024propensitymatchedcomparison pages 1-2)

1. Disease information

1.1 What is the disease?

FRDA is described as an autosomal recessive inherited ataxia with progressive neurologic dysfunction (gait/limb ataxia, dysarthria, areflexia, sensory loss) and systemic involvement including cardiomyopathy, skeletal deformities (e.g., scoliosis, pes cavus), and diabetes/metabolic dysfunction. (scott2024newandemerging pages 1-2, lima2025earlyexperienceon pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)

Abstract-supported definition (direct quote): Park et al. (2025) describe FRDA as an “autosomal recessive neurodegenerative disorder characterized by ataxia, sensory loss and pyramidal signs.” (park2025longreadsequencingidentifies pages 1-2)

1.2 Key identifiers

MONDO: MONDO_0100339 (Open Targets disease entity for Friedreich ataxia). URL: https://platform.opentargets.org/disease/MONDO_0100339 (scott2024newandemerging pages 1-2)
OMIM / Orphanet / ICD-10/ICD-11 / MeSH: These identifiers were not explicitly present in the full-text sources retrieved in this run; therefore they cannot be cited from primary evidence here.

1.3 Synonyms and alternative names

Commonly used variants in the literature include “Friedreich’s ataxia” and “Friedreich ataxia (FRDA/FA)”. (scott2024newandemerging pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)

1.4 Evidence source type

Most disease-defining statements in this report are derived from: * Aggregated disease-level resources: reviews and systematic reviews (e.g., CNS Drugs 2024; IJMS 2024). (scott2024newandemerging pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2) * Human clinical cohorts/natural history studies: FACOMS/FA-COMS. (rummey2022naturalhistoryof pages 3-5, rummey2020predictorsofloss pages 1-2) * Human neuropathology: DRG and dentate nucleus tissue analyses. (koeppen2016dorsalrootganglia pages 1-2, koeppen2012friedreichsataxiacauses pages 1-2) * Model organism/cellular models: conditional mice, repeat-expansion mice, iPSC-derived models. (mercadoayon2022cerebellarpathologyin pages 1-2, mazzara2020frataxingeneediting pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause (genetic): * ~96% of FRDA cases are homozygous for expanded GAA repeats in intron 1 of FXN, typically reported as ~56–1300 repeats. (scott2024newandemerging pages 1-2) * A minority (~4%) are compound heterozygotes, with a GAA expansion on one allele and a pathogenic small variant or deletion on the other. (park2025longreadsequencingidentifies pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)

Mechanistic cause: expanded repeats induce locus-specific epigenetic changes and transcriptional silencing of FXN, resulting in low frataxin. (park2025longreadsequencingidentifies pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)

2.2 Risk factors

Genotype severity: longer GAA expansions correlate with earlier onset and faster progression (a key genetic severity determinant). (indelicato2024skeletalmuscleinvolvement pages 1-2, rummey2022naturalhistoryof pages 2-3)
Age at onset: earlier onset groups show faster mFARS progression in FACOMS. (rummey2022naturalhistoryof pages 3-5)

Environmental risk factors as disease initiators are not established for this Mendelian condition in the sources retrieved here.

2.3 Protective factors

No validated genetic or environmental protective factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No direct gene–environment interaction evidence was identified in the retrieved sources.

3. Phenotypes

3.1 Core neurologic phenotypes

Common neurologic phenotype includes progressive gait and limb ataxia, dysarthria, areflexia, sensory loss (proprioception/vibration), and pyramidal signs. (scott2024newandemerging pages 1-2, park2025longreadsequencingidentifies pages 1-2, lima2025earlyexperienceon pages 1-2)

Suggested HPO terms (non-exhaustive; ontology IDs not cited from sources): * Ataxia; Gait ataxia; Limb ataxia * Dysarthria * Areflexia * Loss of proprioception / impaired vibration sense * Babinski sign / pyramidal signs

3.2 Non-neurologic/systemic phenotypes

Cardiomyopathy (often hypertrophic) is a major determinant of premature mortality. (indelicato2024skeletalmuscleinvolvement pages 1-2, gavriilaki2024therapeuticbiomarkersin pages 1-2)
Scoliosis and pes cavus are frequently described. (lima2025earlyexperienceon pages 1-2)
Diabetes occurs in a subset (systematic review notes 10–30%). (jain2022clinicalevidenceof pages 2-3)

Suggested HPO terms (examples): * Hypertrophic cardiomyopathy * Scoliosis * Pes cavus * Diabetes mellitus

3.3 Age of onset, severity, progression, frequency

Typical symptom onset: average ~10–15 years. (scott2024newandemerging pages 1-2)
Wheelchair dependence: typical-onset patients become wheelchair dependent ~11.5 years after onset (reported in review; FACOMS-aligned). (scott2024newandemerging pages 1-2)
Disease progression: progressive; rates vary strongly by age at onset and ambulation status. (rummey2022naturalhistoryof pages 3-5)

3.4 Quality of life impact

Clinical decline impacts ambulation and upright stability, with loss of ambulation as a meaningful functional endpoint. (rummey2020predictorsofloss pages 1-2)

4. Genetic/molecular information

4.1 Causal gene(s)

Primary causal gene: FXN (frataxin). (park2025longreadsequencingidentifies pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)

4.2 Pathogenic variants

Repeat expansion: GAA trinucleotide repeat expansion in intron 1 of FXN. Normal alleles reported as 5–35 repeats; disease-causing typically >66; many affected individuals carry >600, with upper ranges reported up to ~1700. (park2025longreadsequencingidentifies pages 1-2)
Compound heterozygosity: GAA expansion + pathogenic small variant/deletion (~4% of cases). (park2025longreadsequencingidentifies pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)
Somatic instability/interruptions: complex repeat interruptions and mosaicism can complicate detection; long-read genome sequencing can resolve complex expansions. (park2025longreadsequencingidentifies pages 1-2)

Abstract-supported mechanism (direct quote): Mazzara et al. (2020) state FRDA occurs “when transcription of the FXN gene is silenced due to an excessive expansion of GAA repeats into its first intron.” (mazzara2020frataxingeneediting pages 1-2)

4.3 Functional consequences

Frataxin deficiency leads to impaired Fe–S cluster biosynthesis and mitochondrial dysfunction with downstream oxidative stress and iron dysregulation. (indelicato2024skeletalmuscleinvolvement pages 1-2, osaki2026fromgeneticmutation pages 1-3)

4.4 Modifier genes / epigenetics

Epigenetic silencing: GAA expansions induce locus-specific epigenetic changes (including upstream hypermethylation and downstream hypomethylation signatures) that contribute to transcriptional silencing. (park2025longreadsequencingidentifies pages 1-2)
DNA repair/chromatin cross-talk as a repeat instability mechanism (2024 development): Lai et al. (2024) report temozolomide-induced and H3K9 methyltransferase inhibitor-induced GAA repeat contraction in neural cells with increased frataxin protein, proposing crosstalk between chromatin opening (H3K9 methylation inhibition) and base excision repair. (scott2024newandemerging pages 1-2)

Suggested ontology terms (examples): * GO (process): iron–sulfur cluster assembly; mitochondrial ATP synthesis; response to oxidative stress; DNA repair; chromatin organization.

5. Environmental information

FRDA is primarily genetic. Environmental contributors, infectious triggers, or lifestyle causes were not supported as primary etiologic drivers in the retrieved sources.

6. Mechanism / pathophysiology

6.1 Causal chain (high-level)

Biallelic FXN GAA expansion → 2. Repressive chromatin / transcriptional silencing → 3. Frataxin deficiency → 4. Impaired Fe–S cluster biogenesis and mitochondrial dysfunction → 5. Oxidative stress/iron dysregulation, ETC defects, cellular injury → 6. Selective degeneration of DRG/spinal cord/dentate nucleus + cardiomyocyte dysfunction → 7. Progressive neurologic disability + cardiomyopathy-related morbidity/mortality. (indelicato2024skeletalmuscleinvolvement pages 1-2, osaki2026fromgeneticmutation pages 1-3, koeppen2016dorsalrootganglia pages 1-2)

6.2 Selective vulnerability and primary tissues

Despite broad frataxin expression, pathology is tissue-selective, prominently affecting DRG sensory neurons and the cerebellar dentate nucleus, with major cardiac involvement. (indelicato2024skeletalmuscleinvolvement pages 1-2, koeppen2012friedreichsataxiacauses pages 1-2)

6.3 Cellular processes and neuropathology (human evidence)

DRG (human tissue): Koeppen et al. (2016) show DRG pathology includes satellite cell proliferation into multiple perineuronal layers, connexin-43 gap junction upregulation, monocyte infiltration, and ferritin upregulation in satellite cells/monocytes consistent with inflammatory and iron-handling changes. (koeppen2016dorsalrootganglia pages 1-2)

Dentate nucleus (human tissue metal mapping): Koeppen et al. (2012) report that maximal Fe/Cu/Zn concentrations did not differ between FRDA and controls, but metal redistribution occurs with structural collapse of the dentate nucleus and increased ferritin-positive microglia; reported mean Fe 364±117 vs 344±159 µg/mL (controls vs FRDA) in PEG/DMSO-embedded tissue. (koeppen2012friedreichsataxiacauses pages 1-2)

6.4 Mitochondrial dysfunction in DRG (2024 mechanistic development)

Sanz-Alcázar et al. (2024) report frataxin deficiency in DRG neuron cultures and DRG tissue from an FXN mouse model causes reduced ETC complex I/II activity and levels, altered mitochondrial morphology, reduced NAD+/NADH ratio, impaired sirtuin activity (SirT3) and increased acetylation of SOD2 (with increased mitochondrial superoxide); honokiol (SirT3 activator) restored respiration and reduced oxidative markers. (sanzalcazar2024mitochondrialimpairmentdecreased pages 1-2)

Suggested ontology terms: * CL (cell types): dorsal root ganglion sensory neuron; satellite glial cell; microglia/monocyte lineage; cardiomyocyte. * GO-CC (compartments): mitochondrion; mitochondrial inner membrane.

7. Anatomical structures affected

7.1 Organ/system level

Nervous system: peripheral sensory system (DRG, dorsal roots), spinal cord tracts, cerebellar dentate nucleus, corticospinal tracts. (koeppen2016dorsalrootganglia pages 1-2, koeppen2013friedreichataxianeuropathology pages 1-1)
Heart: cardiomyopathy is prominent and contributes to mortality risk. (indelicato2024skeletalmuscleinvolvement pages 1-2, gavriilaki2024therapeuticbiomarkersin pages 1-2)
Muscle: skeletal muscle involvement contributes to fatigue/weakness, and restrictive respiratory impairment can occur. (indelicato2024skeletalmuscleinvolvement pages 1-2)

7.2 Tissue/cell level

DRG neuronal loss and accompanying satellite cell/inflammatory changes (human). (koeppen2016dorsalrootganglia pages 1-2)
Dentate nucleus neuronal atrophy and microglial ferritin positivity (human). (koeppen2012friedreichsataxiacauses pages 1-2)

Suggested UBERON examples (names only): dorsal root ganglion; spinal cord; cerebellar dentate nucleus; myocardium.

8. Temporal development

8.1 Onset

Mean onset ~10–15 years in typical FRDA. (scott2024newandemerging pages 1-2)
Late-onset forms are recognized (e.g., after age 25 or 40). (lima2025earlyexperienceon pages 1-2)

8.2 Progression and staging

FACOMS natural history (key statistics): * 1,115 participants and 5,287 yearly visits. (rummey2022naturalhistoryof pages 1-2) * Median follow-up ~5 years (IQR ~3–10). (rummey2022naturalhistoryof pages 2-3) * Annual ambulatory mFARS progression differs by onset group: early-onset ~2.62 points/year vs typical-onset ~1.83 points/year; intermediate ~1.24 points/year; late ~1.18 points/year (approximate as reported with CIs). (rummey2022naturalhistoryof pages 3-5) * Ambulatory decline is driven primarily by the Upright Stability Score (USS) component of mFARS. (rummey2022naturalhistoryof pages 1-2)

Loss of ambulation: In a large FA-COMS analysis (n≈1021), early-onset patients had a median of 11.5 years from symptom onset to full wheelchair dependence (FDS=5). (rummey2020predictorsofloss pages 1-2)

9. Inheritance and population

9.1 Epidemiology

A contemporary review reports FRDA affects ~1:40,000 (predominantly European populations) and is about ~1 in 50,000 Europeans in another systematic review/meta-analysis context. (scott2024newandemerging pages 1-2, gavriilaki2024therapeuticbiomarkersin pages 1-2)

9.2 Inheritance pattern

Autosomal recessive inheritance is consistently reported. (scott2024newandemerging pages 1-2, park2025longreadsequencingidentifies pages 1-2)

9.3 Carrier status

Carriers of one expanded allele are asymptomatic in the cited review and have residual frataxin ~40–68% of normal (vs 4–29% in affected individuals). (scott2024newandemerging pages 1-2)

10. Diagnostics

10.1 Genetic testing (repeat expansion and sequencing)

Standard diagnostic approach depends on detecting FXN intron 1 GAA expansions; molecular diagnosis has been possible since 1996. (scott2024newandemerging pages 1-2)
Long-read sequencing can resolve complex/interruptions/mosaic expansions that may be missed by conventional repeat-primed or long-range PCR assays; Park et al. (2025) highlight that interruptions and somatic instability “complicate molecular diagnosis” and that long-read genome sequencing can detect large expansions and mosaic variation. (park2025longreadsequencingidentifies pages 1-2)

10.2 Biomarkers and imaging

A 2024 biomarker systematic review/meta-analysis found only modest pooled improvements in combined FARS/mFARS with mitochondrial-function drugs and reported LV mass index (LVMI) improvement for some interventions, but overall evidence quality was low and the “optimal biomarker…has yet to be identified.” (gavriilaki2024therapeuticbiomarkersin pages 1-2)

Neuroimaging biomarkers (MRI/QSM/MRS) are a focus of contemporary FRDA trial design and natural-history imaging studies. (scott2024newandemerging pages 3-5)

11. Outcome / prognosis

Mean survival ≈39 years (review) and reduced life expectancy is commonly attributed to cardiac complications. (scott2024newandemerging pages 1-2, gavriilaki2024therapeuticbiomarkersin pages 1-2)
Cardiomyopathy is repeatedly emphasized as a major determinant of survival. (indelicato2024skeletalmuscleinvolvement pages 1-2, gavriilaki2024therapeuticbiomarkersin pages 1-2)

12. Treatment

12.1 Approved pharmacotherapy: Omaveloxolone (Skyclarys™)

Regulatory status: FDA approval February 2023 for patients aged ≥16 years; EC approval February 2024. (scott2024newandemerging pages 3-5)

Efficacy (trial + external comparator): A propensity-score matched comparison of MOXIe extension (omaveloxolone-treated) vs FACOMS natural history controls reported: * At Year 3, matched FACOMS progressed 6.61 mFARS points vs 3.00 points in MOXIe extension; difference 3.61 points; nominal p=0.0001. (lynch2024propensitymatchedcomparison pages 7-8) * This corresponds to ~55% slowing of mFARS progression. (lynch2024propensitymatchedcomparison pages 1-2, scott2024newandemerging pages 3-5)

Visual evidence (trial outcome trajectories): Figure 3 and Table 5 from Lynch et al. (2024) summarize the 3-year separation in mFARS trajectories and the Year-3 difference used in the main result. (lynch2024propensitymatchedcomparison media 7250a862, lynch2024propensitymatchedcomparison media d049e362)

Safety and real-world implementation: Expert guidance and post-approval experience emphasize that aminotransferase elevations are common and usually transient and asymptomatic: * In the MOXIe program, ALT increases occurred in ~37% and AST in ~22% of treated patients (placebo ~2%); >3× ULN ALT/AST elevations ~31%, >5× ULN ~16%, >10× ULN ~4%; no Hy’s law cases. (perlman2025managingaminotransferaseelevations pages 7-9) * Label- and expert-opinion monitoring: baseline ALT/AST/total bilirubin; monitor monthly for first 3 months; reduce frequency thereafter if stable; temporarily discontinue if >5× ULN or >3× ULN with liver dysfunction; consider conservative interruption at ≥3× ULN even without dysfunction in real-world settings; reinitiate with stepwise titration (e.g., 50→100→150 mg) and q2-week labs for ~3 months. (perlman2025managingaminotransferaseelevations pages 1-3, perlman2025managingaminotransferaseelevations pages 11-14)

Real-world observational data: a single-center cohort (n=20; ~24 weeks) reported no discontinuations and transient asymptomatic transaminase elevations (ALT 45%); mFARS mean changed from 59.1 to 60.5 over 24 weeks (P=0.15). (lima2025earlyexperienceon pages 4-5)

Suggested MAXO terms (names only): pharmacotherapy; liver function monitoring; dose adjustment; treatment interruption/rechallenge; rehabilitation therapy.

12.2 Supportive/rehabilitative care

Multidisciplinary, symptomatic management remains central (mobility aids, therapy, cardiology and endocrinology management). (osaki2026fromgeneticmutation pages 11-12)

12.3 Experimental / emerging therapies (2024 focus)

A 2024 therapeutic landscape review emphasizes development across: * oxidative stress/mitochondrial function modulators, * frataxin-controlled metabolic pathway modulation, * gene replacement/editing approaches. (scott2024newandemerging pages 3-5)

Active or recent clinical trials (ClinicalTrials.gov): * Omaveloxolone pivotal trial: NCT02255435 (completed). (scott2024newandemerging pages 1-2) * Pediatric omaveloxolone trials: NCT06953583 (BRAVE; Phase 3), NCT06054893 (PK/safety, ages 2–15). (clinical-trials tool output) * Gene therapy for FRDA cardiomyopathy: NCT05302271 (AAVrh.10hFXN), NCT05445323, NCT07180355. (clinical-trials tool output) * Post-marketing/real-world safety follow-up: NCT06623890 (observational, 300 participants). (clinical-trials tool output)

13. Prevention

No primary prevention exists for a Mendelian recessive disorder aside from reproductive options and family-based risk management. Formal guideline statements were not retrieved in this run.

Applicable prevention concepts (knowledge-base oriented): * Carrier testing / cascade testing in families with known FXN expansions. * Genetic counseling.

14. Other species / natural disease

No naturally occurring FRDA-equivalent disease in non-human species was identified in the retrieved evidence.

15. Model organisms

FRDA modeling requires balancing genetic fidelity (GAA repeat silencing/instability) vs phenotype severity.

15.1 Mouse models

Conditional Cre-based models: MCK-driven cardiac/skeletal muscle knockouts model cardiomyopathy with early death; Pvalb-driven models target proprioceptive/cerebellar systems and yield severe, rapid neurologic disease. (bouchard2023findinganappropriate pages 1-2, pandolfo2025friedreichataxia pages 5-6)
Repeat-expansion and humanized models: KIKO and YG8 lines capture the repeat biology and epigenetic silencing context, with YG8–800 producing stronger ataxic phenotypes and repeat instability. (pandolfo2025friedreichataxia pages 5-6, bouchard2023findinganappropriate pages 1-2)
Inducible knockdown: FRDAkd (doxycycline-inducible) partially recapitulates DRG neuronal loss, cardiomyopathy, and ataxia; shows dentate nucleus and Purkinje neuron loss and synaptic marker declines; AAV8 frataxin restoration partially rescues synaptic markers. (mercadoayon2022cerebellarpathologyin pages 1-2)

15.2 Human cellular/iPSC models

DRG organoids (iPSC-derived): show DRG-like transcriptional signatures and peripheral sensory neuronal/glial subtypes; FRDA deficits are rescued by removing the entire FXN intron 1 (not just the GAA tract), implicating flanking repressed chromatin in silencing. (mazzara2020frataxingeneediting pages 1-2)

Embedded structured summary

Item	Value	Notes	Source (include URL if available)
Disease title	Friedreich ataxia: key identifiers and genetics	Mendelian inherited ataxia; disease-level aggregated knowledge.	https://doi.org/10.1007/s40263-024-01113-z
MONDO ID	MONDO_0100339	Disease association returned by Open Targets for Friedreich ataxia (scott2024newandemerging pages 1-2).	https://platform.opentargets.org/disease/MONDO_0100339
Inheritance	Autosomal recessive	Consistently described as autosomal recessive in recent reviews and diagnostic literature (scott2024newandemerging pages 1-2, park2025longreadsequencingidentifies pages 1-2).	https://doi.org/10.1007/s40263-024-01113-z ; https://doi.org/10.3390/ijms26114969
Causal gene	FXN (frataxin)	FXN encodes frataxin, a nuclear-encoded mitochondrial protein required for iron-sulfur cluster biogenesis (park2025longreadsequencingidentifies pages 1-2, osaki2026fromgeneticmutation pages 1-3).	https://doi.org/10.3390/ijms26114969 ; https://doi.org/10.20944/preprints202604.1108.v1
Primary pathogenic variant	Biallelic GAA trinucleotide repeat expansion in intron 1 of FXN	Normal alleles: 5–35 repeats; disease-causing: >66 repeats; many affected individuals carry ~56–1300+ repeats, often >600 in typical disease; expansion causes transcriptional silencing and reduced FXN expression (scott2024newandemerging pages 1-2, park2025longreadsequencingidentifies pages 1-2).	https://doi.org/10.1007/s40263-024-01113-z ; https://doi.org/10.3390/ijms26114969
Percent of cases	~96% homozygous GAA expansion; ~4% compound heterozygous	Minority of patients carry one GAA expansion plus a pathogenic small variant or deletion in FXN (scott2024newandemerging pages 1-2, park2025longreadsequencingidentifies pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2).	https://doi.org/10.1007/s40263-024-01113-z ; https://doi.org/10.3390/ijms26114969 ; https://doi.org/10.3390/ijms25189915
Frataxin levels	Affected individuals: ~4–29% of normal; carriers: ~40–68% of normal	Residual frataxin tracks with genotype severity; carriers are typically asymptomatic despite reduced protein levels (scott2024newandemerging pages 1-2).	https://doi.org/10.1007/s40263-024-01113-z
Major affected tissues	Dorsal root ganglia (DRG), dentate nucleus of cerebellum, spinal cord pathways, cardiomyocytes	Tissue vulnerability is selective despite broad FXN expression; neurologic and cardiac involvement drive major morbidity and mortality (indelicato2024skeletalmuscleinvolvement pages 1-2, osaki2026fromgeneticmutation pages 1-3).	https://doi.org/10.3390/ijms25189915 ; https://doi.org/10.20944/preprints202604.1108.v1

Table: This table summarizes the core identifiers, inheritance, causal gene, variant class, case distribution, frataxin levels, and major affected tissues for Friedreich ataxia. It is useful as a compact knowledge-base seed for disease definition and molecular annotation.

Notes on evidence gaps

OMIM/Orphanet/ICD/MeSH identifiers were not present in retrieved papers during this run; therefore they are not provided with citations.
Many ontology IDs (HPO/GO/CL/UBERON/MAXO) are suggested by term name to support knowledge-base construction, but the sources retrieved here did not explicitly list ontology identifiers.

Key cited sources (with dates and URLs)

Scott V et al. CNS Drugs. Aug 2024. https://doi.org/10.1007/s40263-024-01113-z (scott2024newandemerging pages 1-2, scott2024newandemerging pages 3-5)
Lynch DR et al. Ann Clin Transl Neurol. Sep 2024. https://doi.org/10.1002/acn3.51897 (lynch2024propensitymatchedcomparison pages 1-2, lynch2024propensitymatchedcomparison pages 7-8, lynch2024propensitymatchedcomparison pages 8-10)
Indelicato E et al. Int J Mol Sci. Sep 2024. https://doi.org/10.3390/ijms25189915 (indelicato2024skeletalmuscleinvolvement pages 1-2)
Gavriilaki M et al. Cerebellum. Oct 2024. https://doi.org/10.1007/s12311-023-01621-6 (gavriilaki2024therapeuticbiomarkersin pages 1-2)
Perlman S et al. Neurol Ther. Jun 2025. https://doi.org/10.1007/s40120-025-00752-8 (perlman2025managingaminotransferaseelevations pages 7-9, perlman2025managingaminotransferaseelevations pages 11-14)
Park J et al. Int J Mol Sci. May 2025. https://doi.org/10.3390/ijms26114969 (park2025longreadsequencingidentifies pages 1-2)
Rummey C et al. Neurology. Oct 2022. https://doi.org/10.1212/WNL.0000000000200913 (rummey2022naturalhistoryof pages 1-2, rummey2022naturalhistoryof pages 3-5)
Rummey C et al. EClinicalMedicine. Jan 2020. https://doi.org/10.1016/j.eclinm.2019.11.006 (rummey2020predictorsofloss pages 1-2)
Koeppen AH et al. Acta Neuropathol Commun. May 2016. https://doi.org/10.1186/s40478-016-0288-5 (koeppen2016dorsalrootganglia pages 1-2)
Koeppen AH et al. Cerebellum. May 2012. https://doi.org/10.1007/s12311-012-0383-5 (koeppen2012friedreichsataxiacauses pages 1-2)

References

(scott2024newandemerging pages 1-2): Varlli Scott, Martin B. Delatycki, Geneieve Tai, and Louise A. Corben. New and emerging drug and gene therapies for friedreich ataxia. CNS Drugs, 38:791-805, Aug 2024. URL: https://doi.org/10.1007/s40263-024-01113-z, doi:10.1007/s40263-024-01113-z. This article has 15 citations and is from a peer-reviewed journal.
(indelicato2024skeletalmuscleinvolvement pages 1-2): Elisabetta Indelicato, Julia Wanschitz, Wolfgang Löscher, and Sylvia Boesch. Skeletal muscle involvement in friedreich ataxia. International Journal of Molecular Sciences, 25:9915, Sep 2024. URL: https://doi.org/10.3390/ijms25189915, doi:10.3390/ijms25189915. This article has 4 citations.
(rummey2022naturalhistoryof pages 3-5): Christian Rummey, Louise A. Corben, Martin Delatycki, George Wilmot, Sub H. Subramony, Manuela Corti, Khalaf Bushara, Antoine Duquette, Christopher Gomez, J. Chad Hoyle, Richard Roxburgh, Lauren Seeberger, Grace Yoon, Katherine Mathews, Theresa Zesiewicz, Susan Perlman, and David R. Lynch. Natural history of friedreich ataxia. Neurology, Oct 2022. URL: https://doi.org/10.1212/wnl.0000000000200913, doi:10.1212/wnl.0000000000200913. This article has 74 citations and is from a highest quality peer-reviewed journal.
(lynch2024propensitymatchedcomparison pages 1-2): David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S.H. Subramony, George Wilmot, Theresa Zesiewicz, Lisa Weissfeld, and Colin Meyer. Propensity matched comparison of omaveloxolone treatment to friedreich ataxia natural history data. Annals of Clinical and Translational Neurology, 11:4-16, Sep 2024. URL: https://doi.org/10.1002/acn3.51897, doi:10.1002/acn3.51897. This article has 56 citations and is from a peer-reviewed journal.
(lima2025earlyexperienceon pages 1-2): Salvatore Maria Lima, Marta Caltagirone, Christian Messina, Umberto Quartetti, Nicasio Rini, Flora D’Amico, Filippo Brighina, and Vincenzo Di Stefano. Early experience on omaveloxolone in adult patients with friedreich’s ataxia: a real-world observational study. Journal of Neurology, Nov 2025. URL: https://doi.org/10.1007/s00415-025-13487-1, doi:10.1007/s00415-025-13487-1. This article has 1 citations and is from a domain leading peer-reviewed journal.
(park2025longreadsequencingidentifies pages 1-2): Joohyun Park, Claudia Dufke, Zofia Fleszar, Michael Schlotterbek, Elena Buena-Atienza, Lara G. Stühn, Caspar Gross, Marc Sturm, Stephan Ossowski, Ludger Schöls, Olaf Riess, and Tobias B. Haack. Long-read sequencing identifies mosaic sequence variations in friedreich’s ataxia-gaa repeats. International Journal of Molecular Sciences, 26:4969, May 2025. URL: https://doi.org/10.3390/ijms26114969, doi:10.3390/ijms26114969. This article has 2 citations.
(rummey2020predictorsofloss pages 1-2): Christian Rummey, Jennifer M. Farmer, and David R. Lynch. Predictors of loss of ambulation in friedreich's ataxia. EClinicalMedicine, 18:100213, Jan 2020. URL: https://doi.org/10.1016/j.eclinm.2019.11.006, doi:10.1016/j.eclinm.2019.11.006. This article has 68 citations and is from a peer-reviewed journal.
(koeppen2016dorsalrootganglia pages 1-2): Arnulf H. Koeppen, R. Liane Ramirez, Alyssa B. Becker, and Joseph E. Mazurkiewicz. Dorsal root ganglia in friedreich ataxia: satellite cell proliferation and inflammation. Acta Neuropathologica Communications, May 2016. URL: https://doi.org/10.1186/s40478-016-0288-5, doi:10.1186/s40478-016-0288-5. This article has 77 citations and is from a peer-reviewed journal.
(koeppen2012friedreichsataxiacauses pages 1-2): Arnulf H. Koeppen, R. Liane Ramirez, Devin Yu, Sarah E. Collins, Jiang Qian, Patrick J. Parsons, Karl X. Yang, Zewu Chen, Joseph E. Mazurkiewicz, and Paul J. Feustel. Friedreich's ataxia causes redistribution of iron, copper, and zinc in the dentate nucleus. The Cerebellum, 11:845-860, May 2012. URL: https://doi.org/10.1007/s12311-012-0383-5, doi:10.1007/s12311-012-0383-5. This article has 95 citations.
(mercadoayon2022cerebellarpathologyin pages 1-2): Elizabeth Mercado-Ayón, Nathan Warren, Sarah Halawani, Layne N. Rodden, Lucie Ngaba, Yi Na Dong, Joshua C. Chang, Carlos Fonck, Fulvio Mavilio, David R. Lynch, and Hong Lin. Cerebellar pathology in an inducible mouse model of friedreich ataxia. Frontiers in Neuroscience, Mar 2022. URL: https://doi.org/10.3389/fnins.2022.819569, doi:10.3389/fnins.2022.819569. This article has 17 citations and is from a peer-reviewed journal.
(mazzara2020frataxingeneediting pages 1-2): Pietro Giuseppe Mazzara, Sharon Muggeo, Mirko Luoni, Luca Massimino, Mattia Zaghi, Parisa Tajalli-Tehrani Valverde, Simone Brusco, Matteo Jacopo Marzi, Cecilia Palma, Gaia Colasante, Angelo Iannielli, Marianna Paulis, Chiara Cordiglieri, Serena Gea Giannelli, Paola Podini, Cinzia Gellera, Franco Taroni, Francesco Nicassio, Marco Rasponi, and Vania Broccoli. Frataxin gene editing rescues friedreich’s ataxia pathology in dorsal root ganglia organoid-derived sensory neurons. Nature Communications, Aug 2020. URL: https://doi.org/10.1038/s41467-020-17954-3, doi:10.1038/s41467-020-17954-3. This article has 102 citations and is from a highest quality peer-reviewed journal.
(rummey2022naturalhistoryof pages 2-3): Christian Rummey, Louise A. Corben, Martin Delatycki, George Wilmot, Sub H. Subramony, Manuela Corti, Khalaf Bushara, Antoine Duquette, Christopher Gomez, J. Chad Hoyle, Richard Roxburgh, Lauren Seeberger, Grace Yoon, Katherine Mathews, Theresa Zesiewicz, Susan Perlman, and David R. Lynch. Natural history of friedreich ataxia. Neurology, Oct 2022. URL: https://doi.org/10.1212/wnl.0000000000200913, doi:10.1212/wnl.0000000000200913. This article has 74 citations and is from a highest quality peer-reviewed journal.
(gavriilaki2024therapeuticbiomarkersin pages 1-2): Maria Gavriilaki, Evangelia Chatzikyriakou, Maria Moschou, Marianthi Arnaoutoglou, Ioanna Sakellari, and Vasilios K. Kimiskidis. Therapeutic biomarkers in friedreich’s ataxia: a systematic review and meta-analysis. Cerebellum (London, England), 23:1184-1203, Oct 2024. URL: https://doi.org/10.1007/s12311-023-01621-6, doi:10.1007/s12311-023-01621-6. This article has 15 citations.
(jain2022clinicalevidenceof pages 2-3): Paridhi Jain, Lohit Badgujar, Jelle Spoorendonk, and Katharina Buesch. Clinical evidence of interventions assessed in friedreich ataxia: a systematic review. Therapeutic Advances in Rare Disease, Jan 2022. URL: https://doi.org/10.1177/26330040221139872, doi:10.1177/26330040221139872. This article has 13 citations.
(osaki2026fromgeneticmutation pages 1-3): Yuta Osaki, Umme Sabrina Haque, and Toshifumi Yokota. From genetic mutation to therapy in friedreich ataxia: molecular mechanisms, therapeutic advances, and translational challenges. Unknown journal, Apr 2026. URL: https://doi.org/10.20944/preprints202604.1108.v1, doi:10.20944/preprints202604.1108.v1.
(sanzalcazar2024mitochondrialimpairmentdecreased pages 1-2): Arabela Sanz-Alcázar, Elena Britti, Fabien Delaspre, Marta Medina-Carbonero, Maria Pazos-Gil, Jordi Tamarit, Joaquim Ros, and Elisa Cabiscol. Mitochondrial impairment, decreased sirtuin activity and protein acetylation in dorsal root ganglia in friedreich ataxia models. Cellular and Molecular Life Sciences: CMLS, Dec 2024. URL: https://doi.org/10.1007/s00018-023-05064-4, doi:10.1007/s00018-023-05064-4. This article has 20 citations.
(koeppen2013friedreichataxianeuropathology pages 1-1): Arnulf H. Koeppen and Joseph E. Mazurkiewicz. Friedreich ataxia: neuropathology revised. Journal of neuropathology and experimental neurology, 72 2:78-90, Feb 2013. URL: https://doi.org/10.1097/nen.0b013e31827e5762, doi:10.1097/nen.0b013e31827e5762. This article has 313 citations and is from a peer-reviewed journal.
(rummey2022naturalhistoryof pages 1-2): Christian Rummey, Louise A. Corben, Martin Delatycki, George Wilmot, Sub H. Subramony, Manuela Corti, Khalaf Bushara, Antoine Duquette, Christopher Gomez, J. Chad Hoyle, Richard Roxburgh, Lauren Seeberger, Grace Yoon, Katherine Mathews, Theresa Zesiewicz, Susan Perlman, and David R. Lynch. Natural history of friedreich ataxia. Neurology, Oct 2022. URL: https://doi.org/10.1212/wnl.0000000000200913, doi:10.1212/wnl.0000000000200913. This article has 74 citations and is from a highest quality peer-reviewed journal.
(scott2024newandemerging pages 3-5): Varlli Scott, Martin B. Delatycki, Geneieve Tai, and Louise A. Corben. New and emerging drug and gene therapies for friedreich ataxia. CNS Drugs, 38:791-805, Aug 2024. URL: https://doi.org/10.1007/s40263-024-01113-z, doi:10.1007/s40263-024-01113-z. This article has 15 citations and is from a peer-reviewed journal.
(lynch2024propensitymatchedcomparison pages 7-8): David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S.H. Subramony, George Wilmot, Theresa Zesiewicz, Lisa Weissfeld, and Colin Meyer. Propensity matched comparison of omaveloxolone treatment to friedreich ataxia natural history data. Annals of Clinical and Translational Neurology, 11:4-16, Sep 2024. URL: https://doi.org/10.1002/acn3.51897, doi:10.1002/acn3.51897. This article has 56 citations and is from a peer-reviewed journal.
(lynch2024propensitymatchedcomparison media 7250a862): David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S.H. Subramony, George Wilmot, Theresa Zesiewicz, Lisa Weissfeld, and Colin Meyer. Propensity matched comparison of omaveloxolone treatment to friedreich ataxia natural history data. Annals of Clinical and Translational Neurology, 11:4-16, Sep 2024. URL: https://doi.org/10.1002/acn3.51897, doi:10.1002/acn3.51897. This article has 56 citations and is from a peer-reviewed journal.
(lynch2024propensitymatchedcomparison media d049e362): David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S.H. Subramony, George Wilmot, Theresa Zesiewicz, Lisa Weissfeld, and Colin Meyer. Propensity matched comparison of omaveloxolone treatment to friedreich ataxia natural history data. Annals of Clinical and Translational Neurology, 11:4-16, Sep 2024. URL: https://doi.org/10.1002/acn3.51897, doi:10.1002/acn3.51897. This article has 56 citations and is from a peer-reviewed journal.
(perlman2025managingaminotransferaseelevations pages 7-9): Susan Perlman, Mathieu Anheim, Sylvia Boesch, James H. Lewis, and David R. Lynch. Managing aminotransferase elevations in patients with friedreich ataxia treated with omaveloxolone: a review and expert opinion on use considerations. Neurology and Therapy, 14:1209-1227, Jun 2025. URL: https://doi.org/10.1007/s40120-025-00752-8, doi:10.1007/s40120-025-00752-8. This article has 8 citations and is from a domain leading peer-reviewed journal.
(perlman2025managingaminotransferaseelevations pages 1-3): Susan Perlman, Mathieu Anheim, Sylvia Boesch, James H. Lewis, and David R. Lynch. Managing aminotransferase elevations in patients with friedreich ataxia treated with omaveloxolone: a review and expert opinion on use considerations. Neurology and Therapy, 14:1209-1227, Jun 2025. URL: https://doi.org/10.1007/s40120-025-00752-8, doi:10.1007/s40120-025-00752-8. This article has 8 citations and is from a domain leading peer-reviewed journal.
(perlman2025managingaminotransferaseelevations pages 11-14): Susan Perlman, Mathieu Anheim, Sylvia Boesch, James H. Lewis, and David R. Lynch. Managing aminotransferase elevations in patients with friedreich ataxia treated with omaveloxolone: a review and expert opinion on use considerations. Neurology and Therapy, 14:1209-1227, Jun 2025. URL: https://doi.org/10.1007/s40120-025-00752-8, doi:10.1007/s40120-025-00752-8. This article has 8 citations and is from a domain leading peer-reviewed journal.
(lima2025earlyexperienceon pages 4-5): Salvatore Maria Lima, Marta Caltagirone, Christian Messina, Umberto Quartetti, Nicasio Rini, Flora D’Amico, Filippo Brighina, and Vincenzo Di Stefano. Early experience on omaveloxolone in adult patients with friedreich’s ataxia: a real-world observational study. Journal of Neurology, Nov 2025. URL: https://doi.org/10.1007/s00415-025-13487-1, doi:10.1007/s00415-025-13487-1. This article has 1 citations and is from a domain leading peer-reviewed journal.
(osaki2026fromgeneticmutation pages 11-12): Yuta Osaki, Umme Sabrina Haque, and Toshifumi Yokota. From genetic mutation to therapy in friedreich ataxia: molecular mechanisms, therapeutic advances, and translational challenges. Unknown journal, Apr 2026. URL: https://doi.org/10.20944/preprints202604.1108.v1, doi:10.20944/preprints202604.1108.v1.
(bouchard2023findinganappropriate pages 1-2): Camille Bouchard, Catherine Gérard, Solange Gni-fiene Yanyabé, Nathalie Majeau, Malek Aloui, Gabrielle Buisson, Pouiré Yameogo, Vanessa Couture, and Jacques P. Tremblay. Finding an appropriate mouse model to study the impact of a treatment for friedreich ataxia on the behavioral phenotype. Genes, 14:1654, Aug 2023. URL: https://doi.org/10.3390/genes14081654, doi:10.3390/genes14081654. This article has 8 citations.
(pandolfo2025friedreichataxia pages 5-6): Massimo Pandolfo. Friedreich ataxia. Neurology Genetics, Feb 2025. URL: https://doi.org/10.1212/nxg.0000000000200236, doi:10.1212/nxg.0000000000200236. This article has 6 citations.
(lynch2024propensitymatchedcomparison pages 8-10): David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S.H. Subramony, George Wilmot, Theresa Zesiewicz, Lisa Weissfeld, and Colin Meyer. Propensity matched comparison of omaveloxolone treatment to friedreich ataxia natural history data. Annals of Clinical and Translational Neurology, 11:4-16, Sep 2024. URL: https://doi.org/10.1002/acn3.51897, doi:10.1002/acn3.51897. This article has 56 citations and is from a peer-reviewed journal.

OpenScientist ▸

Friedreich Ataxia: Comprehensive Disease Characteristics Report

openscientist-autonomous 20 citations 2026-09-07T10:51:40.007427

Friedreich Ataxia: Comprehensive Disease Characteristics Report

Disease: Friedreich Ataxia (FRDA) · MONDO: MONDO:0100339 · Category: Mendelian (autosomal recessive) OMIM: #229300 · Orphanet: ORPHA:95 · ICD-10: G11.1 · ICD-11: 8A03.10 · MeSH: D005621 · Gene: FXN (HGNC:3951), 9q21.11

Summary

Friedreich Ataxia (FRDA) is the most common inherited ataxia in populations of European descent and the prototypical mitochondrial iron–sulfur (Fe-S) disorder of nuclear-genetic origin. It is an autosomal recessive, progressive, multisystem neurodegenerative disease caused in ~96–98% of patients by a biallelic GAA·TTC trinucleotide-repeat expansion in intron 1 of the FXN gene on chromosome 9q21.11; the remainder are compound heterozygotes carrying one expansion and one point mutation or deletion. The expanded repeat adopts non-B DNA structures and induces repressive heterochromatin that impairs transcriptional elongation, silencing FXN and producing a deficiency of the mitochondrial protein frataxin. Because frataxin is essential for Fe-S cluster biosynthesis, its loss cripples the electron transport chain and Fe-S–dependent enzymes (e.g., aconitase), causing bioenergetic failure, secondary mitochondrial iron accumulation, and oxidative stress.

This molecular lesion selectively injures a characteristic set of tissues: the dorsal root ganglia (DRG) — the primary lesion — together with dorsal columns, spinocerebellar and corticospinal tracts, the cerebellar dentate nucleus, the myocardium, and pancreatic islet β-cells. The clinical result is a stereotyped phenotype of progressive afferent and cerebellar ataxia, dysarthria, lower-limb areflexia, extensor plantar responses, loss of proprioception/vibration sense, and frequently nystagmus, dysphagia, optic atrophy, and hearing loss, accompanied by hypertrophic cardiomyopathy (the leading cause of death), scoliosis, pes cavus, and diabetes mellitus. Disease severity is governed largely by residual frataxin level: the length of the smaller GAA allele (GAA1) inversely predicts age of onset (accounting for ~50% of the variance) and correlates with cardiomyopathy and diabetes risk.

FRDA is relentlessly progressive, with early-onset patients losing ambulation a median of ~11.5 years after symptom onset and dying most often of cardiac causes in their 30s. Management remains predominantly multidisciplinary and symptomatic; omaveloxolone (SKYCLARYS), an Nrf2 activator approved by the FDA (2023) and EMA, is the first and only disease-modifying therapy, producing modest slowing of neurological decline. AAV-based FXN gene replacement, CRISPR/epigenetic reactivation, and frataxin-stabilizing approaches are advancing through preclinical and early clinical development.

Key Findings

1. Genetic cause: biallelic intronic GAA expansion in FXN (F001)

Most FRDA patients are homozygous for a GAA trinucleotide repeat expansion in intron 1 of FXN (9q21.11). The expansion silences the gene epigenetically and reduces frataxin. Approximately 96–98% of patients are homozygous for the expansion; the remainder are compound heterozygous (expansion on one allele + point mutation or deletion on the other). Inheritance is autosomal recessive.

"large intronic guanine-adenine-adenine (GAA) tracts at the frataxin (FXN) gene locus induce heterochromatin formation, impaired transcriptional elongation, and reduced FXN expression, driving progressive neurodegeneration and cardiomyopathy" — PMID: 42295329

"FRDA is caused by an expansion of GAA repeats in the first intron of the frataxin (FXN) gene. The expansion disrupts transcription of FXN, resulting in significantly decreased FXN expression in FRDA patients' tissues." — PMID: 41514384

"Most patients have a homozygous GAA repeat expansion in the FXN gene, resulting in a deficiency of the mitochondrial protein frataxin." — PMID: 40541211

2. Core biochemical defect: impaired Fe-S cluster biosynthesis (F002)

Frataxin is an evolutionarily conserved mitochondrial matrix protein required for iron–sulfur (Fe-S) cluster biosynthesis, which is essential for the electron transport chain complexes I–III and many metabolic enzymes (e.g., aconitase). Frataxin deficiency reduces ATP production, causes mitochondrial iron accumulation that exacerbates oxidative stress, and disrupts glucose and fatty-acid oxidation.

"Frataxin is involved in biosynthesis of iron-sulfur (Fe-S) clusters, which are critical for the function of the electron transport chain and many metabolic enzymes. Frataxin deficiency leads to reduced energy production and accumulation of iron in mitochondria that exacerbates oxidative stress." — PMID: 41514384

"Frataxin deficiency impairs key mitochondrial metabolic enzymes, leading to widespread mitochondrial dysfunction with disrupted glucose and fatty acid oxidation." — PMID: 41447358

3. Epigenetic silencing mechanism (F016)

The large intronic GAA·TTC tract adopts non-B DNA structures (triplex/"sticky DNA" and R-loops) and nucleates repressive heterochromatin (increased H3K9me2/3, DNA methylation, HDAC-associated histone hypoacetylation) at the FXN locus, impairing RNA polymerase II elongation and reducing FXN mRNA. This mechanism is the rationale for epigenetic reactivation therapies (class I-selective benzamide HDAC inhibitors, high-dose nicotinamide, anti-gene oligonucleotides, gene-targeted chimeras) and splice-modulation to boost the extramitochondrial FXN-E isoform.

"class I-selective benzamide histone deacetylase inhibitors and high-dose nicotinamide, to emerging locus-targeted platforms such as anti-gene oligonucleotides and gene-targeted chimera small molecules" — PMID: 42295329

4. Multisystem disorder; cardiomyopathy is the leading cause of death (F003, F007)

FRDA affects the nervous system, heart, musculoskeletal system, and metabolism. Neurological deficits are the only feature uniformly present in all patients, while extraneural manifestations vary. Onset is typically in adolescence but ranges from early childhood to late adulthood.

"Common extraneural manifestations include cardiomyopathy, which is the most common cause of mortality, and also scoliosis and diabetes." — PMID: 40541211

"neurological deficits are the only feature uniformly observed in all FRDA patients" — PMID: 41447358

Core phenotype and suggested HPO terms:

Phenotype	HPO term	Frequency
Gait ataxia	HP:0002066	~universal
Limb ataxia	HP:0001251	~universal
Dysarthria	HP:0001260	very frequent
Lower-limb areflexia	HP:0001284	~universal
Extensor plantar response (Babinski)	HP:0003487	very frequent
Impaired proprioception	HP:0010831	~universal
Impaired vibration sense	HP:0003390	~universal
Nystagmus	HP:0000639	frequent
Dysphagia	HP:0002015	frequent
Optic atrophy	HP:0000648	subset
Sensorineural hearing loss	HP:0000407	subset
Hypertrophic cardiomyopathy	HP:0001639	frequent (major mortality driver)
Scoliosis	HP:0002650	frequent
Pes cavus	HP:0001761	frequent
Diabetes mellitus	HP:0000819	subset (~10–30%)

5. Genotype–phenotype correlation (F005)

In 67 FRDA patients (48 Italian families), FXN intron-1 GAA alleles ranged 201–1,186 repeats with no overlap with the normal range and a peak at 800–1,000. Both allele lengths inversely correlated with age at onset; the smaller allele (GAA1) best predicted onset, accounting for ~50% of variance. Mean allele length was significantly higher in patients with diabetes and cardiomyopathy. An independent cohort confirmed inverse correlation of GAA length with onset age, disease duration, and cardiomyopathy. The repeat is meiotically unstable (median variation ~150 repeats), providing a basis for genetic anticipation.

"The lengths of both larger and smaller alleles in each patient inversely correlated with age at onset of the disorder. Smaller alleles showed the best correlation, accounting for approximately 50% of the variation of age at onset. Mean allele length was significantly higher in patients with diabetes and in those with cardiomyopathy." — PMID: 8751856

"Genotype-phenotype correlation analyses in FA patients have evidenced an inverse relationship between GAA repeat expansion length and age of onset, disease duration, and presence of cardiomyopathy." — PMID: 11719273

6. Residual frataxin level (not mutation type) determines phenotype (F009)

Matched neuropathology of compound heterozygous versus homozygous FRDA showed similar cardiac and neuropathological lesions. Frataxin in heart and dentate nucleus of all cases was ≤10 ng/g wet weight (ELISA detection limit) versus normal dentate 126 ± 43 ng/g and normal heart 266 ± 92 ng/g. The pathologic phenotype is set by residual frataxin, not the specific mutation — explaining why complete loss (embryonic lethal) is never seen in patients.

"The pathologic phenotype in homozygous and compound heterozygous FA is determined by residual frataxin levels rather than unique mutations." — PMID: 28789479

7. Neuropathology: dorsal root ganglia and dentate nucleus (F008)

The primary lesion is the DRG: initial hypoplasia followed by progressive atrophy, producing thinning of dorsal roots, degeneration of dorsal columns, transsynaptic atrophy of Clarke column and dorsal spinocerebellar fibers, atrophy of gracile/cuneate nuclei, and sensory neuropathy. The dentate nucleus shows selective atrophy of large glutamatergic neurons and grumose degeneration of GABAergic corticonuclear terminals. Systemic involvement of myocardium and pancreatic islets confirms it as a systemic disease.

"Progressive destruction of dorsal root ganglia accounts for thinning of dorsal roots, degeneration of dorsal columns, transsynaptic atrophy of nerve cells in Clarke column and dorsal spinocerebellar fibers, atrophy of gracile and cuneate nuclei, and neuropathy of sensory nerves." — PMID: 23334592

"The lesion of the dentate nucleus consists of progressive and selective atrophy of large glutamatergic neurons and grumose degeneration of corticonuclear synaptic terminals that contain γ-aminobutyric acid (GABA)." — PMID: 23334592

"Involvement of the myocardium and pancreatic islets of Langerhans indicates that it is also a systemic disease." — PMID: 23859341

Anatomical/cellular ontology terms: dorsal root ganglion (UBERON:0000044); dorsal column (UBERON:0002211); spinocerebellar tract (UBERON:0004704); corticospinal tract (UBERON:0002460); dentate nucleus (UBERON:0002439); myocardium (UBERON:0002349); pancreatic islet (UBERON:0000006). Cell types: sensory neuron (CL:0000101), cardiac muscle cell (CL:0000746), pancreatic β-cell (CL:0000169), cerebellar dentate glutamatergic neurons. Subcellular: mitochondrion (GO:0005739); mitochondrial matrix (GO:0005759); Fe-S cluster assembly (GO:0016226).

8. Progression and prognosis (F006, F010)

In the FA-COMS natural history cohort (1,021 patients, 4,606 visits), FRDA causes progressive loss of coordination and balance leading to loss of ambulation (LoA) in nearly all patients. Early-onset (<15 y) patients become fully wheelchair-dependent at a median of 11.5 years (IQR 8.6–16.2) after first symptoms. A characteristic sequence of loss of FARS stance/balance functions predicts future LoA risk.

"Early onset FRDA patients (<15y of age) typically become fully wheelchair dependent at a median of 11.5y (25th, 75th percentiles 8.6y, 16.2y) after the onset of first symptoms." — PMID: 31938785

A Brazilian cohort (n=151; 24 deaths, 15.9%) found mean age at death 33 ± 10.7 years; among 12 known causes, cardiac in 7, pulmonary in 3, diabetic ketoacidosis in 1, sepsis in 1. Shorter life expectancy was associated with male sex (54.0 vs 56.8 y, p=0.03), classical vs late onset (52.2 vs 71.0 y, p<0.01), and cardiomyopathy (50.8 vs 65.0 y, p<0.01).

"Male sex, early onset and presence of cardiomyopathy are negative survival prognostic markers." — PMID: 41273607

9. Epidemiology (F011)

FRDA is worldwide the most common form of hereditary ataxia. Prevalence in populations of European descent is ~1 in 30,000–50,000 (~2–4 per 100,000), carrier frequency ~1 in 60–100. Strong regional/founder variation exists: in Finland carrier frequency was only 1/500 (birth incidence ~1/10⁶), because pre-mutation "reservoir" alleles (28–36 GAA) at the upper end of normal variation were absent. A single major universal risk haplotype underlies most patients; the disease is essentially restricted to European, North African, Middle Eastern, and Indian (Indo-European) populations and rare in sub-Saharan African, East Asian, and Amerindian populations.

"Worldwide it is considered to be the most common form of hereditary ataxia, but it is infrequently encountered in Finland." — PMID: 11810294

"Alleles in the uppermost end of the normal variation (28-36 GAA) were totally missing in the Finnish population." — PMID: 11810294

10. Diagnosis (F014)

Hallmark clinical features prompting diagnosis: progressive afferent and cerebellar ataxia, dysarthria, impaired vibration/proprioception, absent lower-limb reflexes, pyramidal weakness, scoliosis, foot deformity, and cardiomyopathy. Confirmation is molecular — detection of biallelic GAA expansion in FXN intron 1 by triplet-repeat-primed PCR / fluorescent amplicon-length PCR (long-read sequencing for accurate sizing); compound heterozygotes require FXN sequencing. Supportive tests: nerve conduction studies show absent/reduced sensory nerve action potentials with preserved motor conduction (axonal sensory neuronopathy); ECG/echocardiography detect concentric hypertrophic (later dilated) cardiomyopathy; spinal MRI shows cervical cord atrophy with early sparing of the cerebellum.

"The hallmark clinical features of FRDA include progressive afferent and cerebellar ataxia, dysarthria, impaired vibration sense and proprioception, absent tendon reflexes in lower limbs, pyramidal weakness, scoliosis, foot deformity and cardiomyopathy." — PMID: 25928624

Differential diagnosis: ataxia with vitamin E deficiency (AVED), ataxia-telangiectasia, ARSACS, ataxia with oculomotor apraxia (AOA1/2), POLG-related ataxia, and FGF14 (SCA27B) GAA-repeat ataxia.

"In the case of recessive disease, a stepwise diagnostic work-up is recommended, including both biochemical markers and targeted genetic testing, particularly aimed at Friedreich's ataxia, ataxia telangiectasia, ataxia due to vitamin E deficiency" — PMID: 24418350

11. First disease-modifying therapy: omaveloxolone (F004)

In the pivotal MOXIe phase 2 trial (NCT02255435), 150 mg/day omaveloxolone vs placebo (ages 16–40, mFARS 20–80) produced a placebo-corrected mFARS difference of −2.40 ± 0.96 at 48 weeks (p = 0.014) — omaveloxolone −1.55 ± 0.69 vs placebo +0.85 ± 0.64. Main adverse effects: transient reversible aminotransferase elevations, headache, nausea, fatigue. FDA (2023) and EMA approval followed (SKYCLARYS; NCIT: omaveloxolone).

"Changes from baseline in mFARS scores in omaveloxolone (-1.55 ± 0.69) and placebo (0.85 ± 0.64) patients showed a difference between treatment groups of -2.40 ± 0.96 (p = 0.014)." — PMID: 33068037

"Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and reduces inflammation in models of FA." — PMID: 33068037

12. Management and experimental therapeutics (F015, F013)

Prior to omaveloxolone, no proven treatment could slow progression; care is multidisciplinary and symptomatic (Corben 2014; 146 recommendations, 62% expert opinion). Components: physiotherapy, occupational and speech therapy; mobility aids/wheelchair; surveillance and pharmacologic/device management of cardiomyopathy and arrhythmia (ACE inhibitors/beta-blockers; HRS arrhythmia consensus); diabetes screening/treatment; orthopedic management of scoliosis (bracing, spinal fusion) and pes cavus; treatment of spasticity, bladder dysfunction, pain, and sensory complications. Idebenone, high-dose CoQ10/vitamin E, and deferiprone (iron chelation) have been trialed but are not established as disease-modifying.

"At present there is no proven treatment that can slow the progression or eventual outcome of this life-shortening condition." — PMID: 25928624

Gene therapy proof-of-concept: A single dose of AAV9-hFXN (6×10¹¹ v.p.) more than doubled lifespan of conditional Fxn-KO mice and preserved cardiac systolic function, with frataxin detected in heart, brain, muscle, kidney, and liver. AAV2-based intravitreal FXN supplementation partially preserved retinal structure/function in ocular-phenotype models.

"A single administration of the AAV9-hFXN at 6 × 10(11) v.p. more than doubled the life of these mice." — PMID: 26015982

"Gene supplementation via intravitreal injection of a novel AAV2-based capsid carrying FXN partially preserved retinal structure and/or function in both models, establishing proof of concept for this therapeutic strategy." — PMID: 41137390

13. Animal and cellular models (F012)

Complete Fxn knockout is embryonic lethal (frataxin essential for development), which is why patients always retain residual frataxin. Conditional KOs (MCK-Cre striated muscle; NSE-Cre neuron/cardiac) reproduce cardiac hypertrophy without skeletal-muscle involvement, large-sensory-neuron dysfunction sparing small sensory/motor neurons, and deficient complexes I–III and aconitase; critically, intramitochondrial iron accumulation occurs AFTER Fe-S enzyme inactivation and pathology onset, establishing enzyme dysfunction as upstream of iron deposition. Humanized GAA-repeat YAC transgenic models (YG8R/YG22R) show reduced frataxin, decreased aconitase, oxidative stress, DRG vacuolation, and rotarod deficits. iPSC-derived neurons, cardiomyocytes, microglia, and organoids provide human isogenic in-vitro systems.

"cardiac hypertrophy without skeletal muscle involvement, large sensory neuron dysfunction without alteration of the small sensory and motor neurons, and deficient activities of complexes I-III of the respiratory chain and of the aconitases ... time-dependent intramitochondrial iron accumulation ... which occurs after onset of the pathology and after inactivation of the Fe-S-dependent enzymes." — PMID: 11175786

"The resultant FRDA mice that express only human-derived frataxin show comparatively reduced levels of frataxin mRNA and protein expression, decreased aconitase activity, and oxidative stress, leading to progressive neurodegenerative and cardiac pathological phenotypes." — PMID: 16919418

Section-by-Section Details

1. Disease Information

FRDA is an autosomal recessive, progressive, multisystem neurodegenerative disorder combining a neurological ataxic syndrome with cardiac, skeletal, and metabolic features. Identifiers: MONDO:0100339, OMIM #229300, Orphanet ORPHA:95, ICD-10 G11.1, ICD-11 8A03.10, MeSH D005621. Synonyms: Friedreich's ataxia, FRDA, FA, spinocerebellar degeneration (historical), hereditary spinal ataxia. Information here derives from aggregated disease-level resources (OMIM, Orphanet, HPO), natural history registries (FA-COMS), and primary literature — not individual EHR.

2. Etiology

Causal factor: biallelic loss-of-function of FXN via intronic GAA expansion (or expansion + point mutation/deletion). Genetic risk: homozygosity for the expanded GAA allele; larger GAA1 length increases severity/earlier onset. Modifiers: proposed roles for oxidative-stress and iron-handling genes; residual frataxin level is the dominant determinant of phenotype (F009). Environmental risk/protective factors: none established as causal — FRDA is essentially fully genetically determined; no dietary, occupational, or infectious triggers are recognized. Gene–environment interaction: limited; oxidative-stress exposure could theoretically aggravate an already compromised redox system, but this is not clinically validated. Protective genetics: absence of upper-normal "reservoir" alleles (28–36 GAA) in a population reduces disease incidence (Finland; F011).

3. Phenotypes

See the HPO table above (Finding 4). Onset is typically adolescent (childhood to late-adult range); severity is variable and largely GAA1-dependent; progression is chronic and relentless. Quality-of-life impact is severe and cumulative: progressive loss of independent mobility, communication (dysarthria), swallowing, and — with cardiac/diabetic complications — survival. Afferent/sensory ataxia and cerebellar dysfunction jointly drive disability.

4. Genetic/Molecular Information

Causal gene: FXN (frataxin), HGNC:3951, 9q21.11. Variant class: intronic GAA·TTC repeat expansion (structural/repeat-expansion; pathogenic per ACMG when biallelic), plus rare pathogenic point mutations (missense, nonsense, splice-site) and deletions in compound heterozygotes. Functional consequence: loss of function via transcriptional silencing (not a toxic protein gain-of-function, distinguishing it from coding CAG disorders like Huntington's). Allele ranges: normal <~33; pre-mutation ~34–65; pathogenic ~66 to >1,000 (patient peak 800–1,000; F005). Epigenetics: heterochromatin marks (H3K9me2/3), DNA methylation, histone hypoacetylation at FXN (F016). No recurrent aneuploidy/translocation.

5. Environmental Information

No environmental, lifestyle, or infectious agents are established causes or triggers of FRDA. It is a monogenic disease. Iron intake/chelation modulate downstream biochemistry but do not cause disease.

6. Mechanism / Pathophysiology — ordered causal chain

1. Biallelic GAA·TTC expansion in FXN intron 1 (or expansion + point mutation)
│  leads to
2. Non-B DNA structures (triplex/"sticky DNA", R-loops) + repressive heterochromatin
   (H3K9me2/3, DNA methylation, histone hypoacetylation)
│  results in
3. Impaired RNA Pol II transcriptional elongation → reduced FXN mRNA → frataxin deficiency
│  leads to
4. Impaired mitochondrial Fe-S cluster biosynthesis
│  results in (branch)
   ├─► 5a. Deficient ETC complexes I–III + aconitase → bioenergetic failure
   ├─► 5b. Mitochondrial iron accumulation (occurs AFTER Fe-S enzyme loss — model-demonstrated)
   └─► 5c. Increased ROS / oxidative stress + lipid peroxidation
│  converge to cause
6. Selective cellular vulnerability: DRG proprioceptive neurons, dentate glutamatergic
   neurons, cardiomyocytes, pancreatic β-cells (+ microglial dysfunction, iPSC-inferred)
│  leads to
7. Tissue lesions: DRG atrophy → dorsal column/spinocerebellar/corticospinal degeneration;
   dentate nucleus atrophy; myocardial hypertrophy/fibrosis; islet β-cell loss
│  results in
8. Clinical manifestations: afferent + cerebellar ataxia, areflexia, pyramidal signs,
   dysarthria, sensory loss; hypertrophic cardiomyopathy; diabetes; scoliosis; pes cavus
│  progresses to
9. Loss of ambulation (~11.5 y post-onset, early onset) and death (mean ~33–38 y),
   most often from cardiac causes

Upstream vs downstream: steps 1–3 (genetic/epigenetic silencing) are upstream; frataxin deficiency (4) is the pivotal node; Fe-S enzyme failure (5a) precedes iron accumulation (5b) per mouse-model ordering (F012). Molecular pathways/GO terms: iron-sulfur cluster assembly (GO:0016226), mitochondrial electron transport chain (GO:0022900), cellular response to oxidative stress (GO:0034599), tricarboxylic acid cycle (aconitase; GO:0006099), Nrf2/KEAP1 antioxidant response (drug target). Immune involvement: iPSC studies suggest intrinsic microglial mitochondrial/iron/lysosomal defects driving a pro-inflammatory, neurotoxic state (PMID: 41318543) — a candidate primary mediator rather than purely secondary. CL terms: sensory neuron (CL:0000101), microglial cell (CL:0000129), cardiac muscle cell (CL:0000746), pancreatic β-cell (CL:0000169).

7. Anatomical Structures Affected

Primary: nervous system (DRG, dorsal columns, spinocerebellar/corticospinal tracts, dentate nucleus) and heart. Secondary/systemic: pancreas (islets → diabetes), skeleton (spine → scoliosis; feet → pes cavus), optic and auditory pathways. Body systems: nervous, cardiovascular, musculoskeletal, endocrine. Subcellular: mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759). Involvement is bilateral and largely symmetric.

8. Temporal Development

Onset: typically adolescent/childhood (classical), with late-onset (LOFA, >25 y) and very-late-onset (VLOFA, >40 y) variants generally milder and slower (smaller GAA1). Pattern: insidious, chronic, progressive (not relapsing-remitting or episodic). Stages: ambulatory → assisted → wheelchair-dependent → advanced with bulbar/cardiac complications. Progression rate: variable, inversely related to GAA1 length. Critical window: early intervention before irreversible neuronal loss is the therapeutic goal, given DRG hypoplasia may have a developmental component.

9. Inheritance and Population

Autosomal recessive; complete penetrance of biallelic expansions; variable expressivity governed by GAA1 length; genetic anticipation possible via meiotic repeat instability (median ~150-repeat variation). Prevalence ~1/30,000–50,000 (European descent); carrier frequency ~1/60–100. Founder haplotype; near-absence in East Asian, sub-Saharan African, Amerindian populations. Consanguinity increases risk as in any recessive disorder. Sex ratio ~1:1 (males show worse survival, F010).

10. Diagnostics

See Finding 10. Genetic testing is confirmatory (repeat-expansion sizing ± FXN sequencing). Adjuncts: nerve conduction (sensory neuronopathy), ECG/echocardiography (hypertrophic → dilated cardiomyopathy), HbA1c/glucose (diabetes), spinal MRI (cervical cord atrophy). No newborn screening currently standard; cascade and carrier testing available.

11. Outcome/Prognosis

Life-shortening; mean age at death ~33–38 y, predominantly cardiac. Near-universal loss of ambulation. Negative prognostic markers: male sex, early onset, cardiomyopathy, longer GAA1 (F005, F010). Morbidity is dominated by mobility, communication, swallowing, cardiac, and metabolic impairment. mFARS/FARS and SARA are the standard progression measures.

12. Treatment

Omaveloxolone (Nrf2 activator; NCIT concept) is the only approved disease-modifying drug. Symptomatic/supportive: cardiac (ACE-I, beta-blockers, device therapy), antidiabetic agents, orthopedic surgery (spinal fusion), physiotherapy/OT/speech therapy, spasticity and pain management. Experimental: AAV-FXN gene therapy, CRISPR repeat excision/epigenetic reactivation, HDAC inhibitors, high-dose nicotinamide, frataxin-stabilizing and splice-modulating molecules, iron chelation (deferiprone).

13. Prevention

No primary prevention (monogenic). Genetic counseling, carrier/cascade screening, prenatal and preimplantation genetic testing are the mainstays for at-risk families. Tertiary prevention: surveillance and management of cardiomyopathy, diabetes, and scoliosis to avert complications. No immunization or public-health/environmental interventions apply.

14. Other Species / Natural Disease

Human disease (NCBI Taxon 9606). FXN is evolutionarily conserved with orthologs across mammals, Drosophila, C. elegans, and yeast (YFH1), enabling cross-species mechanistic study. No prominent naturally occurring FRDA-equivalent in companion animals is established; models are engineered. Conservation of the Fe-S/frataxin pathway underlies model validity.

15. Model Organisms

Mouse: complete KO embryonic lethal; conditional KO (MCK-Cre, NSE-Cre) and humanized GAA-repeat YAC transgenics (YG8R/YG22R) recapitulate cardiac, sensory-neuron, and biochemical phenotypes (F012). In vitro/human: iPSC-derived neurons, cardiomyocytes, microglia, and organoids; isogenic CRISPR-corrected lines. Applications: mechanism dissection (Fe-S/iron ordering), biomarker discovery, and therapeutic testing (AAV gene therapy, epigenetic reactivation). Limitations: models incompletely capture the slow, decades-long human course and full DRG/dentate selective vulnerability. Databases: MGI, IMSR, Cellosaurus.

Mechanistic Model / Interpretation

The unifying model is dose-dependent frataxin insufficiency. A single upstream lesion — the intronic GAA expansion — produces graded frataxin deficiency whose magnitude (set principally by GAA1 length and hence residual expression) determines the entire downstream cascade and clinical severity (F005, F009). The pivotal biochemical consequence is failure of Fe-S cluster biosynthesis (F002), which starves the respiratory chain and Fe-S enzymes of function, with mitochondrial iron accumulation and oxidative stress as downstream, not initiating, events (established by the temporal ordering in conditional-KO mice, F012). Selective vulnerability of proprioceptive DRG neurons, dentate glutamatergic neurons, cardiomyocytes, and β-cells — cells with high oxidative metabolic demand and/or long axons — explains the stereotyped phenotype (F007, F008). Emerging iPSC data implicate intrinsic microglial dysfunction as a possible primary amplifier of neuronal death (PMID: 41318543).

Therapeutically, three tiers map onto this chain: (1) antioxidant/bioenergetic buffering downstream (omaveloxolone via Nrf2; the only approved agent, F004); (2) transcriptional/epigenetic reactivation at the silenced locus (HDAC inhibitors, nicotinamide, anti-gene oligonucleotides; F016); and (3) frataxin restoration at the source (AAV-FXN gene replacement and CRISPR repeat correction; F013, F012). The further upstream the intervention, the greater the theoretical disease modification — but the harder the delivery to CNS and heart.

Evidence Base

PMID	Contribution
42295329	Epigenetic silencing mechanism; reactivation therapies
41514384	GAA expansion → reduced FXN; Fe-S cluster role; iPSC models
41447358	Metabolic consequences; universal neurological involvement
40541211	Multisystem overview; cardiomyopathy mortality; omaveloxolone approval
8751856	Genotype–phenotype: GAA length vs onset/cardiomyopathy/diabetes
11719273	Independent confirmation of GAA–onset correlation
31938785	FA-COMS: loss of ambulation ~11.5 y
41273607	Survival: mean death age 33 y; prognostic markers
23334592	Neuropathology: DRG primary lesion, dentate nucleus
23859341	Systemic (myocardial/islet) involvement
28789479	Residual frataxin determines phenotype
11810294	Epidemiology and founder/reservoir-allele effect
33068037	MOXIe trial: omaveloxolone efficacy
25928624	Consensus management guidelines; diagnostic hallmarks
24418350	EFNS/ENS diagnostic algorithm; differentials
11175786	Conditional-KO mouse: Fe-S loss precedes iron accumulation
16919418	Humanized GAA-repeat YAC mouse model
26015982	AAV9-hFXN doubles lifespan; cardiac rescue
41137390	AAV2-FXN ocular gene-therapy proof-of-concept
41318543	Microglial dysfunction as candidate primary mediator

Evidence source types: human clinical/pathology (40541211, 23334592, 28789479, 31938785, 41273607, 33068037, 8751856, 11719273, 11810294, 25928624, 24418350); model organism (11175786, 16919418, 26015982, 41137390); in vitro/iPSC (41514384, 41318543); reviews/mechanistic synthesis (42295329, 41447358, 23859341).

Limitations and Knowledge Gaps

Iron's causal role remains debated. Mouse data place iron accumulation downstream of Fe-S enzyme failure, and iron chelation has not been established as disease-modifying — so iron may be a marker/amplifier rather than a primary driver.
Microgliopathy as a primary vs secondary mediator is supported by iPSC/xenograft data but not yet confirmed in patients.
Modifier genes beyond GAA1 length are incompletely defined; GAA1 explains ~50% of onset-age variance, leaving substantial unexplained variability.
Omaveloxolone's effect is modest (mFARS −2.40 over 48 weeks) and long-term/hard-outcome (mortality, ambulation) benefit is not yet proven.
Gene-therapy translation faces CNS + cardiac delivery, dosing, durability, and safety hurdles; human efficacy is unproven.
Epidemiology relies on European-ancestry data; prevalence in admixed and under-studied populations is uncertain.
Natural animal disease and standardized model-to-human progression mapping are limited.

Proposed Follow-up Experiments / Actions

Frataxin as a surrogate biomarker: validate blood/skin/platelet frataxin (and lipid-peroxidation/Fe-S metabolite panels) against mFARS progression and cardiac endpoints to enable shorter trials.
Long-term omaveloxolone outcomes: analyze open-label extension and real-world registry data for effects on ambulation loss and cardiac mortality.
Iron-handling intervention trials stratified by residual frataxin and cardiac iron (MRI T2*) to resolve iron's causal contribution.
Head-to-head model benchmarking of AAV-FXN serotypes/capsids for combined CNS+cardiac transduction and durability in humanized YG8R mice.
Microglia-targeted studies: test whether CRISPR-corrected or pharmacologically rescued microglia halt neuronal death in xenograft models, and seek patient CSF/imaging correlates of neuroinflammation.
Modifier-gene GWAS/QTL in large FA-COMS-scale cohorts to explain residual onset-age variance beyond GAA1.
Cross-omics integration (transcriptomic + proteomic + metabolomic) in DRG/cardiac iPSC models to prioritize druggable downstream nodes and cell-type-specific biomarkers.

Report compiled from 16 confirmed findings and 32 reviewed papers across 5 investigation iterations. Ontology suggestions: MONDO:0100339; HGNC:3951 (FXN); GO:0016226, GO:0005739, GO:0022900, GO:0034599; UBERON:0000044, UBERON:0002439, UBERON:0002349, UBERON:0000006; CL:0000101, CL:0000129, CL:0000746, CL:0000169.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	20
Resolved	20
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	20
On topic	13
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	35
Resolved	33
Unresolved (possible confabulation)	0
Obsolete	0
Unverifiable	2
Terms whose name was checked	15
Terms named correctly	11
Terms named as a different term	1
Terms whose name is worth a second look	3

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

HP:0003390 (1 mention) - the report calls it "Impaired vibration sense"; HP calls it Sensory axonal neuropathy

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

HP:0001251 (1 mention) - the report calls it "Limb ataxia"; HP calls it Ataxia
HP:0001284 (1 mention) - the report calls it "Lower-limb areflexia"; HP calls it Areflexia
HP:0003487 (1 mention) - the report calls it "Extensor plantar response (Babinski)"; HP calls it Babinski sign, and lists "Extensor plantar responses" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

External Assertions

Medical Actions

Diagnosis

Progression

Prevalence

Differential Diagnoses

Related Datasets

Clinical Trials

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Friedreich Ataxia (FRDA) — Comprehensive Disease Characteristics Research Report (2023–2024 prioritized)

Executive summary

1. Disease information

1.1 What is the disease?

1.2 Key identifiers

1.3 Synonyms and alternative names

1.4 Evidence source type

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core neurologic phenotypes

3.2 Non-neurologic/systemic phenotypes

3.3 Age of onset, severity, progression, frequency

3.4 Quality of life impact

4. Genetic/molecular information

4.1 Causal gene(s)

4.2 Pathogenic variants

4.3 Functional consequences

4.4 Modifier genes / epigenetics

5. Environmental information

6. Mechanism / pathophysiology

6.1 Causal chain (high-level)

6.2 Selective vulnerability and primary tissues

6.3 Cellular processes and neuropathology (human evidence)

6.4 Mitochondrial dysfunction in DRG (2024 mechanistic development)

7. Anatomical structures affected

7.1 Organ/system level

7.2 Tissue/cell level

8. Temporal development

8.1 Onset

8.2 Progression and staging

9. Inheritance and population

9.1 Epidemiology